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ABSTRACT 
Streptococus pneumoniae is an important human pathogen, yet in most individuals it 
establishes only transient nasopharyngeal colonisation without causing disease.  Using 
murine models, this thesis explores the hypothesis that colonisation induces acquired 
immune responses which protect against subsequent pneumonia. 
Colonisation models with wild-type (WT) and mutant S. pneumoniae were established 
in outbred CD1 mice.  Mutants lacked either capsule or lipoproteins, or were 
auxotrophs unable to replicate in vivo.  WT colonisation protected against subsequent 
pneumonia.  Mutants were cleared more rapidly than WT, were not immunogenic and 
did not protect.  When the auxotroph was supplemented, colonisation, 
immunogenicity and protection were improved, suggesting duration of a colonisation 
event is an important factor in determining immunogenicity.  This may be one factor 
explaining the poor immunogenicity of the other mutants. 
The mechanism by which previous colonisation protected against subsequent lethal 
pneumonia was then defined in a series of studies in inbred CBA/Ca mice.  
Colonisation induced both mucosal and systemic antibody responses to bacterial 
surface antigens but not capsule.  There was also evidence of more robust cytokine 
production during subsequent pneumonia, including systemic and mucosal IL-17 
responses dependant on the presence of CD4-cells.  Protection was primarily against 
systemic invasion following pneumonia.  Passive transfer studies and experiments 
using genetically modified mice demonstrated that systemic antibody was both 
necessary and sufficient to protect, and in vitro and in vivo models showed this to be 
via opsonophagocytosis and bloodstream clearance of bacteria.  Antigenic protein 
targets of protective serum were defined using Western blotting and multiplex bead 
immunoassay techniques. 
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Overall this thesis demonstrates that nasopharyngeal colonisation can protect against 
lethal pneumonia in mice via opsonophagocytic antibody against surface proteins thus 
preventing bacteraemia. 
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1 GENERAL INTRODUCTION 
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1.1 STREPTOCOCCUS PNEUMONIAE 
1.1.1 Historical overview 
Streptococcus pneumoniae is a major bacterial pathogen responsible for significant 
mortality and morbidity globally.  It was discovered in 1881 by Pasteur and 
Sternberg, and has been renamed several times reflecting advances in microbiological 
understanding.  Such names include Microbe septicèmique du salive (Pasteur), 
reflecting the nature of this organism which is recoverable from the oro/nasopharynx 
and has the capacity on occasion to invade and kill.  The young, old and 
immunocompromised are most vulnerable.  Most morbidity is attributable to 
pneumococcal pneumonia.  Its recognition as the major cause of lobar pneumonia 
earned it the label ‘pneumococcus’, whilst its mortality was ironically reflected in the 
moniker ‘Old Man’s Friend’ attributed to Canadian physician William Osler.  Its 
morphology was reflected in the subsequent appellation Diplococcus, until 1974, 
when it was renamed Streptococcus pneumoniae (Watson et al., 1993) reflecting its 
pattern of growth in liquid media. 
Studies of this prototypic extracellular bacterial pathogen led to many important 
biological discoveries especially in the field of humoral immunity.  In the last century, 
immunisation of African mine workers with killed S. pneumoniae led to large 
reductions in the mortality caused by epidemic lobar pneumonia (Austrian et al., 
1976).  Further studies identified the polysaccharide capsule as an important antigen 
against which serotype specific protection could be induced (Smillie et al., 1938).  
Perhaps the most remarkable discovery to arise from work on S. pneumoniae was 
when Avery demonstrated that deoxyribonucleic acid (DNA) is the molecule that 
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conveys heritable phenotypic characteristics (Avery et al., 1944), explaining the 
transformation of bacterial strains previously described by Griffith (Griffith, 1928).   
1.1.2 Microbiology 
S. pneumoniae is a gram-positive chain-forming coccus.  It produces large amounts of 
hydrogen peroxide and growth is optimal in the presence of a source of catalase.  
Hence, in the laboratory it is often grown on blood agar, where it forms grey-white 
colonies.  Release of the toxin pneumolysin (Ply) leads to degradation of 
haemoglobin, resulting in a green coloration referred to as α-haemolysis.  S. 
pneumoniae is differentiated from other gram-positive chain-forming α-haemolytic 
organisms by its sensitivity to optochin and its solubility in bile salts.  Recent 
identification of optochin-resistant S. pneumoniae has increased the need for genetic 
identification methods where precision is required.  Such approaches include testing 
by polymerase chain reaction (PCR) for the presence of the pia locus (Brown et al., 
2001a). 
1.1.3 Anatomy and physiology 
The components of the S. pneumoniae cell surface are illustrated in Figure 1.1 
(Jedrzejas, 2004). Every invasive isolate of S. pneumoniae and nearly every isolate 
associated with mucosal infection has a polysaccharide capsule.  The only exceptions 
have been occasional cases of pneumococcal conjunctivitis (Ertugrul et al., 1997).  
Capsules consist of repeating oligosaccharide units which are polymerized, and 
transported to the cell surface.  Capsular polysaccharide (CPS) is covalently bound to 
cell wall peptidoglycan and cell wall polysaccharide.  These processes are controlled 
by a genetic cassette consisting of up to 15 genes (Morona et al., 1997).  The precise 
monosaccharides within the oligosaccharide units and the bonds between them 
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provide the epitopes recognised by specific antisera used to distinguish different 
capsular serotypes (Park et al., 2007).  On this basis, at least 91 serotypes can be 
identified, falling into a number of groups within which there are varying degrees of 
cross-reactivity.  The Quellung reaction detects increased refractility of bacterial cells 
to light following incubation with specific anti-capsular antisera (Neufeld, 1902).  
This technique is used to serotype isolates of S. pneumoniae, and initially came to the 
fore when anti-sera where used therapeutically.  It is again of great importance in the 
application of capsular polysaccharide-based vaccines to prevent S. pneumoniae 
disease.  S. pneumoniae have the ability to internalise and incorporate DNA from 
other S. pneumoniae strains or even other species, a process known as competence 
(Tomasz, 1966).  This process itself is under genetic control and responds to 
environmental signals, particularly quorum sensing (Lee and Morrison, 1999).  By 






Figure 1.1.  S. pneumoniae cell surface components 
Proteins are attached to the surface of S. pneumoniae by at least three mechanisms.  (1) 
proteins with choline binding domains attach to phosphocholine residues in cell wall teichoic 
and lipoteichoic acids; (2) proteins with appropriate motifs including LPxTG are covalently 
attached to cell wall peptidoglycan by sortases; (3) lipoproteins are attached to the cell 
membrane by acylation of apolipoprotein (also see Figure 1.2).  (Jedrzejas, 2004). 
 
In common with other streptococci, the bacterial cell wall of S. pneumoniae consists 
of peptidoglycan and teichoic acids (TA) (Tomasz et al., 1975).  Peptidoglycan is 
formed by the cross-linking of long chains of the saccharides N-acetyl-D-glucosamine 
and N-acetylmuramic acid.  Stem peptides, four to six amino acids in length, serve as 
cross-linkers, and are themselves cross-linked by pentaglycine bridges, providing 
substantial strength to the overall structure.  Teichoic acids are phosphorylcholine 
(PC) containing polysaccharides which are covalently linked to peptidogylcan.  
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Lipoteichoic acids (LTA) have a lipid moiety and are attached to the cell membrane in 
addition.  The PC residues in TA and LTA are major antigenic determinants of C-
polysaccharide, or cell wall polysaccharide (CWPS), common to all S. pneumoniae 
strains (Jennings et al., 1980).  Proteins are attached to the cell wall by a variety of 
mechanisms (as illustrated in Figure 1.1).  Certain proteins are capable of binding the 
choline moieties of teichoic acids (Bergmann and Hammerschmidt, 2006).  There are 
10-15 such choline binding proteins (CBPs) including pneumococcal surface protein 
A (PspA), PspC, also known as CbpA, LytA (autolysin) and LytC (lysozyme).  Other 
proteins are covalently anchored to peptidoglycan after cleavage of a LPxTG 
sequence by a transpeptidase known as a sortase (Kharat and Tomasz, 2003).  There 
are approximately 10-20 such proteins, including neuraminidase A (NanA) and β-
galactosidase.  For many of these proteins, important functions have been identified in 
establishing colonisation or in obfuscating host defense mechanisms, as described 
further below.  Other surface-located proteins act enzymatically on host structures to 
enhance binding (e.g. the action of neuraminidase A (NanA) on host sialic acid 
structures) or to facilitate tissue invasion (e.g. hyaluronidase). 
Lipoproteins are important components of the ATP-binding cassette (ABC) 
transporters responsible for influx and efflux of molecules important for nutrition, 
signalling and stress response (Garmory and Titball, 2004).  They are attached to the 
cell membrane by a mechanism that is conserved amongst gram-positive organisms 
(Sutcliffe and Harrington, 2002).  Prolipoproteins containing an N-terminal signal 
peptide are secreted out of the cell by the general secretory pathway.  The enzyme 
diacylglyceryl transferase (Lgt) catalyses the attachment of a universally conserved 
cysteine residue within a ‘lipobox’ domain to the membrane phospholipid 
diacylglycerol (Sutcliffe and Harrington, 2002).  Finally, a type II lipoprotein signal 
peptidase (Lsp) cleaves the N-terminal signal peptide to form the mature membrane-
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attached lipoprotein (Khandavilli et al., 2008).  Pneumococcal surface adhesion A 
(PsaA) is a typical surface lipoprotein that plays an essential role in manganese and 
zinc transport (Lawrence et al., 1998).  Further lipoproteins important to S. 
pneumoniae physiology include iron transporters PiaA and PiuA (Brown et al., 
2001a), and PpmA (Cron et al., 2009) and SlrA (Hermans et al., 2006) which have 
roles in adherence to nasopharyngeal epithelium and evasion of phagocytosis.  There 
are predicted to be approximately 40-50 S. pneumoniae lipoproteins.  Lipoproteins are 
important ligands of Toll-like receptor 2 (TLR2) (Travassos et al., 2004).  Many 
proteins have been predicted to be surface-attached as their genes encode lipobox 
domains, LPxTG motifs or choline-binding domains.  Other proteins have shown to 
be surface-located by more empiric methods.   
S. pneumoniae produces a single exotoxin, pneumolysin (Ply).  It has homology to 
other streptococcal cytolysins (Jefferies et al., 2007).  It plays important an role in 
evading host defences at mucosal surfaces.  Through polymerisation it may form 
pores in eukaryotic host cell membranes leading to cytolysis (Tilley et al., 2005), and 
may trigger apoptosis of a range of host cell types (Littmann et al., 2009).  However, 
it also triggers host defence mechanisms as it is a TLR4 ligand (Malley et al., 2003).   
 
1.1.4 Colonisation and diseases 
S. pneumoniae can transmit between individuals via aerosol and droplet spread 
(Bogaert et al., 2004a).  Following inhalation into the upper respiratory tract, if the 
conditions are appropriate, bacteria may establish viable colonies on the 
nasopharyngeal surface.  Multiple factors dictate the competition between the various 
organisms that vie for occupancy of this limited niche (Bogaert et al., 2004a).  The 
state of colonisation, or carriage, will continue until the bacteria are actively cleared 
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by various host response mechanisms, as described below.  In this thesis, the terms 
colonisation and carriage will be used interchangeably to describe the period during 
which viable bacteria can be cultured from samples collected from the nasopharynx.  
Following acquisition and colonisation of the nasopharynx, S. pneumoniae can spread 
to various sites and lead to disease, as illustrated in Figure 1.2 (Bogaert et al., 2004a).  
Bacteria ascending the eustachian tube can establish infection of the middle ear 
causing otitis media (Rodgers et al., 2009).  Whilst this has minimal associated 
mortality, it probably represents the largest number of disease cases caused by S. 
pneumoniae (Cripps et al., 2005).  Most cases are not microbiologically diagnosed, 
and resolve either through spontaneous resolution or with the assistance of a course of 
antibiotics.  Individuals with structurally abnormal airways can develop S. 
pneumoniae colonisation of the bronchial tree, as part of a chronic bronchitis.  This is 
most commonly recognised as part of chronic obstructive pulmonary disease (Patel et 




Figure 1.2.  Routes for the spread of S. pneumoniae leading to disease 
Nasopharyngeal acquisition from airborne droplets may be asymptomatic.  Mucosal spread 
can lead to diseases such as otitis media or sinusitis.  Aspiration into the alveoli can lead to 
pneumonia which may be complicated by pleural empyema or rarely pericardial effusion 
(empyema).  Pneumonia can lead to septicaemia but this can also arise through direct 
invasion following nasopharyngeal colonisation.  Haematogenous spread can seed distant 
sites leading to peritonitis, bone and joint infection or meningitis.  Pneumonia can also arise 
from haematogenous spread.  (Bogaert et al., 2004a) 
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Aspiration of small numbers of bacteria probably occurs constantly during 
colonisation (van der and Opal, 2009).  However, there are abundant physical, 
chemical and immunological mechanisms which limit the capacity of inhaled bacteria 
to establish pulmonary infection.  Studies in mice would suggest that a threshold 
inoculum is required before these mechanism are overwhelmed (Gingles et al., 2001b, 
Chiavolini et al., 2008), but that the size of this inoculum varies between individuals 
and serotypes.  The innate and adaptive immune defences which protect the host 
against pneumonia are discussed in more detail below.  Epidemiological data would 
suggest that prior exposure to S. pneumoniae may enhance the response to subsequent 
exposure (Lipsitch et al., 2005).  Thus, those components of the immune system that 
can adapt may become more important following previous exposure.  Aspiration of 
bacteria may lead to either a more focal lobar pneumonia or to more diffuse 
bronchopneumonia.  Only rarely is pneumonia believed to develop directly from 
haematogenous spread.  Hallmark clinical features include fever, cough, production of 
purulent sputum and difficulty in breathing (van der and Opal, 2009).  Untreated, this 
can lead to hypoxia, respiratory failure, or septicaemia.  Specific complications 
include the development of parapneumonic pleural effusions, empyema, and rarely 
lung abscess or necrosis.  However, clinically complete resolution is possible, 
especially with prompt antibiotic therapy. 
Histopathological studies show similarity between animal models and human disease 
(Bergeron et al., 1998).  Specific interactions between bacterial pathogen-associated 
molecular patterns (PAMPs) and host soluble and cellular pathogen recognition 
receptors (PRRs) facilitate the recognition of infection and initiate the inflammatory 
response (Calbo and Garau, 2010).  A range of inflammatory mediators are released, 
driving cellular recruitment and activation (Dallaire et al., 2001).  Airspace oedema 
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occurs early and is followed by recruitment of leukocytes to the alveoli.  These are 
predominantly neutrophils, especially in the earlier stages of infection, but by 72-96 h 
monocytes and some lymphocytes dominate.  Interstitial oedema and haemorrhage 
follows from 24-28 h, with proliferation of type II pneumocytes.  As infection 
progresses, tissue architecture is either progressively destroyed, or moves to a 
resolution phase with phagocytosis and apoptosis of inflammatory cells, and gradual 
restoration of a quiescent environment.  The role of these inflammatory processes in 
limiting infection is discussed in detail below. 
Many studies have identified S. pneumoniae as the leading pathogen causing 
community-acquired pneumonia (CAP) (Brown and Lerner, 1998).  Diagnosis can be 
made from culture of sputum, which is specific but lacks sensitivity.  Positive urinary 
antigen test for S. pneumoniae CWPS is a sensitive test, and specific for determining 
the causal pathogen of CAP when used in populations with low carriage rates such as 
adults in developed countries, but remains of low specificity in infants and children 
where it may simply reflect carriage (Charkaluk et al., 2006).  In the majority of cases 
of S. pneumoniae pneumonia, blood cultures remain sterile (Werno and Murdoch, 
2008).  S. pneumoniae can invade the bloodstream either directly across the 
nasopharyngeal epithelium (Bogaert et al., 2004a), or secondary to the inflammation 
associated with pneumonia.  The former is more common in young children, and in 
the absence of a clinical focus for the fevers it triggers, is termed occult bacteraemia 
(Joffe and Alpern, 2010).  When bacteraemia does occur it is most commonly 
secondary to pneumonia and has a high mortality (Trotter et al., 2010).  Once viable 
bacteria have entered the bloodstream they can seed distant sites giving rise to focal 





The majority of studies of the epidemiology of nasopharyngeal carriage are cross-
sectional prevalence studies based on defined populations (Bogaert et al., 2004a).  
These show that carriage rates vary with age, geographical location, socio-economic 
status, immune status, and environmental features.  Initial colonisation occurs at the 
latest within the first few months of life (Gray and Dillon, Jr., 1988, Loda et al., 1975, 
Vives et al., 1997).  In areas of high prevalence this can be within weeks of birth (Hill 
et al., 2008) (Aniansson et al., 1992, Granat et al., 2007, Faden et al., 1997), and is 
nearly ubiquitous by six months of age.  In resource-rich countries, 50% of infants 
have been colonised by one year of age (Syrjänen et al., 2001, Lee et al., 1995), 
whereas nearly 95% of infants were colonised by 6 months of age in Bangladesh 
(Granat et al., 2007).  Repeat colonisation events take place, such that peak carriage 
rates occur at approximately 3-5 years of age and then wane to a stable rate of 
approximately 10% in adult life (Bogaert et al., 2004a, Abdullahi et al., 2008).  It is 
not known whether carriage rates change with increasing age amongst adults.  Human 
immunodeficiency virus (HIV) infection can increase the rate of S. pneumoniae 
colonisation in both children (Madhi et al., 2007) and adults (Gill et al., 2008).  
Patterns of social interaction play a large role in dictating spread between children.  
Thus higher carriage has been observed amongst children attending daycare (Bogaert 
et al., 2001) and in those living in institutions (Raymond et al., 2000).  Carriage rates 
are also enhanced during periods of viral upper respiratory illness (Brimblecombe et 
al., 1958) and during the rainy season in tropical environments (Abdullahi et al., 
2008).  Whilst initial colonisation events may persist for up to 4 months (Gray and 
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Dillon, Jr., 1988), the duration appears to shorten with age.  In adult populations, 
carriage may last 2 to 4 weeks (Ekdahl et al., 1997).  The methodology of such studies 
limits their ability to identify very short carriage events.  If carriage duration is shorter 
with increasing age, prevalence studies will therefore underestimate the total number 
of carriage events as age increases.  As disease is thought to arise shortly after 
acquisition, this may also underestimate the protective effect of prior exposure on the 
development of disease following re-exposure. 
Serotype specific carriage prevalence varies between different populations, with 
limited numbers of serotypes dominating in different communities.    Prior to the 
introduction of the pneumococcal conjugate vaccine (PCV), serotypes 19F, 6B, 6A, 
9V, and 23F were most frequently found among children under 3 years of age in 
several European countries (Bogaert et al., 2001, Bogaert et al., 2006) and in the 
United States US (Yeh et al., 2003).  However, in Kenya, serotypes 13, 15, 14, 6B, 
and 19F are most prevalent (Mbelle et al., 1999).  The serotypes carried also appear to 
change with increasing age (Bogaert et al., 2006, Kaltoft et al., 2000).  Even when the 
effect of age is controlled for, differences in carriage duration for different serotypes 
persist (Hogberg et al., 2007).  Serotype prevalence has been affected by introduction 
of the pneumococcal conjugate vaccine as discussed below.  It is becoming apparent 
that methodologies based on culture and Quellung reaction alone can only identify a 
small number (perhaps 1-2, at most probably 3) colonizing serotypes, and that an 
individual may be colonised with further strains at lower density.  Genetic approaches 
such as multiplex PCR to detect capsule synthesis genes offer the prospect of 
identifying larger numbers of distinct isolates and permitting more sophisticated 
tracking of colonisation (Rivera-Olivero et al., 2009). 
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1.2.2 Pneumonia 
For many years, pneumonia has remained the commonest cause of death from S. 
pneumoniae disease worldwide (WHO, 1999), yet in most cases precise diagnosis is 
elusive.  Culture of sputum or blood is often negative.  It is estimated that 30-50% of 
adult CAP is attributable to S. pneumoniae (Fedson et al., 1998).  Thus, 
epidemiological estimates of the burden of S. pneumoniae pneumonia are largely 
extrapolated from other data.  In this regard, vaccine probe studies have proven 
helpful.  The reduction in total pneumonia following the introduction of a 
pneumococcal conjugate vaccine which specifically protects against seven S. 
pneumoniae serotypes identifies the burden of pneumonia attributable to these or 
related serotypes.  It is then possible to extrapolate to estimate total S. pneumoniae 
pneumonia incidence based on serotype prevalence data.  Using such techniques, over 
800,000 deaths in children under 5 years of age are thought to die each year from S. 
pneumoniae pneumonia (O'Brien et al., 2009).  Such approaches support the concept 
that S. pneumoniae pneumonia is more common in the very young, the old and the 
immunocompromised (Fedson and Scott, 1999, O'Brien et al., 2009).  However, 
epidemiological data are more robust for invasive pneumococcal disease (IPD), 
reflecting the ability to isolate the causative organism.  Nonetheless, non-
microbiologically differentiated pneumonia rates are at their highest in infants and the 
elderly. 
1.2.3 Invasive pneumococcal disease 
Studies from many countries indicate that rates of IPD are highest in children under 3 
years of age, fall during childhood, and rise again in later adult life (Trotter et al., 
2010, Lipsitch et al., 2005, Burman et al., 1985) to rates of approximately 50 cases 
per 100,000 persons.  This fall during the first few years of life is shared between all 
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types of IPD (i.e. meningitis, invasive pneumonia, septicaemia) (Lipsitch et al., 2005).  
Furthermore, similar rates of decline are observed for all serotypes, irrespective of 
how commonly they are carried.  Certain populations have higher rates of IPD, 
including Alaskans (Davidson et al., 1994) and Aboriginal Australians (Torzillo et al., 
1995).  This is associated with higher colonisation rates but the underlying reasons are 
not clear.  Strains of S. pneumoniae vary in their ability to cause invasive disease 
following colonisation.  Traditionally this has been measured as the ‘invasiveness 
odds ratio’, relating IPD data to cross-sectional carriage prevalence (Brueggemann et 
al., 2003, Brueggemann et al., 2004).  To overcome possible bias of carriage duration, 
the ‘attack rate’ for a strain can also be calculated, using data on acquisition events as 
the denominator (Sleeman et al., 2006).  Using this technique it appears that capsular 
serotype is an important determinant of both carriage duration and attack rate.  
However, there is still considerable variation in invasiveness between different 
genetic strains of a given serotype, which correlates with the strains ability to limit 
complement deposition (Sjostrom et al., 2006).    
There is also a seasonal distribution of IPD incidence with higher rates in the winter 
months (Bogaert et al., 2004a), following the pattern seen for respiratory viral 
infection.  Those individuals with viral infection such as influenza have increased risk 
of developing IPD (O'Brien et al., 2000). This may reflect both upper respiratory viral 
infection predisposing to bacterial colonisation, and to lower respiratory viral illness 
affecting lung defences, as discussed below.  
1.2.4 Risk factors for S. pneumoniae disease 
Many risk factors have been identified which predispose to S. pneumoniae pneumonia 
or IPD.  These are listed in Table 1.1 (adapted from (van der and Opal, 2009)).  
Impaired pulmonary defence mechanisms predispose to pneumonia specifically, 
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whereas factors affecting immunity more generally also predispose to non-pneumonic 
bacteraemia and meningitis.  Globally, malnutrition and HIV infection are the most 
significant contributors to the increased burden of S. pneumoniae disease in 
developing countries (Janoff et al., 1992).  As well as increasing the risk of 
progression to disease once colonised, HIV positivity increases the risk of 
colonisation itself (Gill et al., 2008).  HIV may predispose to increased levels of S. 
pneumoniae disease in many ways.  These include direct effects on CD4 T-cells 
impacting on responses to colonisation (Malley, 2010), direct (Swingler et al., 2008) 
and indirect effects on antibody production, and effects of HIV infection on 
macrophage function (Gordon et al., 2005).  Specific mechanisms of defence against 
S. pneumoniae infection are discussed in more detail below. 
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Younger than 2 years 
Older than 65 years 
Isolated populations 
Poverty, crowding 





Chronic lung disease 
Poor mucociliary function 
Diminished cough reflex, aspiration pneumonitis 




Asplenia or hyposplenia 
Defects in humoral immunity (complement or immunoglobulin) 
HIV infection 
Genetic polymorphisms (e.g., complement, MBL) 
Single gene defects in innate immunity (IRAK-4, MyD88) 






Antecedent influenza and other viral infections 
Recent acquisition of a new virulent strain 
Severe liver disease 
Recent exposure to antibiotics 
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1.3 NASOPHARYNGEAL COLONISATION 
Although not a natural commensal of mice, Wu (Wu et al., 1997b) demonstrated that 
inoculation of the nasopharynx of mice with S. pneumoniae can establish stable 
colonisation, and this approach has provided the basis for much research into both the 
factors influencing colonisation and its subsequent effects on the host (Bogaert et al., 
2004a).   
1.3.1 Airway anatomy and the mucosal immune system 
The upper respiratory tract is outside the thorax and consists of the oro- and naso-
pharynx and larynx.  The lower respiratory tract is intra-thoracic and consists of the 
trachea, bronchi, bronchioles and most distally the alveolar spaces.  Specific mucosal 
immune processes operate complimentary to systemic immunity.  There are 
specialized organs within the respiratory tract which act as induction and effector sites 
for localized adaptive immune responses.  During colonisation, bacterial antigens 
within the lumen are in close relation to upper airway mucosa-associated lymphoid 
tissue (MALT) (Matthias et al., 2008).  In humans, this tissue is organized into 
adenoidal and tonsillar structures together forming Waldeyer’s ring (Figure 1.3a).  In 
mice, discrete aggregates of nasal-associated lymphoid tissue (NALT) are found on 
the hard palate (Figure 1.3b) (Heritage et al., 1997).  In addition, bacterial material 
can be transported to draining lymph nodes in the cervical region.  Induction of 
immune responses can occur both in NALT and in the draining cervical lymph nodes 
(Yamada et al., 2005).  Very small numbers of bacteria that enter the lungs during 
colonisation are rapidly cleared and may contribute to some degree to induction of 
responses within bronchial-associated lymphoid tissue (the lower respiratory MALT) 
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and draining mediastinal lymph nodes.  Immune responses may also induced in the 
spleen following systemic trafficking. 
 
A B               
 
Figure 1.3.  Anatomic location of upper airway mucosa-associated lymphoid tissue. 
A, Mouse.  Illustrated view of ventral surface of upper palate.   I, incisor tooth; L, ligament; M, 
molar tooth; N, NALT located on the dorsal surface of upper palate within the stippled area. 
(Image from Heritage, 1997).  B, Adenoid and tonsil location in human (Image adapted from 
Website of Patient UK). 
 
During subsequent antigen re-exposure, there are possible effector sites for the 
mucosal immune system, depending on the location of the infectious challenge.  If 
organisms are inhaled but not significantly aspirated into the lower respiratory tract, 
the nasopharynx itself is the effector site.  If effective, adaptive immune responses 
may prevent re-colonisation.  On the other hand, if organisms are aspirated into the 
lower respiratory tract, the lung itself is the effector site of mucosal immunity.  
Adaptive immune responses will operate in addition to innate reponses in limiting 
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infection, and may prevent the development of pneumoniae.  If bacteria invade the 
lungs, the systemic circulation and reticulo-endothelial system become the effector 
sites that may prevent systemic infection. 
1.3.2 Establishing colonisation 
The first defence mechanism that S. pneumoniae need to overcome on entering the 
nasopharynx is entrapment in lumenal mucus.  Negatively charged sialic acid residues 
on mucus polysaccharides are repelled by the majority of negatively-charged S. 
pneumoniae polysaccharide capsules and strains lacking capsule have greater binding 
to mucus, and can therefore be expelled with mucus from the nasopharynx (Nelson et 
al., 2007).  Thus the capsule is required to establish colonisation (Magee and Yother, 
2001), and it has been suggested that bacteria which colonise the nasopharynx 
evolved capsules specifically to avoid rapid clearance in mucus with the secondary 
effect of avoiding phagocytosis (Nelson et al., 2007).  Adherence to nasopharyngeal 
epithelium requires specific molecular interactions between the bacterium and the 
host cell (Bogaert et al., 2004a).  S. pneumoniae undergoes phase variation 
characterised by variation in the levels of capsule and surface protein expression 
(Weiser et al., 1994), which influences invasive potential.  Bacterial cells with lower 
levels of capsule expression (transparent phenotype) are enhanced in their capacity to 
adhere to respiratory epithelium compared with cells with greater amounts of capsule 
(opaque phenotype).  Whilst transparent S. pneumoniae can readily be washed from 
the nasopharyngeal lumen, further S. pneumoniae identified only through 
homogenisation of tissues are of the opaque phenotype (Briles et al., 2005).  The 
selective presence of opaque bacteria within the epithelium layer and deeper tissue 
suggests that they might be selected for by their resistance to phagocytosis. 
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Once mucus clearance is avoided, several specific molecular interactions enhance the 
capacity of bacterial cells to adhere to epithelial cells.  These operate over and above 
non-specific physico-chemical interactions to facilitate establishment of colonisation.  
The bacterial neuraminidase enzyme NanA cleaves sialic acid residues from 
polysaccharides on the surface of host cells.  This exposes N-acetyl-glucosamine 
residues to which PsaA can bind (Tong et al., 2002).  Attachment is aided further by 
the CBP PspC binding sugars such as sialic acid and lacto-N-neotrehalose as well as 
to the polymeric immunoglobulin receptor (pIgR) on host cells (Rosenow et al., 
1997).  As well as facilitating attachment, these interactions lead to activation of 
signalling pathways within epithelial cells, resulting in production of cytokines and 
type I interferons (Joyce et al., 2009).  Further signalling occurs through PRRs 
including TLR2, which recognise pathogen-associated molecular patterns such as 
bacterial lipoproteins (Aliprantis et al., 1999).  Epithelial cell activation leads to 
enhancement of bacterial binding through upregulation of surface expression of pIgR 
and platelet activating factor (PAF) receptor (PAFr), to which PC residues in S. 
pneumoniae cell wall can bind.  Pre-existing viral infection enhances the expression 
of PAFr and increases levels of cytokines including interleukin (IL)-1 and tumour 
necrosis factor (TNF)-α at the respiratory mucosa, which predisposes to bacterial 
transcytosis and invasive disease (Tuomanen, 1997).  Immunoglobulin (Ig) A1 and 
IgA2 are actively secreted across epithelial cells into the lumen, and can bind 
specifically to S. pneumoniae antigens.  However, the ability of IgA1 to enhance 
opsonophagocytosis is impaired as S. pneumoniae encodes an IgA protease, which 
cleaves the functional domain of IgA1.  This results in enhanced bacterial binding to 
epithelium but impaired opsonic clearance (Weiser et al., 2003).  Thus, through a 
range of specific and dynamic interactions, S. pneumoniae attach and can enter into 
nasopharyngeal epithelial cells. 
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Colonisation appears to involve a degree of superficial tissue invasion in addition to 
surface attachment (Briles et al., 2005).  This is aided by surface located serine 
proteases (Mitchell, 2003) in addition to recruitment of host plasminogen to the 
bacterial surface by S. pneumoniae enolase and glyceraldehyde-3-phosphate 
dehydrogenase (Hammerschmidt, 2006).  S. pneumoniae killing by mucosal 
apolactoferrin is prevented by its binding to PspA (Shaper et al., 2004).  Various other 
molecules directly affect the ability of S. pneumoniae to establish colonisation, 
including pneumococcal adherence and virulence factor A (PavA) which binds 
fibronectin (Pracht et al., 2005), an important host extracellular matrix protein. 
The nasopharynx is a competitive niche in terms of limited resources to bacteria, and 
the presence of longer term commensal species may inhibit the establishment of 
colonisation.  In both humans and mice (Borthen et al., 1987, Bernstein, 1992), 
viridans streptococci, lactobacilli and in some cases Staphylococcus aureus form 
important parts of the resident flora.  Viridans streptococci compete with S. 
pneumoniae, Haemophilus influenzae and S. aureus for occupancy of this niche as 
revealed in studies of the effects of antibiotics on nasopharyngeal flora (Faden et al., 
1990, GHAFFAR et al., 1999, Ghaffar et al., 2002).  Furthermore, direct competition 
takes place in the nasopharynx where hydrogen peroxide produced by S. pneumoniae 
kills lysogenic S. aureus (Selva et al., 2009).  This may explain why S. aureus 
colonisation rates increase as S. pneumoniae carriage falls (Bogaert et al., 2004a).  
Direct competition between individual strains of S. pneumoniae has also been shown 
in mice (Lipsitch et al., 2000).  Intra-species competition may involve pneumococcal 
bacteriocins whose expression is regulated by quorum sensing mechanisms (Dawid et 
al., 2007, Dawid et al., 2009).   
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1.3.3 Host immune response to colonisation 
Following colonisation of the nasopharynx, there is a brisk influx of neutrophils to the 
paranasal spaces (van Rossum et al., 2005, Nelson et al., 2007).  Whilst this is not 
sufficient to clear colonisation, this neutrophil influx is important in degradation of 
whole bacteria and release of antigenic material (Matthias et al., 2008).  This is 
enhanced through lysis of neutrophils by Ply.  M-cells sample luminal contents and 
traffic it to underlying nasal associated lymphoid tissue (NALT) for induction of 
immune responses.  Bacterial antigens can be taken up from the lumen by this 
mechanism.  Although direct invasion of M-cells by S. pneumoniae has not been 
described, this has been shown to occur with Streptococcus pyogenes (Park et al., 
2003).  Both antigen-specific B-cell and T-cell responses can be elicited from murine 
NALT (Matthias et al., 2008, Richards et al., 2010), and equivalent responses have 
been shown in the human equivalent, adenoidal mononuclear cells (MNCs) (Zhang et 
al., 2002, Zhang et al., 2007, Ivarsson et al., 2004). 
1.3.3.1 Antibody responses to colonisation 
The early success of vaccines inducing anti-CPS antibody responses established the 
belief that CPS was the only protective S. pneumoniae antigen against S. pneumoniae 
disease.  The presence of anti-CPS antibody became equated with immunity to S. 
pneumoniae, and its absence was taken to indicate lack of natural immunity following 
colonisation (Musher et al., 1986).  However, studies in both humans and animal 
models have revealed that multiple surface and intracellular antigens induce responses 
following natural exposure, many of which can be protective even in the absence of 
an anti-CPS response (Bogaert et al., 2004a).  Studies looking at anti-CPS IgG levels 
have been performed in several countries prior to the introduction of vaccines (Balmer 
et al., 2007, Kayhty et al., 2005, Shinefield et al., 1999).  Using highly-specific 
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enzyme-linked immunosorbant assay (ELISA) techniques with pre-absorption of non-
specific antibodies, pre-existing antibody responses have been demonstrated which 
are likely to reflect natural exposure.  For most capsular serotypes, levels remain low 
in the first year of life, rise in early childhood, and then rise further in the 20-30 age 
group.  This may reflect boosting following further exposure during parenthood.  
Observation of outbreaks in military camps has shown that natural exposure can 
induce anti-capsular antibodies to serotypes 7F and 8 (Musher et al., 1997).  Other 
studies have demonstrated that colonisation with only certain serotypes induces anti-
CPS serum IgG.  Carriage of serotypes 9V, 14, 18C, 19F and 23F by an individual or 
family member was associated with a rise in serotype-specific serum IgG, but this did 
not occur with serotype 6B (Goldblatt et al., 2005).  Children exposed to serotypes 
11A and 14 developed serum IgG responses, but those exposed to serotypes 6B, 19F 
and 23F did not (Soininen et al., 2001).  There is very little data on anti-CPS levels in 
the elderly, but one study suggests that serum IgG to only 2 of 6 serotypes studied 
falls with increasing age, whereas IgM to all serotypes falls (Simell et al., 2008).  
Salivary IgA specific to several serotypes has also been shown to rise following 
natural exposures or mucosal disease (Simell et al., 2002).  Thus, natural exposure to 
S. pneumoniae can induce both systemic and mucosal anti-CPS antibodies, but this 
appears to vary with serotype, and levels only rise significantly after the first year of 
life for most serotypes. 
There is now abundant data demonstrating anti-protein antibody responses develop 
following natural exposure.  Unlike anti-capsular responses, serum anti-protein IgG is 
rapidly detectable following S. pneumoniae exposure in the first year of life.  Serum 
IgG to PspA, PsaA and Ply is detectable from 6 months of age, and correlates with 
exposure or previous mucosal disease (Rapola et al., 2000).  Indeed, in Kenya, 100% 
of infants under one year of age had serum IgG to these protein antigens (Laine et al., 
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2004).  Antibodies to pneumococcal proteins in early infancy may be due to passive 
placental transfer.  Levels of antibodies to PhtD, PspC and LytC were found to fall 
after birth, but then rise again following natural exposure from just 4 to 5 months of 
age (Holmlund et al., 2009).  In addition to induction in infancy, there is also evidence 
that levels may be boosted following exposure in adult life.  In a longitudinal 
household study, serum anti- PsaA and anti-Ply rose amongst adults following 
carriage, although there was no change in anti-PspA (Goldblatt et al., 2005).  In the 
only published report of anti-S. pneumoniae protein IgG levels in the elderly, levels of 
serum IgG against all protein antigens investigated fell with increasing age (Simell et 
al., 2008), correlating with increasing risk of S. pneumoniae pneumonia and IPD.  
Allelic differences between S. pneumoniae strains such as for PspA can limit the 
cross-reactivity of antibodies, restricting the interpretation of some studies that link 
colonisation with immunogenicity.  Recent data suggests that adults have broader 
anti-PspA responses probably reflecting multiple exposures to different protein 
variants (Melin et al., 2008).  Salivary IgA to PspA, PsaA and Ply is also detectable 
from 6 months of age, and again correlates with exposure or previous mucosal disease 
(Simell et al., 2001).  Mononuclear cells isolated from human adenoidectomy samples 
have been shown to secrete antibodies against PspA, Ply, PsaA and CbpA (Zhang et 
al., 2002) suggesting that mucosal lymphoid tissue is an important site of antibody 
production.  These approaches to identify serum correlates of protective immunity 
have selected antigens based on evidence of protective efficacy in animal models or 
on the basis that they are surface expressed and thus antibody targeting them may be 
opsonophagocytic.  An alternative unbiased approach at the genomic scale has 
identified further antigens that are immunogenic in humans following natural 
exposure (Giefing et al., 2008), some of which are protective in animal models and 
are being developed as novel vaccine candidates.  Thus, natural exposure to S. 
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pneumoniae induces serum and mucosal anti-protein antibodies in infancy, with levels 
boosted during adult life, but probably waning in the elderly. 
From such human observational studies, it is not possible to disaggregate the 
immunising contribution of colonisation per se from that of milder disease such as 
otitis media or undiagnosed pneumonias.  Furthermore, due to the near universal 
prevalence of S. pneumoniae, it is not possible to identify never-colonised controls.  
Given the cross-reactivity between certain S. pneumoniae antigens and those of 
related species (Jefferies et al., 2007), such naturally acquired responses in some cases 
may also reflect exposure to other species.  In the only published human colonisation 
experiment to date, adult volunteers were colonised with serotype 23F or 6B strains of 
S. pneumoniae (McCool et al., 2002, McCool et al., 2003) and the antibody response 
to a range of putative antigens was assessed.  Colonisation induced serum IgG and 
salivary IgA against PspA and serum IgG against PspC, but not against several other 
protein antigens or the homologous CPS.  Pre-existing serum IgG against PspA 
correlated with protection against experimental colonisation in this model.  
Colonisation with the 23F strain lasted for 42 days, similar to mouse models using 
this strain. 
There is limited data on murine antibody responses to experimental nasopharyngeal 
colonisation as a model of first exposure in humans.  Experimental colonisation of 
BALB/c mice with a serotype 23 strain induced serum IgG to unidentified bacterial 
antigens, but none specific to the type 23 CPS.  Colonisation with a serotype 19 strain 
(Palaniappan et al., 2005) also induced non-capsular responses, with both serum IgG 
and mucosal IgA against PspA, PsaA, PspC and PdB (a Ply toxoid derivative (Paton, 
1996).  Colonisation of MF1 mice with D39, a serotype 2 strain, induced serum IgG 
against PspA, a weak serum IgM response to the type 2 capsule but again no serum 
anti-CPS IgG.  Colonisation of BALB/c mice with a serotype 14 strain did not induce 
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significant serum IgG against type 14 CPS, but did prime B-cells for more robust 
responses to pneumococcal conjugate vaccine (PCV) (Rabquer et al., 2007), perhaps 
reflecting a need for multiple B-cell antigen encounters prior to induction of anti-CPS 
responses.  Most recently, using unbiased analysis of antibody binding, the dominant 
responses to colonisation of C57/BL6 mice appeared to vary depending on colonizing 
bacterial strain (Roche and Weiser, 2010).  An unencapsulated serotype 4 strain 
(TIGR4) induced serum IgG to PspA and PpmA, unencapsulated 6A induced IgG to 
PsaA, and a wild-type 23F strain induced IgG only to PpmA.  IgG to other antigens 
was also induced but in lesser amounts.  Thus, colonisation may induce both systemic 
and mucosal antibodies specific to capsule or protein antigens, but there appears to be 
much variation both between various animal models and between differing human 
studies.  Although studies are limited, it appears that a single colonisation event in 
mice is sufficient to induce specific antibody responses but not to CPS antigens. 
1.3.3.2 T-cell responses to colonisation 
In addition to inducing antibody responses to bacterial antigens, colonisation with S. 
pneumoniae can induce the generation of antigen-specific memory T-cells (Zhang et 
al., 2009).  The polarisation of the T-cell response is influenced by the PRR signals 
received by the antigen presenting cell (APC) and the cytokines it produces in 
response (Gerosa et al., 2008).  Thus, IL-12 induces Th1 responses leading to 
interferon (IFN)-γ on recall; IL-1β, IL-6 and transforming growth factor (TGF)-β 
prime for Th17 cells responses leading to production of the signature cytokines IL-
17A, IL-17F and IL-22; IL-4 primes for Th2 responses leading to production of IL-4, 
IL-5 and IL-13.  In other circumstances, TGF-β can induce regulatory T-cells which 
produce IL-10 (Zhu and Paul). 
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There appears to be a propensity towards the development of Th17 responses at 
mucosal surfaces in response to antigen exposure, perhaps reflecting the relative 
abundance of TGF-β at such sites (Zygmunt et al., 2009, Pepper et al., 2009).  APC 
signals can also influence the generation of Th17 cells.  TLR2 (which recognises 
lipoproteins) (Reynolds et al., 2010) and nucleotide oligomerisation domain (NOD)-2 
(which recognises peptidoglycan) (van Beelen et al., 2007) signalling in the APC can 
polarise naïve T cells towards the Th17 lineage.  Cells of the Th17 lineage can rapidly 
expand in response to IL-23 production by various cells at the time of challenge 
(Khader et al., 2007).  The effects of IL-17A, IL-17F and IL-22 are discussed in the 
context of lung defence mechanisms below.  Nasopharyngeal colonisation of mice 
with live wild-type S. pneumoniae can induce a Th17-cell response both mucosally 
and systemically (Zhang et al., 2009).  This response was dependant on TLR2, 
perhaps necessary for induction of IL-6 in APCs.  Such responses can also be elicited 
using killed bacteria (Lu et al., 2008) or bacterial antigens alone (Basset et al., 2007) 
with appropriate adjuvants as described below.  Such Th17-cell responses are critical 
for both primary clearance of colonizing bacteria and in limiting subsequent re-
colonisation in mice. 
Evidence supporting such processes in humans is currently more limited.  Adenoidal 
tissue from healthy children undergoing adenoidectomy contains T-cells which 
proliferate in response to S. pneumoniae antigens such as Ply, and this appears to 
negatively correlate with carriage (Zhang et al., 2007).  Similarly, human peripheral 
blood mononuclear cells (PBMCs) from Gambian adults proliferate in response to as 
range of S. pneumoniae protein antigens, but such responses did not correlate with 
carriage (Mureithi et al., 2009).  IL-17 can be elicited in antigen-specific manner from 
culture of human PBMC’s with S. pneumoniae antigens but not from cells from 
newborn babies who are antigen naïve (Lu et al., 2008).  To date there is no reported 
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experimental evidence of an in vivo Th17 response following a colonisation event in 
humans. 
1.3.4 Clearance of colonisation 
1.3.4.1 Mice 
The mechanisms responsible for primary clearance of S. pneumoniae colonisation in 
mice have recently been elucidated.  It was noted several years ago that the time taken 
for three immunocompetent naïve mouse strains (BALB/c, CBA/J and C57Bl/6) to 
clear carriage of a serotype 23F S. pneumoniae strain was similar (McCool and 
Weiser, 2004).  Furthermore, this time was similar to that taken to clear the same 
strain in human colonisation experiments (McCool et al., 2002).  This time period 
(approximately 6 weeks) was suggestive of the need to induce a primary adaptive 
response.  Antibody-deficient mice cleared carriage at a similar rate to WT mice, but 
this was markedly delayed in mice lacking CD4 T-cells, suggesting a T-helper cell 
mediated mechanism (McCool and Weiser, 2004).  This clearance was subsequently 
shown to be mediated by mucosal Th17 cells (Zhang et al., 2009).  IL-17 produced by 
antigen-specific Th17 cells induces chemokine release from cells including 
nasopharyngeal epithelium (Roussel et al., 2010).  In turn this leads to both neutrophil 
and monocyte/macrophage recruitment to paranasal spaces and thus enhances the 
phagocytic clearance of colonizing bacteria (Zhang et al., 2009).  This clearance of 
primary colonisation is mediated primarily by monocyte/macrophages rather than 
neutrophils.  However, on re-challenge, a robust Th17 recall response leads to rapid 
recruitment of neutrophils to the nasopharynx leading to clearance of bacteria within 
two days. 
Such Th17-cell responses can also be primed using heat-killed whole S. pneumoniae 
cells if the adjuvant cholera toxin is included (Malley et al., 2005).  This protects 
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against subsequent wild-type S. pneumoniae colonisation in a non-serotype specific 
manner, dependant on a Th17-cell response (Trzcinski et al., 2008, Lu et al., 2008).  
Protective responses can be induced using single antigens such as CWPS (Malley et 
al., 2006) or combinations of purified S. pneumoniae proteins (Basset et al., 2007).  
CWPS is a zwitterionic PS, and such PS are processed and presented by the major 
histocompatibility complex (MHC) and recognised by the T-cell receptor (Duan et al., 
2008).  In this regard it behaves similar to a protein antigen.  Induction and recall of 
Th17-cell responses in this system are antigen-specific.  Protection against 
colonisation correlates with but was not mediated by serum antibody responses to 
PsaA, PspA and CWPS (Trzcinski et al., 2005). 
A murine model of Group A Streptococcus (GAS) nasopharyngeal infection has also 
been established (Park et al., 2003).  In this model, rapid clearance of re-colonisation 
is also dependent on an antigen-specific Th17-cell response (Wang et al., 2010a).  
This raises the possibility that such mechanisms may be broadly important in control 
of colonisation at this site.  No data have been reported to date for other organisms 
which occupy this niche.  Features of rheumatic fever and post-streptococcal 
glomerulonephritis, complications of GAS infection, bear similarities with auto-
immune disorders in which Th17 cells play a critical pathogenic role (Paust et al., 
2009, Lubberts, 2010).  Whether anti-GAS Th17 cells are important in the pathology 
of these complications remains to be discovered.   
1.3.4.2 Humans 
The serotype-specific success of PCV in reducing carriage of vaccine-type strains 
indicates that anti-CPS antibody is capable of limiting colonisation.  The precise 
serological correlate of PCV-induced protection against carriage is not known, but 
serum concentrations of specific IgG of 5µg/ml serum have been suggested (Goldblatt 
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et al., 2005).  However, there are limited data to suggest that such protection underlies 
natural immunity induced through exposure.  In a study of Gambian infants, previous 
carriage was associated with reduced risk of re-acquisition or shorter subsequent 
recolonisation only for serotype 14 (Hill et al., 2008).  A study of children attending 
day-care in Israel indicated that only for serotypes 6A, 14 and 23F was previous 
colonisation associated with reduced likelihood of homologous recolonisation.  This 
correlated with increased levels of CPS-specific antibody (Weinberger et al., 2008).  
Whilst for certain serotypes, there is evidence that naturally induced anti-CPS 
antibody is associated with protection against colonisation, a contrasting study from 
Bangladesh has shown immunity to colonisation to be serotype-independent (Granat 
et al., 2009).  Thus, naturally acquired anti-CPS antibodies may only make a limited 
contribution to the adaptive immunity to colonisation that emerges with age. 
Non-CPS antibody responses or T-cell mediated responses similar to the Th17 
responses described in mice may be more important.  In a UK study, S. pneumoniae 
colonised children were found to have lower serum and salivary IgG levels to proteins 
CbpA and Ply than uncolonised children (Zhang et al., 2006).  In Gambian children, 
higher serum anti-PsaA antibody levels were found in non-carriers.  However, such 
associations do not prove causality.  In a neonatal study in Papua New Guinea, where 
infants are colonised at a median of 17 days of life, higher umbilical cord blood anti-
Ply levels were associated with delayed acquisition, but anti-PspA was associated 
with earlier acquisition (Francis et al., 2009).  As for the murine studies, antibody 
responses may only be indicators of exposure history, and it is possible that Th17 
cells are the actual mediators of protection. 
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1.4 NATURAL IMMUNITY AGAINST S. 
PNEUMONIAE PNEUMONIA 
Many mechanisms converge to prevent or limit the development of pneumonia once 
S. pneumoniae enter the lungs.  Breakdown in one or more of these mechanisms 
renders an individual at increased risk of developing pneumococcal disease.  
Established risk factors are listed in Table 1.1 (van der and Opal, 2009), and reflect 
either abnormalities of respiratory tract structure and physiology, or of the supporting 
inflammatory and immunological systems.  Many of the environmental risk factors, 
including alcoholism, malnutrition, renal insufficiency, diabetes mellitus, smoking 
and pre-existing lung disease affect multiple protective mechanisms.  The ways in 
which prior or current viral infection predispose to S. pneumoniae infection are 
becoming increasingly unravelled at a molecular level (Sun and Metzger, 2008, 
Didierlaurent et al., 2008).  There appears to be redundancy between some of these 
immune mechanisms, especially where multiple mediators exist with similar 
functional properties.  However, the identification of individuals with genetic 
predisposition to pneumococcal pneumonia has identified where components of the 
immune system are essential for protection against S. pneumoniae and other 
pathogens (Picard et al., 2003).   
1.4.1 Innate mechanisms of protective immunity 
The bacteria entering the lung are swept along by the lining fluid which is constantly 
moved towards the pharynx by the ciliary escalator.  This is subsequently swallowed 
and bacteria destroyed by the digestive system.  This process of ciliary clearance can 
be neutralised by S. pneumoniae products such as hydrogen peroxide and the toxin 
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Ply (Feldman et al., 2002, Feldman et al., 2007).  The mucus itself contains abundant 
substances which assist in maintaining sterility of the lower airway.  These soluble 
factors have either intrinsic anti-microbial properties, or facilitate cellular anti-
microbial responses by binding to the bacterial surface and enhancing interaction with 
cell surface receptors of phagocytes. 
1.4.1.1 Respiratory tract soluble factors  
The respiratory tract lumen contains a broad range of soluble factors which aid in 
defence against infection.  Collectins such as surfactant proteins are found in alveolar 
lining fluid and mucous and can bind bacterial carbohydrate structures to assist both 
phagocytic clearance and triggering of innate immune responses to pathogens.  
Surfactant protein A facilitates S. pneumoniae phagocytosis mediated by alveolar 
macrophage (AM) scavenger receptors (Kuronuma et al., 2004), and deficiency of 
surfactant protein D leads to increased disease in mice (Jounblat et al., 2005).  
Collectins can also modulate signalling via TLRs (Shimizu et al., 2009).  Other 
antimicrobial molecules present in alveolar lining fluid include cationic antimicrobial 
peptides and proteins such as lysozyme, defensins and cathelicidins which can bind 
and kill bacteria directly (Kolls et al., 2008). Defensins and cathelicidins operate 
synergistically and kill microbes through disruption of the bacterial cell membrane 
(Schneider et al., 2005, Zanetti, 2005).  α-defensins can also block the ability of Ply to 
lyse host cells (Lehrer et al., 2009).  Other cell types may also be important for 
production of antimicrobial molecules.  Sub-lytic concentrations of Ply trigger human 
lung mast cell killing of S. pneumoniae in vitro via cathelicidin LL-37 (Cruse et al., 
2010), although the role of mast cells in host defence against infection in vivo is not 
known.  In addition to their direct antimicrobial role, certain antimicrobial proteins 
such as S100A8 and S100A9 play a role in facilitating phagocyte migration to alveoli 
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(Raquil et al., 2008).  Whilst some of these molecules are constitutively present, 
expression of many is induced in a cytokine dependent fashion following recognition 
of the presence of S. pneumoniae.  Their production by epithelial cells is closely 
regulated in parallel with that of chemokines in response to cytokine triggers (Kolls et 
al., 2008).  Although this role is traditionally ascribed to cytokines belonging to the 
IL-1 family (Cowland et al., 2003), other cytokines are also involved.  IL-17A acts 
upon the bronchial epithelial IL-17RA to induce production of human β-defensin-2 
and the chemokine CCL20 (Kao et al., 2004).  In mouse tracheal epithelium, IL-17 
and IL-22 synergise to induce lipocalin-2, critical for defence against Klebsiella 
pneumoniae (Chan YR FAU - Liu et al., 2009). 
S. pneumoniae has evolved mechanisms to overcome some of these defences.  The 
lytic action of lysozyme on peptidoglycan (PG) is evaded via enzymatic modification 
of PG by PgdA, an N-acetylglucosamine deacetylase, and Adr, an O-acetyl 
transferase (Davis et al., 2008).  Cationic antimicrobial peptides become entrapped 
within anionic CPS further limiting their ability to reach the bacterial cell membrane 
(Llobet et al., 2008).  A further mechanism of host defence is to limit the availability 
of iron at mucosal surfaces.  This is achieved through high-affinity sequestering 
molecules such as lactoferrin.  S. pneumoniae overcomes this limitation through the 
ability of pneumococcal PspA to bind lactoferrin (Hammerschmidt et al., 1999).  
Whilst the relative ability of many of these molecules to limit S. pneumoniae growth 
in vitro has been described (Lee et al., 2004), their contributions in vivo remain 
unclear and there may be extensive redundancy between them.  Overall, however, 
they contribute to a relatively hostile environment such that the majority of small 
aspirated inocula do not lead to established infection. 
Over 30 proteins constitute the complement system, which, when activated, contribute 
to orchestrated defence against invading microorganisms (Walport, 2001a, Walport, 
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2001b).  Binding and activation of complement components on the surface of S. 
pneumoniae leads to opsonophagocytosis and the induction of an inflammatory 
response.  The complement system can be activated through three distinct pathways, 
which appear to play different roles in defence against S. pneumoniae.  The classical 
pathway is activated by antibody–antigen complexes (Walport, 2001a) but also 
through microbial binding to soluble mediators such as serum amyloid protein (Yuste 
et al., 2007), SIGN-R1 (Kang et al., 2006), or C-reactive protein which binds PC 
(Mold et al., 2002).  Secondly, the lectin pathway is triggered by mannose binding 
lectin (MBL) or ficollin recognition of surface carbohydrate residues (Garred et al., 
2009).  Finally, the alternative pathway is continuously activated but controlled at low 
levels of activation unless amplified through interaction with foreign surfaces.  Using 
panels of knockout mice, it has been shown that the classical pathway appears most 
important in initial recognition of S. pneumoniae (Brown et al., 2002).  In particular, 
the role of natural cross-reactive IgM antibodies in triggering classical pathway 
activation was demonstrated.  These antibodies are known to bind PC residues in 
teichoic and lipoteichoic acids (Kolberg et al., 1997).  Once complement deposition is 
triggered, secondary amplification occurs via the alternative pathway (Brown et al., 
2002).    These finding are supported by the observation that humans with genetic 
deficiency in early complement pathway proteins such as C2 (Jonsson et al., 2005) are 
markedly predisposed to recurrent S. pneumoniae infection, due to inability to 
enhance phagocytosis through complement deposition (Yuste et al., 2008).  In 
contrast, the risk of infection is smaller in those with MBL deficiency (Roy et al., 
2002, Brouwer et al., 2009). 
S. pneumoniae has evolved several strategies to evade the deposition of complement.  
Most important of these is probably the polysaccharide capsule, which significantly 
limits the deposition of C3 on the bacterial surface (Hyams et al., 2010a).  In addition, 
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the initial activation of the complement pathway through C1q deposition can be 
inhibited by the abundant S. pneumoniae surface protein PspA (Tu et al., 1999).  The 
released pneumococcal exotoxin Ply also reduces the level of C3 deposition on the 
bacterial surface (Yuste et al., 2005).  Ply activation of the complement pathway is 
independent of specific antibody (Mitchell et al., 1991).  It has been suggested that 
Ply may be acting as a decoy for complement activation away from bacterial surface 
(Paterson and Mitchell, 2006).  Where C3 is deposited, it can be degraded by the 
surface protein PhpA (Hamel et al., 2004).  The ability of the alternative pathway to 
amplify complement deposition is also impeded by S. pneumoniae protein PspC 
which binds the complement regulatory protein factor H (Dave et al., 2004, Dave et 
al., 2001).  These mechanisms act together to limit the amount of complement 
deposition on S. pneumoniae, and attenuate its clearance from the airways. 
1.4.1.2 Cellular recognition of S. pneumoniae 
There are several cell types which express surface PRRs designed to respond to the 
presence of pathogens in the lower airway.  These include AM resident quiescently in 
the uninfected lung (Marriott and Dockrell, 2007) and structural cells including 
epithelial cells (Armstrong et al., 2004).  In addition, dendritic cells have processes 
interdigitating into the alveolar spaces, allowing contact with aspirated bacteria.  
Specialised subsets of lymphocytes operating as part of a non-adaptive immune 
response are also involved in recognition of S. pneumoniae.  These include both γδ-T-
cells (Nakasone et al., 2007) and NKT-cells (Kawakami et al., 2003) as discussed 
below.  The PRRs which recognise S. pneumoniae have recently been reviewed (van 
der and Opal, 2009).  They include TLRs, mannose receptors and scavenger receptors 
such as macrophage receptor with collagenous structure (MARCO).  Other soluble 
factors such as complement components and immunoglobulins which have bound 
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bacterial structures can trigger responses via complement receptors (CR) and Fc-
receptors (FcR).  Once internalised, further intracellular PRRs may trigger responses 
to the presence of bacterial products, including further TLRs, NODs receptors and 
other NOD-like receptors (NLRs).  Expression of PRRs can be affected by recent 
viral infection.  For example, IFN-γ produced by CD4+ and CD8+ T-cells in 
influenza infection leads to downregulation of MARCO expression on AMs, 
inhibiting clearance of S. pneumoniae and increasing the incidence of secondary 
bacterial infection (Sun and Metzger, 2008). 
Several of these mechanisms have been specifically implicated in host defence against 
S. pneumoniae.  TLR2 recognises lipidated bacterial motifs including lipoproteins and 
lipopeptides in conjunction with TLR1 (for triacylated lipoproteins) or TLR6 (for 
diacylated lipoproteins as found in S. pneumoniae) (Kang et al., 2009).  TLR4 was 
originally identified as the recognition molecule for lipopolysaccharide (LPS), the 
Gram-negative endotoxin (Poltorak et al., 1998).  However, it also mediates 
recognition of the S. pneumoniae toxin Ply (Malley et al., 2003).  Endosomal TLR9 
can recognise bacterial unmethylated CpG from S. pneumoniae (Albiger et al., 2007).  
The relative contribution of these TLRs towards in the host response to S. pneumoniae 
infection is still unclear, partly as a result of the use of differing models (Mogensen et 
al., 2006).  TLR2 deficiency leads to more severe disease in murine S. pneumoniae 
meningitis (Echchannaoui et al., 2002, Koedel et al., 2003).  Whilst in vitro, AM 
production of the important inflammatory mediator TNF-α is entirely dependent on 
TLR2 signalling, TLR2 signalling appears to make only a modest contribution 
towards host defence in murine models of S. pneumoniae pneumonia (Knapp et al., 
2004).  TLR2 signalling is modulated via S. pneumoniae peptidoglycan binding to 
lipopolysaccharide binding protein (LBP) (Weber et al., 2003).  Whilst increased 
quantities of LBP are found in alveolar fluid during S. pneumoniae pneumonia, its 
 67 
deficiency does not lead to more severe disease (Branger et al., 2004a).  In this 
context, TLR2 redundancy may be due to the ability of Ply to directly activate TLR4 
on the AM surface (Malley et al., 2003).  Similar to TLR2, the contribution of TLR4 
towards protection against S. pneumoniae pneumonia appears modest (Branger et al., 
2004b).  Other studies have shown TLR9 to be the most critical TLR for S. 
pneumoniae recognition in the lung (Albiger et al., 2005).  These differences may be 
due to the differing strains of both mouse and bacteria used.  However, the TLR 
adapter molecule myeloid differentiation factor 88 (MyD88) which is common to the 
function of all these TLRs is critical for induction of host responses irrespective of its 
upstream receptor (Albiger et al., 2005). 
Further PRRs, in addition to TLRs, may be important for S. pneumoniae defence.  
Intracellular NOD-2 recognises bacterial peptidoglycan (Girardin et al., 2003).  S. 
pneumoniae induces responses via NOD-2 in vivo, but its specific contribution is 
unclear (Opitz et al., 2004).  MARCO has been implicated in the recognition of S. 
pneumoniae (Arredouani et al., 2006), although its bacterial ligand remains 
unidentified.  S. pneumoniae CPS is recognised by the macrophage C-type lectin 
SIGN-R1 (Kang et al., 2004).  This appears important for defence against invasive 
infection and perhaps meningitis as it mediates S. pneumoniae CPS uptake by 
microglial cells (Park et al., 2009).  SIGN-R1 does not appear to be expressed on 
alveolar macrophages (Koppel et al., 2005).  However, splenic marginal zone 
macrophage uptake of S. pneumoniae and it products by SIGN-R1 facilitates 
production of natural IgM which is of crucial importance in defence against 
subsequent pulmonary S. pneumoniae infection.  Thus, SIGN-R1 is indirectly 
important in S. pneumoniae pulmonary defence. 
PRR activation leads to signalling via several intracellular pathways which are 
important in orchestrating an appropriate cellular response to S. pneumoniae.  These 
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include the canonical NF-κB pathway (Albiger et al., 2005) and various mitogen-
activated protein kinase (MAPK) pathways, all of which respond to the presence S. 
pneumoniae (Xu et al., 2008).  In theory, there appears to be a degree of redundancy 
between the multiple mechanisms of innate immune recognition of S. pneumoniae.  
However, clues to important pathways can be gleaned from experiments of nature 
where single gene mutations lead to increased susceptibility to disease.  Individuals 
deficient in either functional interleukin-1 receptor associated kinase (IRAK)-4 or NF-
κB essential modulator (NEMO) are at increased risk of bacterial infections including 
S. pneumoniae (Picard et al., 2003).  IRAK-4 is part of the downstream signalling 
between TLRs and NF-κB (Suzuki et al., 2002).  NEMO, formerly known as IKK-γ is 
subsequently required for NF-κB activation (Rothwarf et al., 1998).  A recent meta-
analysis of case-control studies investigating the contribution of single nucleotide 
polymorphisms (SNPs) in the genes encoding TLR2 and TLR4 did not show 
increased risk of S. pneumoniae infection (Brouwer et al., 2009).  This may be limited 
by sample size and the authors advocate a pooled biobank to overcome such 
challenges.  Thus, of the many PRRs capable of responding to the presence of S. 
pneumoniae in the lungs, at the least TLR signalling plays a non-redundant role in 
activating mechanisms of host defence. 
1.4.1.3 Gamma-delta T-cells and NKT cells 
Up to 10% of T-lymphocytes present in the lung under resting conditions express the 
γδ-T-cell receptor (TCR) (Wands et al., 2005).  Unlike classical αβ-TCR bearing T-
lymphocytes, TCR gene expression is oligoclonal (Takagaki et al., 1989).  Specific 
genotypes are enriched at different mucosal sites, with a preponderance of Vγ1+, Vγ4+ 
and Vγ6+ cells within the lung (Wands et al., 2005).  They make intimate contact with 
macrophages and dendritic cells.  The number of γδ-T-cells generally and Vγ4+ 
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specifically increases by 3 h following S. pneumoniae pulmonary infection in mice 
(Nakasone et al., 2007).  Survival and lung bacterial clearance of mice deficient in 
TCR-Vγ4 is reduced, and associated with impaired neutrophil recruitment and reduced 
levels of pulmonary TNF-α and the cytokine MIP-2 (Nakasone et al., 2007).  TCR-γ-/- 
mice have lower levels of IL-17 present in lung tissue and higher numbers of S. 
pneumoniae 4 h following infection (Ma et al., 2009). 
The S. pneumoniae ligands and their respective receptors triggering IL-17 production 
by γδ-T-cells are not known.  However, a subset of γδ-T-cells expressing TLR1 and 
TLR2 have been shown to produce the cytokines IL-17 and IL-22 in response to 
direct pathogenic stimulation with C. albicans or E. coli (Martin et al., 2009).  IL-17 
production in response to S. pneumoniae is further enhanced by the presence of IL-23, 
which may be released by APCs upon appropriate stimulation (see below).  Thus, γδ-
T-cells they form a potentially rich source of IL-17 prior to the recruitment of 
adaptive Th17 cells.  γδ-T-cells have also been reported to professionally 
phagocytose, process and present opsonised antigen on MHC class II (Wu et al., 
2009).  Whether this is the case for S. pneumoniae is unknown. 
Invariant NKT-cells expressing TCR-Vα14 have also been implicated in mediating 
pulmonary neutrophil recruitment following S. pneumoniae infection (Kawakami et 
al., 2003).  Their genetic deficiency leads to reduced levels of MIP-2 and TNFα in 
response to infectious challenge.  This defect can be overcome with exogenous 
administration of IFNγ (Nakamatsu et al., 2007).  The interpretation of such data is 
limited by the broader effects of specific gene knockouts on the intertwined elements 
of the developing immune system.  Thus, although defective in a single gene, other 
cell types may be affected in underappreciated ways, and the effects of deficiency in 
certain cell types on pathogenesis of S. pneumoniae pneumonia may not be as direct 
as suggested. 
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1.4.1.4 Inflammatory mediators 
Activation of AMs in early S. pneumoniae pneumonia leads to abundant production of 
TNF-α (Bergeron et al., 1998, Kirby et al., 2005).  Reciprocal cytokine signalling 
between AMs and epithelial cells leads to regulated production and release of 
cytokines.  Whilst both TNF-α and IL-1 lead to NF-κB activation, which is necessary 
and sufficient for neutrophil recruitment in pneumococcal pneumonia, there appears 
to be some redundancy between them (Jones et al., 2005, Quinton et al., 2007).  
Whilst there are extensive reports of increased risk of Mycobacterium tuberculosis 
infection in individuals receiving anti-TNF therapy for auto-immune disease, reports 
of S. pneumoniae pneumonia are fewer, despite greater exposure in populations 
receiving such therapy (Colombel et al., 2004).  Nonetheless, in animal models, 
administration of anti-TNF-α antibody worsened the course of pneumococcal 
pneumonia (Takashima et al., 1997), and regulation of such inflammatory factors may 
be crucial to outcome in human infection.  Other cytokines play important roles in 
defence against S. pneumoniae pneumonia.  IL-6 is an important inducer of acute 
phase protein production by the liver (Deban et al., 2009), include CRP and SAP 
which are important in opsonic enhancement of S. pneumoniae phagocytosis (Mold et 
al., 1982, Yuste et al., 2007).  IL-6 also delays neutrophil apoptosis and enhances 
neutrophil cytotoxic function (Biffl et al., 1996). An IL-6 promoter polymorphism 
which enhances IL-6 production protects against bacterial dissemination during S. 
pneumoniae infection (Schaaf et al., 2005).  The counterbalancing role of IL-10, a 
regulatory anti-inflammatory cytokine is crucial to avoid excessive inflammation 
including macrophage deactivation (Bogdan et al., 1991).  However, the highest IL-10 
levels are associated with worst outcome in CAP (Gallagher et al., 2003), suggesting 
that a fine dynamic balance exists in the regulation of these processes to achieve 
bacterial clearance and inflammatory resolution with the least lasting tissue damage. 
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The cytokines IL-17 (IL-17A), IL-17F and IL-22 are produced by inducible memory 
Th17 cells on antigen recall.  IL-17 is also produced by a range of innate cells in an 
otherwise naïve host, including γδ-T-cells and NKT-cells as discussed above (Cua 
and Tato, 2010).  In addition to this inducible lineage, a non-inducible naturally 
occurring CD4+ Th17 producing cell type known as nTh17 (as opposed to the now 
canonical iTh17 cell) has recently been implicated in airway responses to antigens 
(Tanaka et al., 2009).  Its contribution to host defence remains poorly understood.  
The effects of IL-17 and its lesser characterised homologue IL-17F (Tesmer et al., 
2008) are pleiotropic and have been extensively investigated in recent years for their 
pathogenic role in a range of autoimmune diseases (Ouyang et al., 2008) and their 
protective role against infection at the mucosa (Dubin and Kolls, 2008).  IL-17 
induces TNF-α, IL-1 and MMP-9 production by macrophages (Jovanovic et al., 
1998).  Neutrophils are activated and produce more myeloperoxidase and MMP-9 
(Zelante et al., 2007).  Both epithelial cells and fibroblasts (Aujla et al., 2007) produce 
a broad range of anti-microbial peptides, chemokines and other inflammatory 
mediators (reviewed in (Iwakura et al., 2008)).  Through induction of granulocyte 
colony stimulating factor (G-CSF), neutrophils are released from the bone marrow 
(Schwarzenberger et al., 2000).  These traffic to the lung under the influence of 
chemokines which ligate CXCR1 and CXCR2 as described in further detail below 
(Laan et al., 1999).  IL-17 induces expression of the polymeric Ig receptor enhancing 
transportation of IgA and IgM into the airway (Jaffar et al., 2009).  IL-22 has been 
specifically implicated in airway mucosal protection.  It increases lung epithelial cell 
proliferation and enhances transepithelial resistance to injury during Klebsiella 
pneumoniae infection (Aujla et al., 2008).  Innate and adaptive sources of IL-17 in the 





Figure 1.4.  Innate and adaptive mechanisms of IL-17 production 
IL-23 production by antigen presenting cells (APCs) including macrophages and dendritic 
cells stimulates IL-17 production from innate cells including γδ-T-cells and NKT cells.  Certain 
innate cells may also produce IL-17 in direct response to bacterial pathogen-associated 
molecular patterns (PAMPs).  Memory CD4+ Th17 cells are induced through presentation of 
antigen by APCs under the influence of cytokines including TGF-β and IL-6.  Re-presentation 
of the cognate antigens at the time of infection in the context of IL-23 production by APCs 
leads to further IL-17 production.  Amongst its diverse roles, IL-17 can enhance the response 
to infection by enhancing neutrophil recruitment through stimulation of chemokine (e.g. 
CXCL8) and G-CSF production and by inducing the production of bacteriocidal molecules 
such as β-defensins.  (Matsuzaki and Umemura, 2007). 
 
Chemokines which assist in the recruitment of leukocytes to sites of inflammation are 
critical for the early infiltration of neutrophils into alveolar spaces (Matsuzaki and 
Umemura, 2007).  Neutrophils expressing CXCR1 and CXCR2 receptors are attracted 
to chemokines including CXCL1 (also known as Gro-α in humans and KC in mice) 
and CXCL8 (also known as IL-8 in humans with murine functional homologue MIP-
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2) (Holmes et al., 1991).  They are expressed by epithelial cells in response to TNF-α, 
IL-1 and IL-17 as a result of NF-κB activation.  Further mediators including G-CSF 
and GM-CSF enhance bone marrow production of granulocytes and monocytes, 
leading to increased numbers in peripheral blood (Fossiez et al., 1996).  These are 
discussed under cellular recruitment below. 
1.4.1.5 Cellular recruitment 
In the absence of infection, alveolar fluid contains resident AMs maintaining a 
quiescent state through crosstalk with pulmonary epithelium (Hussell and Goulding, 
2010).  Resident AMs are of critical importance both for early recognition of S. 
pneumoniae, activation of further host defence mechanisms, and initial clearance of 
bacteria through phagocytosis (Xu et al., 2008).  By 4 h following infection there is a 
massive influx of neutrophils into the alveolar spaces (Dallaire et al., 2001, Bergeron 
et al., 1998), and these rapidly become the dominant phagocyte clearing bacteria 
(Knapp et al., 2003).  They continue to increase in number for 24 to 48 h (Dallaire et 
al., 2001).  Both host and pathogen-derived factors promote the massive neutrophil 
recruitment into the alveolar spaces.  Host factors produced in response to S. 
pneumoniae infection include CXC-chemokines (including IL-8 and GRO-α in 
humans or their counterparts macrophage inflammatory protein 2 [MIP-2] and KC in 
mice), in addition to complement component C5a, leukotriene B4 and PAF (Ali et al., 
1999).  These CXC-chemokines bind to the CXC receptors CXCR1 and CXCR2 on 
neutrophils.  CXCR2 is also expressed on monocytes, and appears necessary in 
preventing lethal pneumonia (Herbold et al., 2010).  Whether this requirement for 
CXCR2 reflects the specific importance of neutrophil recruitment or monocyte 
recruitment is not clear.  Bacterial factors promoting neutrophil recruitment and 
activation include N-formyl peptides such as N-formyl-methionyl-leucyl-
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phenylalanine (fMLP) which binds to formyl peptide receptors on neutrophils 
(Selvatici et al., 2006).  There appears to be redundancy between the various factors 
which recruit neutrophils, although this may depend on the relative number of 
bacteria.  When low bacterial inocula are present, the host-derived CXC chemokines 
are critical to neutrophil recruitment.  However, when the inoculum is large, these 
become redundant as bacterial N-formyl peptides are sufficient to achieve neutrophil 
chemotaxis (Gauthier et al., 2007).  Thus, enhanced chemokine responses would 
facilitate more rapid responses early in infection.  The precise mechanism of 
neutrophil recruitment from the vasculature into the alveolar spaces in S. pneumoniae 
infection is not fully understood.  It requires the soluble lectin galectin-3, but is 
independent of classical β2-integrin mediated adhesion (Nieminen et al., 2008). 
Peripheral neutropenia is a specific risk factor for enteric gram-negative sepsis, but 
not S. pneumoniae disease (Morrison, 2005).  However, neutropenic patients have an 
increased risk of all cause pneumonia (Rolston, 2001), and neutropenia worsens the 
prognosis in established IPD (Kumashi et al., 2005).  Studies using cyclophosphamide 
to render mice neutropenic prior to infection have suggested that neutrophils are 
essential in defence against S. pneumoniae pneumonia.  However, cyclophosphamide 
has much broader immunosuppressive actions.  Where neutrophils were selectively 
depleted by monoclonal antibody, there was little effect on lung bacterial clearance or 
cytokine responses, but enhanced inflammation and higher levels of bacteraemia and 
associated mortality.  Thus, unlike for Pseudomonas aeruginosa (Koh et al., 2009), 
neutrophils may not be entirely essential in protecting against in S. pneumoniae 
pneumonia.  Furthermore, excessive or uncontrolled neutrophil influx may lead to 
adverse effects.  Production of reactive oxygen species and release of matrix 
metalloproteinases from neutrophils (Cockeran et al., 2009) leads to host tissue 
damage as a bystander effect of the attempt to control infection. 
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Neutrophil recruitment is followed by monocyte recruitment as part of the 
orchestrated inflammatory response.  As neutrophils adhere to the blood vessel wall, 
azurocidin is released from granules, leading to endothelial cell activation and 
capillary leak, contributing to the development of pulmonary oedema (Linder et al., 
2010).  Released cathelicidins, defensins, cathepsin G and azuricidin promote the 
recruitment of monocytes which follow the neutrophil influx into lung tissue and 
alveolar spaces (Soehnlein and Lindbom, 2010).  The neutrophil granular protein 
proteinase-3 further induces chemokine release from neighbouring cells.  These 
chemokines then undergo N-terminal modification by released neutrophil serine 
proteases greatly enhancing their potency adding to the drive to monocyte recruitment 
(Soehnlein and Lindbom, 2010).  Once inflammation is established and in the face of 
a large bacterial burden, monocyte apoptosis leads to reduced production of 
inflammatory cytokines and limits neutrophil recruitment (Marriott et al., 2006), 
important for the eventual resolution.  Several factors contribute to actively switch off 
neutrophil recruitment to sites of inflammation.  A switch in the lipid mediators 
produced by platelets and epithelial cells with prostaglandin E2 and D2 (Levy et al., 
2001) promoting production of lipoxins and resolvins.  These can limit neutrophil 
recruitment (Chiang et al., 2006) and inhibit TNF signalling (Arita et al., 2007).  
Annexin 1 released by apoptotic neutrophils enhances their phagocytosis by 
monocytes and macrophages (Scannell et al., 2007).  This is supported by a change in 
the inflammatory milieu towards higher levels of anti-inflammatory IL-10, TGF-β and 
PGE2.  Neutrophil phagocytosis by macrophages limits macrophage production of IL-
23 (Stark et al., 2005), which drives neutrophil production and recruitment through 
IL-17 released by CD4+ T-cells, γδ-T-cells and NKT cells.  Thus, once neutrophils 
are phagocytosed, mechanisms driving further recruitment to sites of inflammatory 
are terminated. 
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Recruitment of lymphocytes also occurs during S. pneumoniae pneumonia.  Numbers 
of Vγ1+, Vγ4+ and Vγ6+ γδ-T-cells quickly rise following S. pneumoniae infection, and 
continue to do so for up to 10 days, after which time they slowly reduce (Kirby et al., 
2007).  This is in contrast to CD4+ and CD8+ T-lymphocytes for which changes are 
more modest (Kadioglu et al., 2000).  Numbers of AM and pulmonary dendritic cells 
also increase over this time period (Kirby et al., 2006).  Both pulmonary dendritic 
cells and AM appear capable of transferring antigenic material from the lungs to the 
draining lymph nodes facilitating the adaptive immune responses which occur 
following non-lethal pneumonia (Kirby et al., 2009).  
1.4.1.6 Neutrophil killing 
Neutrophils may kill bacteria in their extracellular environment by first trapping them 
in DNA and histone protein containing neutrophil extracellular traps (NETs) 
(Brinkmann et al., 2004).  However, S. pneumoniae CPS limits trapping by NETs, and 
subsequent killing by antimicrobial components is impeded by bacterial D-alanylated 
LTA (Wartha et al., 2007).  Bacterial phagocytosis by neutrophils is enhanced by 
recognition of complement or immunoglobulin G or M on the bacterial surface by 
neutrophil CRs or Fcγ receptors (FcγR) respectively (Berger et al., 1994).  The 
presence of the capsule inhibits both of these interactions (Hyams et al., 2010a).  
Once internalised, the phagosome merges with intracellular granules which contain a 
range of antimicrobial substances.  Unlike several other bacterial species, S. 
pneumoniae are not killed by reactive oxygen species or mechanisms dependant upon 
their generation (Kaplan et al., 1968).  Killing appears to be mediated by a range of 
antimicrobial proteins and peptides.  The presence of negatively charged surface CPS 
sensitises the bacterial cells to lysis by the α-defensins human neutrophil proteins 1 to 
3 (Beiter et al., 2008).  In addition, serine proteases contained in neutrophil 
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azurophilic granules including neutrophil elastase, cathepsin G and proteinase-3 can 
kill S. pneumoniae (Standish and Weiser, 2009).  Thus, neutrophils possess several 
mechanisms by which internalised bacteria can be killed.  Similar processes may be 
involved in macrophage killing of internalised S. pneumoniae, since they can kill S. 
aureus by means of proteinases such as elastase (Houghton et al., 2009).  There are 
probably degrees of synergy and redundancy between these various mechanisms. 
1.4.2 Adaptive mechanisms of protective immunity 
The relative contributions of specific antibody and cell mediated immunity to S. 
pneumoniae have recently been reviewed (Malley, 2010).  These responses may be 
induced naturally by S. pneumoniae carriage, mucosal disease, survival following 
infection, cross-protection from other organisms, or artificially induced through 
vaccination.  Vaccine-mediated protection is specifically discussed later.  Adaptive 
immunity against extracellular bacteria has traditionally been attributed to opsonic 
antibodies enhancing neutrophil phagocytosis.  This paradigm has recently been 
challenged by data demonstrating the ability of non-CPS antibodies to effect 
protection.  The place of Th17 cells in protection against S. pneumoniae 
nasopharyngeal colonisation (Zhang et al., 2009, Lu et al., 2008) has already been 
discussed.  It is not currently known whether adaptive Th17 cells have a role in 
augmenting protection against S. pneumoniae pneumonia.  It is of note, however, that 
Th17 cells can mediate protection against lung disease caused by Bordatella pertussis 
(Higgins et al., 2006) and M. tuberculosis (Khader et al., 2007).   
1.4.2.1 Antibody-mediated adaptive immunity 
Pre-existing IgA and IgG within alveolar fluid may enhance protection by opsonising 
bacteria, thereby enhancing S. pneumoniae phagocytosis by AMs and recruited 
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neutrophils.  Although traditionally ascribed only to antibodies against CPS, it is now 
clear that antibody to surface proteins (Jomaa et al., 2005) can enhance phagocytosis 
of bacteria, at least in vitro.  Antibody may further limit disease progression by 
neutralising virulence factors that aid invasion e.g. Ply (Garcia-Suarez et al., 2004), or 
those which subvert host defences such as PspA (Shaper et al., 2004, Tu et al., 1999).  
Finally, opsonic serum IgG can facilitate clearance of bacteria from the blood via 
macrophages of the reticulo-endothelial system (Holdsworth et al., 1989).  All of 
these mechanisms depend on pre-existing levels of mucosal or systemic antibody as 
secondary recall responses from memory B-cells re-exposed to S. pneumoniae 
antigens during disease are too slow to assist in protection against rapidly progressive 
S. pneumoniae pneumonia.  The importance of antibody-mediated protection against 
S. pneumoniae disease is reflected in the strong tendency to develop sino-pulmonary 
S. pneumoniae infection in patients with antibody deficiency syndromes.  These 
include X-linked agammaglobulinaemia and common variable immune deficiency 
(Picard et al., 2003).  The incomplete protection against recurrent pulmonary infection 
in common variable immune deficiency patients receiving prophylactic intravenous 
immune globulin has been attributed to the need for natural IgM to protect against 
such infection, which is lacking in commercial intravenous immunoglobulin 
preparations (Carsetti et al., 2005).  IgA deficiency is common affecting 1/400 
individuals, but not consistently associated with predisposition to S. pneumoniae 
infection.  Since S. pneumoniae produces an IgA1ase enzyme (Wani et al., 1996), 
IgA1 may be redundant in defence against S. pneumoniae at the mucosal surface 
where it is the dominant IgA subclass (Kett et al., 1986).  The specific contribution of 
IgA2 (the dominant subclass in the serum) is therefore not clear.  Variability in 
tendency toward S. pneumoniae infection in these susceptible IgA-deficient patients 
may reflect associated deficiency of IgG subclasses (Picard et al., 2003).  Finally, 
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polymorphisms of FcγR may affect the ability of phagocytes to recognise and respond 
to antibody-opsonised S. pneumoniae (Endeman et al., 2009), although the proven 
association between such polymorphisms and predisposition to S. pneumoniae 
infection remains weak to date. 
The success of capsule type-specific serum therapy to treat S. pneumoniae pneumonia 
historically demonstrates efficacy against disease, but may be operating to limit 
septicaemia and give time for other innate mechanisms to resolve the pulmonary 
infection (Austrian, 1984).  Immunisation with CPS antigens offers strong protection 
against serotype-specific IPD, but weaker protection against non-invasive pneumonia. 
In mouse models IgM against PC residues, either natural IgM or induced through 
exposure to other bacterial species such as H. influenzae may also offer protection 
against S. pneumoniae IPD (Goldenberg et al., 2004, Brown et al., 2002, Briles et al., 
1981, Baxendale et al., 2008, Carsetti et al., 2005), although its role in protecting 
humans is not known.  There is now abundant evidence from murine models that 
antibodies against S. pneumoniae proteins can protect against both pneumonia and 
invasive disease.  IgG binding PspA (Briles et al., 2003), PhtE (Hamel et al., 2004), 
Ply-derivatives (Alexander et al., 1994), the combination of SlrA and IgA1 protease 
(Audouy et al., 2007) or the combination or PiaA and PiuA (Jomaa et al., 2006) are 
protective against pneumonia.  These and additional antigens will be discussed further 
in the context of protein vaccination below. 
1.4.2.2 T-cell-mediated adaptive immunity 
S. pneumoniae antigen-specific memory T-cell responses may also offer protection 
against pneumonia.  Such T-cells may be located within the lung tissue or in draining 
lymph nodes.  The role of IFN-γ producing Th1 cells in acquired protection against S. 
pneumoniae is unclear, and individuals with defects of the IFN-γ / IL-12 / Th1 axis 
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are not predisposed to S. pneumoniae infections (Picard and Casanova, 2004).  Th2 
cell production of cytokines such as IL-4, IL-5 and IL-13 is of great importance in 
directing an appropriate B-cell response following initial antigen encounter 
(Mosmann et al., 1986), but it is not clear how recall production of these cytokines 
during subsequent disease would assist in protection.  Th17 cells could assist in 
protection by enhancing levels of mucosal and systemic IL-17 and IL-22 during early 
infection.  The roles of these cytokines have been discussed above in their innate 
context, in terms of phagocyte recruitment and activation, epithelial cell activation, 
chemokine and antimicrobial peptide production.  Adaptive responses leading to their 
further production would augment levels of these cytokines already produced in the 
innate response to infection by other cell types. 
The role of Th17 cytokines in vaccine-mediated protection against infection has been 
recently reviewed (Lin et al., 2010).  Pulmonary Th17-cell responses induced by prior 
systemic immunisation with Bordetella pertussis antigens are sufficient to protect 
against pulmonary B. pertussis disease (Higgins et al., 2006).  Th17 cell responses to 
M. tuberculosis antigens can protect against pulmonary M. tuberculosis infection by 
enhancing recruitment of protective Th1 cells into lung (Khader et al., 2007).  
Induction of a pulmonary Th17-cell response by nasal immunisation with live 
attenuated Pseudomonas aeruginosa was recently shown to protect against P. 
aeruginosa pneumonia (Priebe et al., 2008).  In contrast, an over-exuberant adaptive 
Th17 response can also be detrimental in response to a micro-organism, leading to 
excessive inflammation, as recently shown for Helicobacter pylori (DeLyria et al., 
2009). 
The importance of T cells for adaptive immunity against S. pneumoniae is supported 
by the association of several T-cell immunodeficiency syndromes with increased risk 
of S. pneumoniae disease in humans.  Severe combined immune deficiency and other 
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T-cell immunodeficiencies affecting CD4+ T-cells predispose at least through effects 
on antibody production (Picard et al., 2003).  MHC class I deficiency which leads to a 
lack of CD8+ T-cells has also been associated with S. pneumoniae disease but the 
mechanism is not clear.  Deficiency of the signalling molecule STAT3, a cause of 
hyper-IgE syndrome (also known as Job syndrome) (Minegishi et al., 2007), is 
associated with mucosal infections (primarily caused by Staphylococcus aureus and 
fungal including Candida) and pulmonary infections (primarily caused by S. aureus) 
(Milner et al., 2008).  As a result of signal transduction and activator of transcription 3 
(STAT3) deficiency, there is failure of APCs to produce IL-6, essential for developing 
Th17 cell responses to these specific pathogens.  There are weaker associations 
between hyperIgE syndrome and S. pneumoniae infection (Buckley and Becker, 1978, 
Geha and Leung, 1989, Grimbacher et al., 2008).  The effect of lack of specific Th17 
cells on nasopharyngeal carriage of bacteria has not been reported.  The induction of 
Th17-cell responses following nasal colonisation with S. pneumoniae has been 
discussed previously.  Whilst this response is sufficient and necessary to clear 
recolonisation of a previously colonised mouse, its role in protection against invasive 
disease is still not clear. 
1.4.2.3 Protective responses following colonisation with live attenuated S. 
pneumoniae 
There are no published reports to date on the ability of nasopharyngeal colonisation 
with potentially virulent wild-type S. pneumoniae to induce protection against 
subsequent pneumonia.  There are two reports utilising attenuated mutant strains of S. 
pneumoniae to induce protection (Roche et al., 2007, Richards et al., 2010).  In these 
models, carriage with either Ply-deficient or capsule-deficient strains is attenuated in 
terms of colonisation density and duration.  Although rapidly cleared from the 
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nasopharynx, unencapsulated strains of S. pneumoniae are immunogenic in C57Bl/6 
mice, inducing both serum IgG and mucosal IgA to several S. pneumoniae proteins 
(Roche et al., 2007).  Such vaccination is protective against subsequent lethal 
pneumonia, including in IgA deficient mice (Roche and Weiser, 2010), but not in 
µMT mice (which lack all classes of antibody), suggesting that antibody is required 
for this protection.  In this study, it was observed that nasal vaccination of MHCII-/- 
mice (that congenitally lack CD4 cells) with an unencapsulated strain was also not 
protective (Roche et al., 2007).  It is incorrect to conclude from this, however, that 
memory CD4 T-cells (including Th17-cells) necessarily play a role in colonisation-
induced protection against lethal pneumonia, since the lack of CD4 cells at the time of 
colonisation will impact on the nature of the antibody responses that develop.  In this 
model, vaccination with a PspA/Ply-deficient double mutant was also immunogenic 
and protective. 
Nasal vaccination with a single mutant Ply-deficient strain of D39 can also protect 
against subsequent lethal pneumonia challenge (Richards et al., 2010).  This strain 
was carried for one week, whereas its parent WT strain was carried for over four 
weeks.  Previous data has suggested Ply-deficient strains are carried for longer than 
their parent WT (van Rossum et al., 2005), attributed to reduced lysis of neutrophils 
following bacterial phagocytosis leading to a weaker Th17-cell response (Matthias et 
al., 2008).  Mouse and bacterial strain differences may explain the more rapid 
clearance observed by Richards (Richards et al., 2010).  Weak serum anti-capsule 
IgM and anti-PspA IgG responses were also reported to be induced by the Ply 
deficient mutant.  In both the work of Roche and Richards, cross-protection against a 
heterologous serotype was demonstrated.  Can this be extrapolated to imply that 
natural exposure to a WT strain of S. pneumoniae induces adaptive protective 
immunity against pneumonia?  Lack of either capsule or Ply affects the interaction of 
 83 
S. pneumoniae with the host immune system.  This includes interactions with 
phagocytic cells (Hyams et al., 2010a), complement (Tu et al., 1999) and T-cell 
responses (Kadioglu et al., 2004).  Since direct comparison with WT strains was not 
made in these studies, it is not clear whether similar protective responses would occur 
in a more natural WT setting.  Furthermore, a direct comparison of the effects of 
colonisation with mutant versus WT strains may elucidate important factors required 
in naturally acquired immunity.  
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1.5 VACCINE-MEDIATED IMMUNITY AGAINST 
S. PNEUMONIAE PNEUMONIA 
1.5.1 Vaccination aims and approaches  
Systemic immunisation with CPS-based vaccines originally demonstrated efficacy in 
preventing IPD (Smillie et al., 1938).  In this context, opsonic IgG to CPS is an 
established serotype-specific correlate to protection against IPD (Jokinen et al., 2004).  
Conjugation of CPS to carrier proteins led to improved immunogenicity and 
protection in infants (Black et al., 2000).  This included evidence of protection against 
pneumonia and changes in colonisation dynamics leading to herd immunity (Lipsitch, 
2001).  However, the serum correlates of anti-CPS antigen-induced protection against 
pneumonia and colonisation are not clear.  Other vaccine approaches under intense 
investigation include S. pneumoniae protein-based vaccines, heat-killed whole 
bacterial cells and live attenuated organisms (both S. pneumoniae and other 
organisms) carrying S. pneumoniae antigens.  It is important to recognise that 
responses to vaccination may be influenced by pre-existing natural immunity to S. 
pneumoniae, due to either passively transferred maternal antibody in infancy 
(Holmlund et al., 2009), or following natural exposure (Baxendale et al., 2000). 
Whilst current vaccines are only licensed for systemic administration by 
intramuscular injection, protection against mucosal disease and colonisation may be 
greater following mucosal administration.  These approaches along with their 
successes and limitations are discussed further below. 
The ultimate aim of vaccination against S. pneumoniae is to prevent disease.  
However, certain vaccination approaches may lead to protection against subsequent 
colonisation in addition to protection against disease (O'Brien et al., 2007).  
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Elimination of colonisation by common S. pneumoniae strains could have major 
effects on the bacterial ecology of the nasopharynx, allowing increased colonisation 
with other potentially more virulent S. pneumoniae strains or even other bacterial 
pathogens. Alternatively, this ecological niche could be filled by weakly invasive S. 
pneumoniae strains hence resulting in a new stable but lower incidence of IPD.  The 
dynamics of colonisation are complex and it is difficult to predict the outcome of such 
a strategy.  
1.5.2 Pneumococcal plain polysaccharide vaccines 
Immunisation with purified S. pneumoniae CPS antigens, known as plain 
pneumococcal polysaccharide (PPS) has been known to protect against lethal disease 
for nearly one century (Smillie et al., 1938).  A 23-valent PPS vaccine 
(Pneumovax™) and its derivatives have been in use for over 20 years.  It contains 
CPS from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F (Summary of Product Characteristics, Sanofi Pasteur 
MSD Ltd, Berkshire, England).  Its efficacy is greatest (approximately 50-80%) in 
protecting immunocompetent adults against IPD (Fedson and Scott, 1999) (Mangtani 
et al., 2003, Fine et al., 1994).  However, it does not appear to protect against non-
bacteraemic pneumonia (Jackson et al., 2003) or other mucosal disease such as 
chronic bronchitis or otitis media.  As a T-independent vaccine, PPS is not 
immunogenic or protective in infants (Fedson and Scott, 1999).  This has been 
attributed to several factors relating to immunological immaturity, including function 
of B-cells, the splenic marginal zone, germinal centre immaturity and limited bone 
marrow niches to establish plasma cells (Pollard et al., 2009, Siegrist and Aspinall, 
2009).  A combination of intrinsic B-cell factors and those relating to supporting 
microenvironments also lead to poor immunogenicity in the later adult life (Siegrist 
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and Aspinall, 2009).  When PPS is immunogenic, it does not prime for memory, 
requiring repeat doses every five years (Butler et al., 1993).  It is recommended for 
use in developed countries in high-risk adults, including those over 65 years of age, 
with predisposing cardiopulmonary disease or who are immunocompromised 
including HIV infection and sickle-cell disease.  However, evidence of efficacy in 
these specific populations is weak, particularly in resource-poor countries.  Thus, PPS 
vaccines are not a priority recognised by the World Health Organisation (WHO, 
2008), which instead supports more widespread use of pneumococcal conjugate 
vaccines (PCV) in infancy to reduce the burden of colonisation in high risk 
communities.  PCV were developed to overcome many of these obstacles and are 
discussed below. 
1.5.3 Pneumococcal conjugate vaccines 
The ability to conjugating a T-cell independent PS antigen to a carrier protein to 
improve immunogenicity in infants was first demonstrated for the pathogen 
Haemophilus influenzae type b (Anderson et al., 1985).  Using the same strategy and 
indeed same carrier protein (the diphtheria toxoid CRM197), 7-valent PCV were 
developed and found to be immunogenic (O'Brien et al., 1996, Ahman et al., 1998).  
In a landmark study involving 38,000 children in California, S. pneumoniae vaccine 
serotype bacteraemia and meningitis were nearly eliminated (Black et al., 2000).  This 
has been replicated in further studies (Pavia et al., 2009).  More modest reductions 
have also been seen for mucosal diseases including non-bacteraemic pneumonia and 
otitis media (Shinefield and Black, 2000), including a decline in radiologically 
confirmed pneumonia of up to 35%.  PCV has also been shown to be immunogenic in 
other high risk groups such as following bone marrow transplantation (Molrine et al., 
2003) (Meisel et al., 2007).  Unlike PPS, PCV is also effective in preventing IPD in 
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HIV-infected adults in areas of high S. pneumoniae burden (French et al., 2010).  The 
WHO Strategic Advisory Group of Experts has recently recommended the 
introduction of PCV into developing countries and significant funds are being made 
available to support this effort (O'Brien et al., 2009).  In a recent immunogenicity and 
safety study, PCV was more immunogenic in terms of antibody levels and 
opsonophagocytic killing than PPS in the elderly (de Roux et al., 2008).  Responses to 
PCV are different in the elderly compared to younger adults, particularly in terms of 
recruitment of memory B cells (Baxendale et al., 2010b, Baxendale et al., 2010a).  
The efficacy of PCV in the elderly remains to be tested.  In addition to reduction in 
disease, PCV use has led to significant falls in carriage rates in the immunised 
population (Dagan et al., 2002).  As strains are often transferred between family 
members, this has led to changes in carriage amongst non-immunised persons, with 
consequential falls in disease rates due to herd immunity (Whitney et al., 2003, 
Givon-Lavi et al., 2003).  An unanticipated further benefit has been reduction in 
carriage of antibiotic-resistant strains in vaccines recipients, since the most commonly 
carried strains are most exposed to antibiotics (Kyaw et al., 2009). 
The cost and physical bulk of these glycoconjugates limits the number of serotypes 
that can be included in a vaccine formulation.  However, work to improve the 
synthesis of PS for use in PCV is ongoing and may facilitate the inclusion of larger 
numbers of serotypes in the future.  The 7 serotypes included in the most widely used 
vaccine Prevenar™ (4, 6B, 9V, 14, 18C, 19F, 23F) were chosen as they represent 
over 80% of IPD causing strains in many developed countries (Butler et al., 1995).  
However, they represent only 50% IPD isolates at most in many developing countries 
(Hausdorff et al., 2000b, Hausdorff et al., 2000a), which inherently limits their 
impact.  To partly overcome this, newer PCV containing either 10 or 13 PCV have 
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recently been licenced, offering protection against serotypes 1, 3, 5, 6A, 7F, 19A in 
addition (Bryant et al., 2010). 
Loss of vaccine strains from their nasopharyngeal ecological niche has been 
associated with an increase in carriage and invasive disease by non-vaccine serotypes 
(Hanage, 2008, Melegaro et al., 2010).  This may be due to a combination of direct 
replacement, genetic capsule switching between strains and pre-existing trends.  The 
impact of this has been reported to differ in the USA and the UK.  In the USA, there 
appears to be a sustained reduction in IPD over an 8-year period since PCV 
introduction (Pilishvili et al., 2010).  In the UK, replacement disease caused by non-
vaccine serotypes is believed to be the cause of little overall change in IPD rates 
compared to before PCV introduction (Kaye et al., 2010).  These differences may 
reflect operational factors underlying data collection, but concern exists as to the 
longer term utility of this approach and the feasibility of reformulating such vaccines 
on an ongoing basis and for different geographical locations.  Furthermore, prior 
natural exposure to CPS antigens affects the nature of the immune response to 
subsequent immunisation (Baxendale et al., 2000)  There is emerging evidence 
natural exposure to CPS as a T-independent antigen can lead to hyporesponsiveness to 
subsequent immunisation with PCV, reducing its efficacy (Dagan et al., 2010).  This 
may limit the efficacy of PCV in population with high neonatal exposure rates where 
need is greatest.  To enhance mucosal protection in addition to systemic, the 
immunogenicity of mucosally administered PCV has been investigated.  Whilst PCV 
is immunogenic via this route, protection against invasive disease may be improved 
by the inclusion of various adjuvants such as the cytokine IL-12 (Lynch et al., 2003).  
Thus, PCV have been and continue to be highly effective vaccines.  Shortcomings 
remain and there is therefore much interest in alternative approaches to preventing S. 
pneumoniae disease.  
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1.5.4 Peptide mimotopes 
In an attempt to overcome some of the limitations of CPS-based vaccines described 
above, peptide mimotopes of CPS antigens have been investigated (Valadon et al., 
1996).  Using either rational design of antigens (Westerink et al., 1995) or phage 
display technology (Oldenburg et al., 1992), peptides are identified which 
immunologically mimic the parent CPS.  Immunisation leads to antibodies which not 
only bind the peptide antigen but also the CPS structure that it mimics (Westerink et 
al., 1995).  Thus, the mechanism of inducing protection differs to that of the parent 
CPS, but the method of effecting protection is the same, namely, opsonophagocytic 
anti-CPS antibody.  The advantage over using CPS antigens themselves is that the 
peptide mimotopes will be T-dependent antigens and thereby immunogenic in 
infancy.  In addition, they would be cheaper and simpler to manufacture than CPS 
vaccines (Valadon et al., 1996).  Furthermore, inclusion of multiple peptides 
representing broad capsular serotypes would be more feasible than for CPS antigens 
whether as PPS or PCV.  To date, only a limited number of S. pneumoniae CPS 
mimotopes have been identified (Buchwald et al., 2005, Smith et al., 2009), and there 
are no current human trials.  They may have a role in inducing antibodies against 
carbohydrate antigens that are otherwise tolerated by the immune system, such as 
Neisseria meningitides type B capsular antigen (Park et al., 2004) or tumour antigens 
(Kieber et al., 1997). 
1.5.5 Protein vaccines 
To overcome serotype-specificity of vaccine antigens, many S. pneumoniae species-
wide proteins have been investigated.  In addition to their ability to overcome 
serotype restriction, protein vaccines are easier and cheaper to manufacture that CPS 
based vaccines (Bernatoniene and Finn, 2005).  Protein vaccines are immunogenic in 
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infants and responses to them are boosted upon repeat immunisation.  For certain 
abundant surface proteins such as PspA, genetic variation leads to families and clades 
of proteins, with some limitations to cross-protection (Hollingshead et al., 2000).  
Other protein antigens, in particular lipoproteins such as PsaA, PiuA and PiaA, are 
heavily conserved between S. pneumoniae strains (Brown et al., 2001b)and could 
potentially provide full cross-protection.  Proteins may need modification to render 
them non-toxic, as is the case with PdB, a derivative of Ply (Briles et al., 2003).  
Whilst concerns have been expressed regarding the accessibility of surface proteins to 
antibody in vivo due to CPS (Gor et al., 2005), there are now abundant reports of 
protective efficacy of this approach in murine models of S. pneumoniae disease, in 
particular when proteins are used in combination (Briles et al., 2003).   
Antibodies binding S. pneumoniae proteins may protect in several ways.  They may 
opsonise the bacteria for enhanced phagocytosis (e.g. PiaA and PiuA (Jomaa et al., 
2005)).  Disease may be prevented by antibodies blocking S. pneumoniae surface 
proteins required for either colonisation (e.g. PsaA (Pimenta et al., 2006)) or in 
establishing disease (e.g. PspA(Briles et al., 2003), PsrP (Rose et al., 2008).  
Antibodies can neutralise the toxin Ply (Alexander et al., 1994).  In addition to this, 
neutralisation of mechanisms by which S. pneumoniae evades the host immune 
response to infection may shift the balance in the host’s favour, e.g. by preventing 
PspA interfering with complement activation (Tu et al., 1999).   It appears that 
immunisation with combinations of proteins leads to stronger protection.  The 
combination of PspA and PsaA protects better against colonisation than either antigen 
alone whereas the combination of PspA and Ply protects better against invasive 
disease than either antigen alone (Briles et al., 2000a).  This may be due to both 
synergy in opsonophagocytosis and between other mechanisms of antibody-mediated 
protection.  Other S. pneumoniae proteins protective in animal models include the 
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choline binding protein PspC (Ogunniyi et al., 2001), lipoproteins SlrA (Audouy et 
al., 2007) and other cell wall anchored proteins including NanA (Long et al., 2004) 
and IgA1 protease (Audouy et al., 2007).  Antibodies to the surface located protein 
PhtD (Adamou et al., 2001) are also protective and this may involve blockade of 
complement evasion (Melin et al., 2010).  Immunisation with the more recently 
characterised S. pneumoniae pilus proteins RrgA and RrgB is also protective against 
disease (Gianfaldoni et al., 2007). 
S. pneumoniae proteins have also been administered mucosally either as purified 
proteins with accompanying adjuvant (Wu et al., 1997a) or expressed on other 
avirulent organisms including Lactobacillus casei (Ferreira et al., 2009) and 
genetically engineered live attenuated Salmonella enterica serovar typhimuirum (Xin 
et al., 2009, Wang et al., 2010b).  The mucosal route induces both mucosal IgA and 
systemic IgG(Wu et al., 1997a).  An alternative expression system is to display 
proteins on the surface of a non-recombinant, killed Lactococcus lactis-derived 
delivery system called Gram-positive Enhancer Matrix (GEM) (Audouy et al., 2007). 
The GEM particles induce the production of macrophage TNF-α and enhance the 
maturation of dendritic cells. Other strategies under investigation include 
immunisation with both PspA DNA and protein (Moore et al., 2006).  S. pneumoniae 
proteins have also been used as the carrier proteins for PCV, and induce anti-protein 
antibody-based cross-protection in mice (Lee et al., 2001).  To date, such proteins 
have not been used for carriers in human vaccine studies. 
Based on the concept of that antibody neutralisation of virulence factors would aid 
protection, many of these proteins were initially screened on the basis that genetic 
mutant S. pneumoniae strains which lacked them had reduced virulence.  An 
alternative direction of investigation has been to identify surface-located proteins by 
more empiric means (Hamel et al., 2004).  Genomic data has been scrutinised to 
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identify proteins likely to be surface expressed based on the presence of secretion 
motifs including cell wall anchors, signal peptidase signals, choline binding domains 
and integrin binding domains (Wizemann et al., 2001).  Whilst not exhaustive, this 
has led to the identification of several immunogenic and protective proteins, including 
the Pht family of surface expressed proteins (Adamou et al., 2001).  Of these, PhtA, 
PhtB and PhtD protected against sepsis (Adamou et al., 2001). PhtE, formerly known 
as BvH-3, protected against both sepsis and pneumonia (Hamel et al., 2004).  Other 
have adopted an entirely unbiased approach and used pooled serum from humans 
exposed to or surviving S. pneumoniae infection to screen an antigen display library 
expressed in E. coli (Giefing et al., 2008).  This has led to the discovery of several 
further S. pneumoniae proteins which are surface expressed, immunogenic following 
natural exposure, lead to opsonophagocytic antibodies, and which protect against 
disease in animal models.  These include the proteins SktP and PcsB (Giefing et al., 
2008).  Whilst immunisation with many S. pneumoniae proteins induces protection in 
models of sepsis, only a limited number of proteins have been shown to protect 
specifically against pneumonia.  These include systemic administration of either PspA 
(Briles et al., 2003), PhtE (Hamel et al., 2004), PhtD (PATH, 2010) or Ply-derivatives 
(Alexander et al., 1994), or nasal administration of the combination of SlrA and IgA1 
protease in the GEM system (Audouy et al., 2007) or the combination or PiaA and 
PiuA (Jomaa et al., 2006). 
Human studies of the immunogenicity of S. pneumoniae proteins are limited to date.  
Immunisation of adult human volunteers with PspA led to serum antibody against this 
protein which when passively transferred into naïve mice was able to protect against 
lethal disease (Briles et al., 2000b).  Other protein vaccines currently in phase I/II 
clinical trials include the combination of StkP, PcsB and PspA (PATH, 2010) and 
PhtD (PATH, 2010).  In addition to inducing antibodies, protein immunisation could 
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potentially elicit protective T-cell responses to S. pneumoniae.  Whilst this can 
prevent colonisation, the ability of anti-protein T-cell responses to protect against 
disease independently of antibody has not been reported to date.  Based on murine 
data demonstrating Th17-cell mediated protection against colonisation, others are 
using T-cell antigen discovery approaches to identify the S. pneumoniae protein 
antigens which lead to the strongest Th17 cell responses for use in a protein vaccine 
engineered to induce both protective antibody and T-cell responses (PATH, 2010). 
1.5.6 Nasopharyngeal immunisation with whole bacteria 
As an alternative to generating subunit vaccines, investigators have introduced either 
killed or live attenuated whole bacterial cells into the nasopharynx of mice as a means 
of vaccinating against disease.  Inspired by the observations that natural mucosal 
exposure can induce antibodies and Th-17 cells responses to a range of bacterial 
antigens, this approach also exposes nasopharynx to the bacteria, and allows the host-
bacteria interaction to dictate the antigens which dominate the immune response.  
Such approaches have identified protective immunisation regimes.  Furthermore, they 
offer insights into the mechanisms by which the naturally-induced immune response 
may offer protection against subsequent disease.  However, genetic modification of S. 
pneumoniae or use of adjuvants may affect the immune response to the bacteria.  
Thus, the immunity they induce may differ to that generated by nasopharyngeal 
exposure to non-adjuvanted live wild-type bacteria. 
1.5.6.1 Killed whole cell S. pneumoniae 
Nasal administration of killed whole S. pneumoniae is protective only when given 
with cholera toxin (CT) (Malley et al., 2001).  The bacterial strain used was acapsular, 
lacked autolysin and was ethanol killed prior to administration.  Th17 cell responses 
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induced with this vaccine were both necessary and sufficient to protect against 
subsequent colonisation (Malley et al., 2005, Lu et al., 2008).  Passive transfer of 
serum from immunised mice protected naïve recipients against lethal pneumonia in an 
infant rat model (Malley et al., 2001).  Furthermore, when administered systemically, 
this vaccine was protective in murine models of colonisation, pneumonia and sepsis 
(PATH, 2010).  Clinical trials of systemic administration of this vaccine are planned 
to commence in 2011 (PATH, 2010). 
1.5.6.2 Live attenuated S. pneumoniae 
Nasal immunisation with live genetically attenuated strains of S. pneumoniae lacking 
either capsule, PspA or both (Roche et al., 2007) or lacking Ply (Richards et al., 2010) 
have also been investigated for their ability to induce protection against colonisation 
and disease.  Using live bacteria offers the prospect of onward transmission of the 
vaccine enhancing possible protection.  This approach has the further advantage of 
presenting a large number of B-cell antigens to the immune system, and overcoming 
the potential limitation of MCH restriction of T-cell epitopes.  As discussed in detail 
in the context of adaptive immunity against pneumonia, mice were protected against 
both colonisation and lethal disease.  However, no comparison has been made with 
the parent WT strains, and many questions remains as to the precise mechanisms of 
protection induced through colonisation with these strains. 
1.5.6.3 Importance of capsule in colonisation-induced protection 
Despite more rapid clearance from the nasopharynx, colonisation with unencapsulated 
strains of S. pneumoniae may still protect against subsequent pneumonia (Roche et 
al., 2007), via non-capsular immunity.  It is possible that the presence of capsule 
would impede the presentation of sub-capsular antigens to the adaptive immune 
system and thus an encapsulated strain may be less immunogenic and less protective 
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than its unencapsulated mutant.  Furthermore, lack of capsule can lead to enhanced 
pro-inflammatory responses (Hyams et al., 2010a), affecting the immune response 
further.  Direct comparison of isogenic encapsulated and unencapsulated strains could 
explore how this balance influences immunogenicity and protection.  D39-D∆ 
(Morona et al., 2004) and TIGR4∆cps (Trzcinski et al., 2003) are unencapsulated 
mutants of the virulent type 2 strain D39 and the virulent type 4 strain TIGR4, 
respectively.  They are used in this thesis to address this question.  Absence of capsule 
has been previously confirmed by electron microscopy and the Stains-all techniques 
(Hyams et al., 2010b). D39-D∆ was generated by deletion of just the type 2 cpsD 
gene (Morona et al., 2004) and so differs from AM1000, an unencapsulated D39 
strain previously reported to have attenuated colonisation capacity in which the entire 
type 2 capsule locus cpsABCDETFGHI has been deleted (Magee and Yother, 2001). 
TIGR4∆cps was generated by deletion of the entire capsule locus(Trzcinski et al., 
2003).  Both D39-D∆ and TIGR4∆cps are avirulent in mouse models of pneumonia, 
attributable to rapid opsonophagocytosis compared to their WT parent strains (Hyams 
et al., 2010a).   
1.5.6.4 Importance of lipoproteins in colonisation-induced protection 
The contribution of surface lipoproteins to colonisation-induced protection is not 
known.  Lack of surface lipoproteins may affect responses to colonisation in several 
ways.  Their roles in nutrient transport and cellular adhesion may be important in 
establishing and maintaining colonisation in the nasopharynx.  Thus, the presence of 
surface lipoproteins may be essential to induce colonisation-induced immunity.  In 
addition, lipoproteins are important TLR2 agonists.  Whilst TLR2 signalling is known 
to be essential for colonisation-induced Th17 cell responses, its role in antibody 
responses to colonisation is not known.  Comparison of responses to colonisation with 
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wild-type and lipoprotein-deficient mutant strains of S. pneumoniae would enable 
these questions to be addressed.  To facilitate this, a lipoprotein-deficient D39∆lgt 
mutant has been used in this thesis.  This mutant was generated and characterised by 
Dr Suneeta Khandavilli in the laboratory of Dr Jeremy Brown (Centre for Respiratory 
Research, Rayne Building, 5 University Street, London, WC1E 6JF) by in frame 
mutagenesis and replacement of the SP1412 gene with a chloramphenicol resistance 
cassette, as shown in Figure 1.5 (unpublished data).  Absence of the lgt gene and 
presence of the chloramphenicol resistance cassette were confirmed by PCR (data not 
shown).  Coomassie staining of a Triton-X extract of lysed ∆lgt mutants confirmed 
absence of lipoproteins from the lipid phase (Figure 1.6a), and immunoblotting 
bacterial lysates demonstrated retention of the prolipoproteins within the aqueous 
phase (Figure 1.6b).  Absence of the lipoprotein PpmA from the bacterial surface was 
also demonstrated by immuno-electron microscopy (data not shown).  The ∆lgt 
mutant was attenuated in growth in vitro (Figure 1.7a) and there was complete loss of 
virulence in vivo (Figure 1.7b). 
 
 
Figure 1.5.  Generation of S. pneumoniae ∆lgt deletional mutants 
(A-B) The lgt locus Sp1412 present in WT (A) was replaced with a chloramphenicol 
resistance cassette to create a ∆lgt mutant (B).  Experiments performed and figures kindly 





Figure 1.6.  Absence of lipoproteins in ∆lgt mutant. 
Coomassie blue stained SDS-PAGE separated proteins present in Triton-X extract of WT and 
∆lgt mutant S. pneumoniae.  (B) Immunoblots of lipoproteins PiuA, PiaA, PpmA and SlrA in 
Triton-X and aqueous extracts of WT and ∆lgt mutant S. pneumoniae.  Experiments 
performed and figures kindly supplied by Dr S Khandavilli. 
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Figure 1.7.  Growth and virulence of of ∆lgt mutant. 
(A) Growth curves of WT and ∆lgt S. pneumoniae in THY medium.  (B) Survival curves of 
CD1 mice challenged i.p. with either WT of ∆lgt S. pneumoniae.  Experiments performed and 
figures kindly supplied by Dr S Khandavilli. 
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1.5.6.5 Importance of colonisation duration in colonisation-induced protection 
Lack of capsule or surface lipoprotein may affect the ability of a S. pneumoniae strain 
to colonise the nasopharynx, with resulting effects on colonisation-induced immunity.  
However, this will also be affected by the inflammatory and immunological effects of 
capsule or lipoprotein deficiency.  To address the question of the impact of 
colonisation duration per se on immunogenicity and colonisation-induced protection, 
it is necessary to control colonisation duration without impacting on these other 
factors.  The growth of auxotrophic strains of bacteria is dependent upon an 
exogenous nutrient.  Providing and withholding this nutrient may be a tool to control 
colonisation duration of an auxotrophic mutant strain.  Comparison with the parent 
wild-type strain would allow examination of the impact of colonisation duration on 
immune responses and protection.  This would allow for further interpretation of the 
data generated with the other mutants.  The S. pneumoniae pabB gene (SP0665) 
encodes para-amino-benzoic acid (PABA) synthetatse, an enzyme required by S. 
pneumoniae for folate synthesis (Figure 1.8).  Deletion mutants on the D39 and 
TIGR4 backgrounds were generated by Dr Suneeta Khandavilli in the laboratory of 
Dr Jeremy Brown by in frame mutagenesis and replacement of the Sp0665 gene with 
a kanamycin resistance cassette, as shown in Figure 1.9 (unpublished data).  Absence 
of the pabB gene and presence of the kanamycin resistance cassette were confirmed 
by PCR (data not shown).  The strains were characterised by Dr Khandavilli.  The 
∆pab strain grew well in complete medium (data not shown) but not in serum unless 
supplemented with PABA (Figure 1.10a).  Virulence in a mouse sepsis model was 
dependant on supplementation of PABA at 1 mg/ml to mouse drinking water.   
These mutant strains are used in this thesis to address underlying questions about how 
colonisation with WT S. pneumoniae strains may induce protection against 
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pneumonia.  In this sense they are live attenuated vaccines.  However, there are strong 
safety considerations before introducing such vaccines into a human population, and 
any such vaccine would require multiple attenuations to guarantee lack of virulence 
whilst maintaining immunogenicity. 
1.5.7 Summary 
Whilst PCV and PPS have led to significant reductions in IPD and contributions 
towards reduced pneumonia, newer approaches to protection are under intense 
investigation.  Protein vaccines may offer species-wide protection, overcoming the 
limitations of CPS-based vaccines.  Both rational and empiric approaches to selection 
of optimal proteins for inclusion have been pursued.  Aside from their potential as 
vaccination strategies, studies using heat-killed and live attenuated S. pneumoniae 
have led to the identification of novel mechanisms of protection against colonisation.  
However, the mechanisms by which they protect against pneumonia are still not clear. 
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Figure 1.8.  S. pneumoniae folate biosynthesis pathway 
Chorismate is produced during phenylalanine biosynthesis.  It is converted via para-amino-
deoxychorismate to para-aminobenzoic acid (PABA) by the enzyme PABA synthetase, which 
is encoded by pabB.  Reaction with pteridines feeds into folate biosynthesis.  In the absence 





Figure 1.9.  Generation of S. pneumoniae ∆pab deletional mutants 
The pabB locus Sp0665 present in WT (A) was replaced with a kanamycin resistance 
cassette creating a ∆pab mutant (B).  Experiments performed and figures kindly supplied by 




Figure 1.10.  Growth and virulence of ∆pab mutant  
(A) Growth curves of WT and ∆pab  S. pneumoniae in serum with or without supplementation 
with PABA.  (B) Survival of CD1 mice challenged by i.p. route with either WT or ∆pab S. 





S. pneumoniae is a major pathogen and the second commonest cause of fatal bacterial 
infection worldwide.  Following acquisition through aerosol and droplet spread, 
bacteria can establish nasopharyngeal colonisation through a series of molecular 
interactions with host epithelial cells.  This requires avoidance of mucosal clearance 
which is assisted by the presence of a polysaccharide capsule.  This capsule also 
serves to reduce opsonophagocytic clearance.  Colonisation can occur from early 
infancy, and occurs earlier in areas of high prevalence.  Most infants have recurrent 
episodes of S. pneumoniae carriage.  Colonisation rates fall to 10% by late childhood.  
Most S. pneumoniae deaths are due to pneumonia which results from aspiration of 
nasopharyngeal bacteria into the lungs.  Pneumonia can subsequently progress to 
septicaemia.  Colonisation can also lead to direct haematogenous spread and seeding 
of distal sites.  Whilst nasopharyngeal colonisation is a pre-requisite for infection, it 
may also induce adaptive immune responses that could be protective against disease 
following subsequent nasopharyngeal re-exposure.  Despite the ubiquity of S. 
pneumoniae exposure, the majority of individuals do not develop disease as a 
combined result of innate and adaptive immune response. 
Serological studies in human populations suggest that natural nasopharyngeal 
exposure induces mucosal and systemic anti-protein antibody responses already 
detectable in infancy.  Such exposure also may also induce antibody responses to CPS 
antigens, but this appears to vary with capsular serotype and is often not detectable 
until the second year of life, by which age disease rates are already significantly lower 
than in infancy.  Although limited, data from murine studies suggests that multiple 
antigen encounters may be required for colonisation to induce a systemic anti-CPS 
IgG response.  In addition to antibody responses, murine models have demonstrated 
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that colonisation induces a TLR2-dependant Th17-cell response to S. pneumoniae 
antigens, and that this response is required for both clearance of primary 
nasopharyngeal colonisation and protection against subsequent recolonisation.  
However, there is no evidence to date that Th17 cells play a role in directly preventing 
S. pneumoniae disease.  Peripheral blood and mucosal Th17-cell responses to S. 
pneumoniae antigens are detectable in humans.  They are likely to be induced through 
nasopharyngeal exposure but their contributions to the prevention of colonisation or 
disease are not known. 
S. pneumoniae pneumonia results from aspiration of colonising bacteria from the 
nasopharynx into the lungs.  The bacteria then overwhelm the combined efforts of 
both innate and adaptive immune defence mechanisms.  Pathogen recognition through 
PRRs such as TLRs is critical to activation of resident AMs which can then 
phagocytose bacteria.  Cytokine production by AMs, DCs and γδ-T-cells in response 
to the presence of bacteria leads to epithelial cell activation, and the production of 
chemokines and anti-microbial molecules.  Such cytokines include TNF-α, IL-1, IL-6 
and IL-17.  Further anti-bacterial soluble factors including complement proteins aid 
augment bacterial killing and bacterial uptake by phagocytes.  Chemokines such as 
IL-8 (MIP-2) or GRO-α (KC) are important in neutrophil recruitment to alveolar 
spaces to assist in bacterial clearance.  If these responses are not adequate, disease 
progresses and can lead to lethal bacteraemia.   
Adaptive immune responses have the potential to augment these innate protective 
mechanisms.  Both anti-CPS and anti-protein antibodies can protect against lethal 
pneumonia in animal vaccination models using CPS and protein antigens.  
Vaccination-induced Th17-cells can protect against pneumonia caused by several 
other pathogens by enhancing IL-17 and IL-22 production over and above the innate 
IL-17 response to infection.  The contribution of adaptive Th17-cells in protection 
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against S. pneumoniae pneumonia is not known.  Infants and the elderly are 
particularly susceptible to S. pneumoniae pneumonia.  Although the reasons for the 
changing susceptibility with age remain poorly understood, it may reflect the 
development and subsequent waning of adaptive immune responses.  Of note, anti-
protein antibody responses appear to wane with age more than those against CPS 
antigens.  Little is known of Th17-cell responses in the elderly.  Previous natural 
exposure may protect against subsequent disease by different immunological 
mechanisms to those generated through vaccination.  Systemic immunisation with 
PPS vaccines protects adults primarily against IPD by inducing opsonic anti-CPS 
antibodies.  Infants respond best to PCV and this reduces both disease and carriage in 
a serotype-specific fashion.  This has positive effects such as herd immunity, but has 
also led to replacement serotypes occupying a vacated nasopharyngeal niche and 
causing replacement disease.  PCVs are expensive and difficult to manufacture.  
There is an urgent need to develop novel S. pneumoniae vaccines to overcome such 
limitations.  Species-wide protein antigens have been investigated extensively in 
murine models and can protect against both pneumonia and IPD.  Unbiased 
serological studies have identified several novel immunogenic S. pneumoniae 
antigens, several of which are now in early phase clinical trials.   
Studies with heat-killed and live attenuated whole S. pneumoniae demonstrate that 
nasopharyngeal exposure is sufficient to induce adaptive responses protective against 
pneumonia.  Heat-killed bacteria are only protective if introduced with a mucosal 
adjuvant.  This suggests that brief exposure to non-replicating bacterial antigens alone 
is insufficient to induce protective responses, and that in the absence of an artificial 
adjuvant, persistence of antigens in the nasopharynx may be important.  The only 
studies of the protective efficacy of prior colonisation with live S. pneumoniae strains 
have utilised genetic mutants with attenuated virulence, such as lack of capsule, lack 
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of the surface protein PspA or lack of the toxin Ply.  Such mutations will affect host-
bacterial interaction, and may have specific effects on the immune response in the 
nasopharynx.  Since no comparisons have been made between mutant and WT strains, 
extrapolation of these mechanisms of protection to those following WT exposure are 
not appropriate.  Thus, it is not known whether prior exposure to a live WT strain is 
protective against pneumonia.  Although colonisation with an acapsular strain is 
sufficient to protect, the specific role of capsule in colonisation-induced protection by 
encapsulated strains remains unclear.  Bacterial lipoproteins are a further group of 
abundant surface molecules.  They play crucial roles in nutrient uptake, and may be 
important in colonisation.  In addition, they are bacterial antigens and TLR2 agonists.  
Whilst colonisation-induced Th17-cell responses are TLR2 dependant, the role of 
TLR2 and lipoproteins in antibody responses to colonisation are not known.  Studies 
comparing the immunogenicity and protective efficacy of WT S. pneumoniae strains 
with acapsular mutants and ∆lgt mutants lacking lipoproteins could address these 
questions.  If colonisation duration could be controlled using auxotrophic strains such 
as ∆pab, this may identify the minimal requirements of a colonisation event to induce 
protection.  Where prior colonisation does protect against subsequent pneumonia, the 
specific contributions of antibody versus cell-mediated immunity remain unclear.  
Furthermore, whether colonisation protects through mucosal or systemic immunity is 
not known, and the antigenic targets of such protective immunity remain to be 
defined. 
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1.7 AIMS OF THIS THESIS 
1.7.1 General aim and scope 
This thesis aims to define the mechanisms by which prior colonisation can protect 
against subsequent lethal S. pneumoniae pneumonia in mice. 
1.7.2 Specific aims 
• To establish whether prior colonisation with potentially virulent wild-type strains 
of S. pneumonia protect against subsequent lethal pneumonia  
• To determine how the inability to replicate and the absence of capsule and surface 
lipoproteins affects nasopharyngeal colonisation with S. pneumoniae  
• To explore whether these factors affect the ability of previous colonisation to 
protect against subsequent wild-type lethal pneumonia 
• To characterise how previous colonisation affects the progression of 
pathophysiology of lethal pneumonia  
• To identify the relative contributions of antibody and T-cell responses to 
colonisation on the progress of subsequent pneumonia  
• To determine the precise function of the protective elements of the immune 
responses to colonisation  






2.1 BACTERIAL METHODS 
2.1.1 Bacterial strains 
The following wild-type (WT) strains were used in experiments: 
D39, a mouse-virulent invasive serotype 2 strain that has been genome sequenced 
(Lanie et al., 2007) and was a kind gift from Prof James Paton (University of 
Adelaide, Level 4, Molecular Life Sciences, SA5005, Adelaide, Australia).  This 
strain was first described in experiments determining the role of DNA in transferring 
heritable characteristics (Avery et al., 1944). 
TIGR4, a highly virulent capsular serotype 4 strain clinical isolate that has been 
genome sequenced (Tettelin et al., 2001) and was given as a kind gift by Prof Jeffery 
Weiser (Department of Micriobiology, University of Pennsylvania, 402A Johnson 
Pavilion, Philadelphia, PA 19104-3511, USA). 
Strain 0100993, a serotype 3 human pneumonia isolate, originally maintained by 
SmithKlineBeecham (Lau et al., 2001). This strain was a kind gift from Prof David 
Holden (Centre for Molecular Microbiology and Infection, Imperial College London, 
Flowers Building, Exhibition Road, London, SW7 2AZ, UK).  This WT strain will be 
referred to as ST3 within this thesis. 
The following mutant strains derived from the above WT strains were used in 
experiments: 
D39-D∆, an unencapsulated avirulent mutant created from the D39 WT strain by in-
frame deletion of capsule biosynthesis gene cps2D by overlap-extension PCR 
(Morona et al., 2004).  This also confers erythromycin resistance. 
D39∆lgt, a mutant of WT strain D39 that lacks surface lipoproteins was generated by 
Dr Suneeta Khandavilli in the laboratory of Dr Jeremy Brown.  The SP1412 gene (lgt) 
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encoding prolipoprotein diacylglyceryl transferase was replaced with a 
chloramphenicol resistance cassette. 
D39∆pab, an auxotrophic mutant of WT strain D39 was also generated by Dr Suneeta 
Khandavilli in the laboratory of Dr Jeremy Brown.  The gene SP0665 (pabB) was 
replaced with a kanamycin resistance cassette. 
TIGR4cps, an unencapsulated avirulent mutant created from the TIGR4 WT strain.  It 
contains a Janus cassette in place of the capsule gene locus, conferring resistance to 
kanamycin (Trzcinski et al., 2003).  This strain was a kind gift from Prof J Weiser. 
TIGR4∆pab, an auxotrophic mutant of WT strain TIGR4 was also generated by Dr 
Suneeta Khandavilli in the laboratory of Dr Jeremy Brown.  As for D39 ∆pab, the 
gene SP0665 (pabB) was replaced with a kanamycin resistance cassette. 



























































































































































































































































    
   
   
   
   
   
   
   
   
   
   
   
   
   
   





























2.1.2 Bacterial culture 
Bacteria were cultured at 37 °C in 5% CO2 on Columbia agar (Oxoid) containing 5% 
defibrinated horse blood (TCS Biosciences).  Working stocks were made by 
transferring one colony of S. pneumoniae to Todd-Hewitt broth (Oxoid) supplemented 
with 0.5% yeast extract (Oxoid) (THY) and grown to an optical density (OD580) 
between 0.3 and 0.4.  This corresponded to approximately 108 colony forming units 
(CFU) per ml.  Single use aliquots of bacteria containing 10% glycerol were stored 
until required at -80 °C.  The precise number of CFU was determined by culturing 
100 µl volumes of a thawed aliquot in 10-fold serial dilution on blood agar in 
duplicate, and counting the number of colonies 16 h later.  The mean of duplicate 
platings was used to derive the number of CFU per ml of the original frozen stock.  
To confirm the identity of mutant S. pneumoniae strains prior to use in experiments 
and whilst maintaining stocks, bacteria were also cultured on blood agar 
supplemented with antibiotics at the following concentrations: erythromycin, 0.2 
µg/ml; kanamycin, 500 µg/ml; chloramphenicol, 4 µg/ml.  Antibiotics were selected 
according to the sensitivity of the mutant strain according as shown in Table 2.1. 
For culture of samples recovered from mice, serial 10-fold dilutions of blood, lung 
homogenate or broncheo-alveolar lavage (BAL) fluid (BALF) were prepared using 
sterile phosphate buffered saline (PBS [Sigma], containing 8 g NaCl, 0.2 g KH2PO4, 
1.15 g Na2HPO4, and 0.2 g KCl).  Sufficient dilutions were plated to both maximise 
sensitivity and ensure numbers of CFU could be robustly counted (<500 CFU/plate).  
Samples recovered from respiratory tract were cultured on blood agar supplemented 
with gentamicin 5 µg/ml to limit overgrowth of contaminants.  Samples recovered 
from blood were cultured on blood agar without antibiotics.  Parallel plating with and 
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without gentamicin confirmed that at this concentration, gentamicin did not affect 
numbers of CFU of S. pneumoniae. 
2.1.3 5-carboxyfluorescein, succinimidyl ester labelling 
S. pneumoniae were labeled with the intra-cellular dye 6-carboxyfluorescein 
succinimidyl ester (FAM-SE) for use in infection experiments and phagocytosis 
assays (Hyams et al., 2010a, Yuste et al., 2008).  Bacteria were cultured overnight on 
5% blood agar at 37 °C in 5% CO2.  A single 10 µl loop (Greiner) of colonies was 
inoculated into 15ml THY medium and grown to late log phase (OD580 0.7-0.8). 
Bacterial cells were harvested by centrifugation and washed once with 5ml 0.1M 
sterile NaHCO3 buffer.  Following resuspension in 1ml NaHCO3 buffer with 50µl 
FAM-SE solution (Cambridge Bioscience, prepared at 10mg/ml in DMSO), bacteria 
were incubated for 1 h at 37 °C in 5% CO2.  Cells were washed six times in Hank’s 
balanced salt solution (HBSS, containing 0.137M NaCl, 5.4mM KCl, 0.25mM 
Na2HPO4, 0.44mM KH2PO4, 1.3mM CaCl2, 1.0mM MgSO4, 4.2mM NaHCO3) 
(GIBCO) supplemented with 0.2% bovine serum albumin (BSA) (Merck), until no 
further free dye appeared in the supernatant.  Single use aliquots of labeled cells were 
frozen with 10% glycerol, protected from light at -80 °C until required.  
2.1.4 Bacterial lysates 
S. pneumoniae lysates were prepared for use in immunoblotting experiments.  
Bacteria were cultured overnight on 5% blood agar at 37 °C in 5% CO2.  A 10 µl loop 
of colonies was inoculated into 4ml THY medium and grown to late log phase (OD580 
0.7-0.8). Bacterial cells were harvested by centrifugation, washed twice with PBS, 
and resuspended to 200 µl with PBS.  Lysates were sonicated for two min using a 
Sonifier 250 instrument (Branson).  Lysates were frozen at -20 °C until use. 
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2.2 IN VIVO METHODS 
2.2.1 Mouse strains 
CD1 outbred mice and CBA/Ca inbred mice were obtained from Charles River UK 
Ltd.  B6.129-S2-Igh-6tm1Cgn/J (µMT) mice containing a targeted mutation in the 
heavy chain locus of immunoglobulin M (IgM) and which do not produce mature B 
cells or antibody (Kitamura et al., 1991) were a kind gift of Dr Claudia Mauri, (UCL 
Division of Medicine, Windeyer Building, 46 Cleveland Street, London, W1T 4JF, 
UK).  They had been bred and maintained at UCL according to institutional 
guidelines.   All mice were female and aged 6-8 weeks at the commencement of 
experiments unless otherwise stated.  They were housed in individually ventilated 
cages with no more than five mice per cage.  Separate cages were used to house mice 
colonised with different bacterial strains. Control mice were also housed in separate 
cages to colonised mice.  Mice were permitted food and water ad libitum in a 
temperature, humidity and light controlled environment.  Experiments were 
performed according to the institutional guidelines for animal use and care, and all 
experiments conducted under Home Office (UK) license. 
2.2.2 Mouse models 
2.2.2.1 Inoculation for colonisation and disease models 
Mice were colonised by atraumatic instillation of 107 CFU S. pneumoniae suspended 
in 10µl PBS into the nares under light halothane anaesthesia.  This inoculum was 
determined as optimal to ensure consistent colonisation as described in Chapter 3 and 
reported by others (Wu et al., 1997b).  Control mice received 10µl PBS alone.  For 
pneumonia challenge, 107 CFU S. pneumoniae suspended in 50 µl PBS was instilled 
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intranasally (i.n.) under deep halothane anaesthesia (Brown et al., 2001a).  Mice were 
held in the upright position for one min following inoculation to ensure aspiration of 
the inoculum.  For intravenous (i.v.) challenge, mice received 5 x 106 CFU S. 
pneumoniae suspended in 100µl PBS via tail vein injection (procedure performed by 
Mr Mick Keegan (UCL Biological Services Unit)).  All inocula were cultured in serial 
dilution on blood agar plates at the time of inoculation to determine the actual number 
of CFU present.  Where mutant strains of S. pneumoniae were used in vivo, bacteria 
were also cultured on blood agar containing the appropriate antibiotic to confirm the 
identity of the mutant. 
2.2.2.2 Survival experiments 
In certain experiments, mice were monitored at regular intervals following pneumonia 
challenge to identify signs of terminal illness (Brown et al., 2001a, Brown et al., 
2002).  Mice were observed every 12 h for the first 24 h, then every six h until day 
seven and again 12-hourly thereafter until the end of the experiment.  Mice displaying 
well-described signs of terminal illness (reduced mobility, haunched posture, starry 
coat) were culled and survival time recorded as the next observation timepoint. 
2.2.2.3 Passive serum transfer 
For passive serum transfer experiments, serum collected from donor mice was pooled 
and frozen immediately after separation.  Serum was thawed immediately prior to use 
and brought to room temperature (RT) prior administration by intraperitoneal (i.p.) 
injection to recipient mice. 
2.2.2.4 CD4-cell depletion 
To deplete CD4+ cells, mice received doses of the monoclonal antibody (mAb) 
GK1.5 (eBiosciences) by i.p. injection as described in Chapter 5 (Zhang et al., 2009).  
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GK1.5 was stored at +4 °C until use.  All vials used were from the same lot and were 
pooled prior to use in vivo. 
2.2.3 Sample Processing 
2.2.3.1 Whole blood and serum 
For experiments requiring sampling of lower respiratory samples in addition to blood, 
mice were anaesthetised with 2 mg pentobarbital i.p. (Euthatal, Rhone-Merieux) 
followed by exanguination via severing the femoral artery.  This prevented the 
contamination of respiratory samples with blood whilst maximising the quantity of 
blood obtained.  When lower respiratory samples were required without blood 
samples, a more rapidly lethal dose of 7 mg pentobarbital was administered.  When 
only nasopharyngeal wash was to be collected, mice were culled by asphyxiation with 
CO2.  When only blood samples were required, but not respiratory samples, cardiac 
puncture and terminal exsanguination under isofluorane anaesthesia was performed to 
maximise the yield.  For non-terminal sampling, blood was collected via tail vein 
bleeding.  Whole blood was collected for bacterial culture into heparinised collection 
tubes.  50 µl heparin (Sigma) was used per 0.5ml tube at 1000 U/ml.  Subsequent 
dilution calculations took account of the volume of heparin.  Blood samples intended 
for serum were collected into plain tubes, allowed to clot at room temperature (RT) 
for 2 h, and centrifuged at 700 g for 20 min.  Separated serum was transferred to fresh 
plain Eppendorf tubes and immediately frozen. 
2.2.3.2 Nasopharyngeal wash 
To assess nasopharyngeal colonisation density, trachea was exposed, catheterized 
with a sterile 20G cannula (BD) which was flushed towards the head with 200µl 
sterile PBS.  Fluid exiting the nares was collected using a sterile Pasteur pipette and 
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cultured in serial dilution on blood agar plates supplemented with 5µg/ml gentamicin 
(Fluka) to prevent overgrowth of contaminants.   
2.2.3.3 Bronchoalveolar lavage fluid (BALF) 
BAL was performed by inserting the sterile cannula towards the lungs into the 
exposed trachea and lavaging three times with 1ml sterile PBS.  BAL fluid (BALF) 
was used for several assays and processed as follows. 
BALF was vortexted prior to reserving 100 µl for cytospin and a further 200 µl for 
bacterial culture.  The remaining volume was recorded for use in calculating the 
absolute cell count (see below).  Cells were harvested by centrifugation at 700 g for 3 
min.  The supernatant was immediately frozen at -80 °C for subsequent analysis.  
Following red blood cell (RBC) lysis, the pellet was used to determine the absolute 
cell count of the original BALF as described below. 
2.2.3.4 Lungs 
Following BAL, the thoracic cavity was opened.  2ml sterile PBS was used to gently 
perfuse the lungs via injection into the right ventricle.  This was done to minimise 
intra-vascular blood content of lungs that may confound cellular and bacterial 
assessments.  Lungs visibly blanched following this procedure.  The left lung was 
removed and placed into 5ml of 4% paraformaldehyde (PFA) solution to fix for 
histological examination.  The right lung was removed and placed into 5ml sterile 
PBS. 
Lung samples collected into PBS were used to prepare single-cell suspensions for 
bacterial culture and flow cytometry analysis.  Lungs were rinsed with sterile PBS to 
remove contaminating surface blood.  They were chopped into 2mm cubes and 
homogenised by mashing through a single cell 70µm strainer (BD Falcon) into a 50ml 
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Falcon tube to a final volume of 4ml.  200 µl of this suspension was reserved for 
bacterial culture.  Cells were harvested following centrifugation at 700 g for 7 min 
and the supernatant discarded.  Following RBC lysis, the pellet was used to determine 
the absolute cell counts and for flow cytometry staining as described below. 




All antibodies were used in experiments at optimal dilutions and temperature 











































































































































































































































































































































































































































































































































































    
   
   
   
   
   
   
   
   
   
   
   
   
   
   













































































































2.4 HISTOPATHOLOGICAL ASSESSMENT 
Sections of lung tissue were kindly prepared and stained by Mr Steve Bottoms 
(laboratory technician, UCL Centre for Respiratory Research, Rayne Building, 5 
University Street, London, WC1E 6JF) using established techniques. Lungs were 
fixed in 4% paraformaldehyde in phosphate-buffered saline for a minimal period of 4 
h. They were then rinsed in 50% ethanol/distilled water and stored in 70% 
ethanol/distilled water at 4 ºC.  The lungs were processed to paraffin wax overnight 
using an automated tissue processor (Leica).  Using a Shandon rotary microtome 
(Thermo Fisher Scientific) 3µm sections were prepared and dried overnight. The 
sections were stained with haematoxylin and eosin using a Sakura Diversified Stainer 
and coverslipped with a Coveraid Coverslipper (both Sakura-Finetek). 
Lungs were scored for inflammatory change using an established scoring system 
(Yuste et al., 2007) by Mr Bottoms who was blinded as to which group of mice 
samples were derived.  Sections were initially examined at x10 magnification to 
assess percentage pathological involvement.  Six randomly selected fields were then 
examined at a magnification of x20.  Typical appearances are shown in Figure 2.1.  
Fields were scored for degree of inflammatory change using an established scoring 
system (Yuste et al., 2007) as shown in Table 2.3.  The mean field score was 





Figure 2.1.  Histopathological appearances of  S. pneumoniae infected mouse lungs. 
Haematoxylin and eosin stained sections of lung tissue harvested from CBA/Ca mice 18 h 
following infection with 107 CFU S. pneumoniae D39 i.n.  BAL was performed prior to 
harvesting of lungs.  Images demonstrate varying amounts of inflammation corresponding to 
the stages of the scoring system used.  (A) No visible inflammatory change. (B) Minimal 
swelling of alveolar walls with slight change in architecture. (C) Increased swelling with 
presence of erythrocytes and inflammatory cells and an increase in type II pneumocytes. (D) 
Considerable haemorrhage with inflammatory cell influx, widespread alveolar disorganisation 
with interstitial swelling and pneumocyte proliferation. 
 
Table 2.3.  Scoring system for assessment of inflammation in mouse lung. 
Score Features 
1 No visible inflammatory change 
2 Minimal swelling of alveolar walls with slight change in architecture 
3 Increased swelling with presence of erythrocytes and inflammatory cells and 
an increase in type II pneumocytes 
4 Considerable haemorrhage with inflammatory cell influx, widespread 
alveolar disorganisation with interstitial swelling and pneumocyte 
proliferation 
 
Total score is determined by multiplying percentage of total area involved by mean 






2.5 CELLULAR METHODS 
2.5.1 Cell isolation and preparation 
2.5.1.1 Broncho-aleveolar fluid (BALF) and lung red blood cell (RBC) lysis 
To facilitate counting total leukocyte counts, RBCs were depleted from BALF and 
lung cell samples.  Samples were resuspended (BALF to 100 µl, lung to 1ml) into red 
blood cell (RBC) lysis buffer (BioLegend, San Diego, USA) and incubated on ice for 
5 min with occasional shaking.  The reaction was stopped by adding a further PBS 
(900 µl for BALF, 10ml for lungs), the cells harvested by centrifugation and the 
supernatant discarded.  The pellet was resuspended with PBS (to 0.5 ml for all 
samples).  This preparation was kept on ice until used for absolute cell counting. 
2.5.1.2 Human neutrophil isolation 
Neutrophil isolation was kindly performed by Dr Catherine Hyams.  Blood was 
donated by healthy human volunteers who had not received pneumococcal 
vaccination.  Polymorphonuclear cells (PMNs) were extracted using an established 
technique (Segal et al., 1980).  100 ml of fresh blood was heparinised (300U / 50 ml) 
and carefully layered onto Lymphoprep (Axis Shield).  This was centrifuged at 700 g 
for 30 min without brakes.  This yielded three distinct cellular layers: an upper 
peripheral blood mononuclear cell (PBMC) cell layer; a middle layer containing 
PMNs suspended within Lymphoprep; and a lower layer of sedimented RBC. The 
PBMC interface was removed and the middle and lower layers pooled to create a final 
volume of 40 ml.  To this, 10 ml of dextran (MW 200,000-300,000) (MP Biomedical) 
at 10% in normal saline was added.  Following very gentle mixing, RBCs were 
allowed to sediment by leaving the preparation undisturbed at RT for one hour.  The 
upper neutrophil-enriched layer was extracted into a fresh container, centrifuged at 
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700 g for 10 min and remaining RBC were removed by hypotonic lysis. Viable cells 
were counted and used within 4 h.   
2.5.1.3 Cell counting 
To determine viable cell counts, samples were diluted with an equal volume of 0.4% 
(w/v) Trypan blue (Sigma) and 10 µl placed into the counting chamber of a Neubauer 
haemocytometer (Camlab, Cambridge, UK).  Cells were counted under microscopy at 
a magnification of x40.  Only viable cells that excluded Trypan blue were counted.  
The viable cell count was determined by multiplying the number of counted cells by 
the dilution factor (x2) and the counting chamber volume factor (x104).  This cell 
count represented the number of cells per ml of prepared cells.   
2.5.2 Cellular analysis 
2.5.2.1 Cytospin 
For differential cell counting, 100µl BALF were spun onto glass slides at 700 
revolutions per min (rpm) for 7 min using a Cytospin 3 instrument (Shandon).  Air-
dried slides were stained with rapid Romanowsky stain (Raymond A Lamb) and again 
allowed to dry.  The slides were coverslipped with a Coveraid Coverslipper (Sakura-
Finetek) and examined microscopically at x40 magnification.  Leukocyte cell types 
were identified using standard morphological criteria.  A total of 300 cells from 
random fields were counted, and numbers of neutrophils and monocyte/macrophages 
recorded.  Thus, the proportion of neutrophils amongst BALF leukocytes was 
obtained.  Using the absolute total leukocyte numbers obtained from haemocytometer 
counting, absolute neutrophil and macrophage numbers in BALF were determined.  
To confirm purity of human neutrophil extractions, cytospin preparations (100 µl at 
1:100 dilution with PBS) were stained with Diff-quick (Merck) and examined 
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microscopically by Dr Hyams.  400 cells were morphologically assessed.  
Preparations used in phagocytosis assays consistently yielded over 95% neutrophils. 
2.5.2.2 Flow cytometry: general methods 
Cells harvested from BALF and lung preparations were stained prior to analysis by 
flow cytometry.  Table 2.2 lists details of antibodies and the dilutions at which they 
were used.  120 µl aliquots of samples were loaded into wells of a 96-well U-
bottomed plate and centrifuged at 700 g for 3 min and washed once with PBS + 1% 
BSA.  This was used as the buffer throughout staining procedures.  Cells were 
incubated with 10 µl of Fc-block at RT for 10 min prior to resuspension with 25 µl of 
antibody mix.  Following 20 min incubation in the dark at 4 °C, cells were washed 
three times and resuspended in 200 µl 4% PFA.  Samples were then kept at 4 °C in 
the dark until acquisition on a FACSCalibur instrument (BD Biosciences). 
On every occasion, aliquots of freshly isolated splenocytes prepared as for lung cells 
above were also included.  Aliquots of splenocytes were either unstained or stained 
with single antibody conjugates in addition to the combinations used within individual 
experiments.  These samples were used to compensate during analysis of multi-colour 
stained samples. 
2.5.2.3 Flow cytometry: gating 
For lung samples, an initial gate was set according to forward scatter (reflecting cell 
size) and side scatter (reflecting cell granularity) to exclude any RBC and small debris 
present in the sample (Figure 2.2).  This gate was used as the denominator in defining 
the proportion of lymphocytes present.  A lymphocyte gate was set within this 
denominator gate on the tight FSClo/SSClo population.  Backgating for CD3 (a pan T-
cell marker) and B220 (B-cell marker) confirmed these cells as lymphocytes.  Multi-

































Figure 2.2.  Representative flow cytometry plots showing lung lymphocyte subsets. 
Single-cell preparation of lung cells (A) harvested from a CBA/Ca mouse 18 h after i.n. 
infection with 107 CFU S. pneumoniae D39.  A gate (B) was set to include all leukocytes but 
exclude red blood cells and small debris and acted as a denominator gate.  Lymphocytes 
were gated within this population and stained for surface markers.  Backgating of CD3+ and 
B220+populations confirmed this population as lymphocytes.  Following compensation for 
multi-colour staining, lymphocyte subsets were identified.  Three representative subset plots 
are shown: C1 shows B-cells (B220+) and T-cells (CD3+); C2 shows CD4+ and CD4- T-cells; 
C3 shows TCRβ and TCRγδ T-cells. 
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For BALF cellular preparations, a gate was required to identify alveolar macrophages.  
Excluding debris/RBC and cells falling in the lymphocyte region, remaining cells 
were either clustered in the FSCmid/SSCmid region or distributed more widely into the 
FSCmid+hi/SSChi region.  Gates were set on these two regions and cells analysed 
according to staining with Gr1 (granulocyte marker) and F4/80 (macrophage marker) 
(Figure 2.3).  The FSCmid+hi/SSChi region contained predominantly F4/80+Gr-1- cells, 
identifying them as predominantly macrophages.  The FSCmid/SSCmid region was 
more heterogeneous, but relatively enriched with Gr-1hi granulocytes compared to 
other regions.  The FSCmid+hi/SSChi region was therefore used for analysis of alveolar 






Figure 2.3.  Representative flow cytometry plots showing macrophage gating of BALF 
cells. 
Cells recovered by BALF 4 h following infection of a CBA/Ca mouse with 107 CFU S. 
pneumoniae D39 i.n., stained with Gr1 (granulocyte marker) and F4/80 (macrophage marker). 
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2.5.3 Phagocytosis assays 
2.5.3.1 Alveolar macrophage in vivo phagocytosis assay 
Following infection with FAM-SE labelled bacteria, phagocytosis by alveolar 
macrophages was assessed by flow cytometric examination of cells recovered from 
BALF of mice (Arredouani et al., 2006).  In this assay, recovered cells were washed 
twice with PBS and fixed with 200 µl 4% PFA prior to flow cytometry.  Macrophages 
were gated according FSC and SSC criteria as established above.  All cells within the 
sample were analysed and the median fluorescence intensity (MFI) for channel FL-1 
(in which FAM-SE emits) of this population determined.  Previous experiments 
indicated that bacteria recovered from BALF remained fluorescently labelled by this 
technique at the timepoints used in this study. 
2.5.3.2 Human neutrophil phagocytosis assay 
This assay was kindly performed by Dr Catherine Hyams (UCL Centre for 
Respiratory Research, Rayne Building, 5 University Street, London, WC1E 6JF) as 
described (Hyams et al., 2010a).  It measures the effect of serum pre-incubation of 
bacteria on subsequent association with freshly isolated human neutrophils.  Aliquots 
of serum pooled from colonised or control mice were thawed and diluted with an 
equal volume of PBS.  10µl diluted serum was added per well in a 96-well plate.  
Wells containing PBS alone were used as controls.  5 x 106 CFU thawed, washed 
FAM-SE labelled S. pneumoniae in 10 µl PBS were added to each well.  Bacteria 
were incubated for 30 min at 37 °C on a horizontal shaker at 150 rpm. Freshly 
isolated human neutrophils were washed and resuspended in HBSS with divalent 
cations.  5 x 105 cells were added per well resulting in a pre-optimised multiplicity of 
infection (MOI) of 10.  Neutrophils were incubated with bacteria for 30 min at 37 °C 
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shaking at 150rpm, and then fixed with 50µl 3% PFA.  Cells were analysed by flow 
cytometry on a FACScalibur instrument.  The MFI of 15,000 cells per well was 
determined.   
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2.6 PNEUMOCOCCAL SPECIFIC 
IMMUNOASSAYS 
2.6.1 Pneumococcal ELISAs 
2.6.1.1 Whole cell ELISA 
S. pneumoniae were grown in THY to late-log phase (OD580 0.7-0.8) was washed 
twice in PBS and resuspended in PBS to OD580 1.0.  50 µl aliquots were placed into 
wells of 96-well Maxisorp (Nunc) plates and incubated overnight at 4 °C.  The 
following day, the plates were washed with PBS + 0.05% Tween-20 (Sigma) 
(PBS/Tw), blocked with 200 µl PBS+1% BSA and incubated for one hour at 37 °C.  
50 µl samples were added in duplicate.  Starting dilution of serum was 1:20 in PBS + 
1% BSA.  For titrations, serial 5-fold dilutions were used.  Blank wells contained 
dilution buffer only.  Following 2 h incubation at RT, plates were washed and 100 µl 
alkaline phosphatase conjugated secondary antibody added, diluted 1:10,000 in 
PBS/Tw (see Table 2.2).  After a further 2 h incubation at RT, plates were washed and 
developed with 100 µl N-nitrophenylphosphate disodium (pNPP) at 1mg/ml in 
diethanolamine (DEA) buffer (see Appendix).  After a further 30 min incubation in 
the dark at RT, absorbance was read at OD405, with correction for absorbance at 
OD620.  These values were further corrected by subtraction of blanks. 
Where required, end-point titres were defined as the dilution of serum giving a 
corrected OD405 of 0.1.  This was extrapolated from results from dilutions resulting in 
OD in the linear range (Figure 2.4).  Samples with OD405 < 0.1 at 1:20 dilution were 
assigned a titre of 1:10 (i.e. half the lower limit of detection). 
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End-point titre = 1 / 103.44









Figure 2.4.  Representative end-point titration of pneumococcal whole cell ELISA. 
The OD580 obtained is plotted against log10 dilution of the sample in serial dilution.  A line is 
plotted based on values falling in the linear portion, from which the sample dilution 
corresponding to an OD of 0.1 is obtained.  This is defined as the titre for that sample. 
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2.6.1.2 Capsular polysaccharide ELISA 
Antibodies to CPS were measured following the established protocol (Wernette et al., 
2003).  Briefly, medium-absorbance plates (Greiner) were coated with 100 µl CPS at 
pre-optimised concentrations (type 2 CPS, 100 µg/ml; type 4 CPS, 1 µg/ml) and 
incubated at 4 °C overnight.  Samples were pre-incubated in PBS/Tw supplemented 
with CWPS (Statens Serum Institut) 10 µg/ml and type 22F CPS (5 µg/ml) (ATCC) 
for 1 h prior to addition of 50 µl in duplicate to the washed plates.  This pre-
incubation stage competes out non-specific binding caused by contaminating CWPS 
and pneumococcal surface proteins present in the CPS preparation, increasing the 
specificity of anti-CPS antibody measurement.  Following 2 h incubation at RT, plates 
were developed as for the whole cell ELISA. 
2.6.1.3 Cell wall polysaccharide ELISA 
To measure anti-CWPS antibodies, plates were coated with CWPS at (10 µg/ml) and 
refrigerated overnight.  Samples were not pre-incubated prior to addition to the coated 
plates.  Otherwise, the assay was the same as for measurement of anti-CPS antibodies. 
2.6.2 Flow cytometry detection of bacterial IgG binding 
To quantitate binding of serum IgG to the surface of bacteria an established assay was 
used (Yuste et al., 2008).  Aliquots of 5 x 105 CFU S. pneumoniae were placed in 
wells of a U-bottomed 96-well plate, centrifuged at 700 g for 3 min and washed twice 
with PBS.  Serum was diluted with an equal volume of PBS and 10 µl added per well.  
Control wells contained no serum.  Bacteria were resuspended and plates incubated 
for 30 min at RT.  After three washes, binding was detected by incubating with anti-
mouse IgG PE conjugate (see Table 2.2) at 1:100 dilution in PBS/Tw for 20 min at 4 
°C.  Following three further washes, bacteria were fixed in 3% PFA.  Fluoresence of 
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bacteria was measured on a FACScalibur instrument.  Data from 25,000 cells was 
collected for analysis.   
2.6.3 Pneumococcal protein immunoblotting 
2.6.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Recombinant pneumococcal proteins expressed from the TIGR4 genome were kindly 
supplied by Dr Carmen Giefing (Intercell AG, Campus Vienna Biocenter 3, 1030 
Vienna, Austria) (Giefing et al., 2008).  Recombinant prolipoproteins expressed from 
the ST3 genome were prepared by Dr Suneeta Khandavilli (Brown et al., 2001a, 
Brown et al., 2001b).  The preparation of bacterial lysates is described above.  
Aliquots of bacterial lysate or recombinant proteins were treated with NuPAGETM 
reducing agent (Invitrogen).  10µl aliquots of reduced samples and 5µl of PageRuler 
PlusTM (Fermentas) protein marker ladder were loaded into lanes of NuPAGETM 4-
12% gradient bis-tris gels (Invitrogen).  Proteins separated with 120V in NuPAGETM 
MOPS running buffer (Invitrogen) until the ladder was well resolved.  For protein 
identification, gels were stained with Coomassie brilliant blue (see Appendix) until 
bands appeared, then destained with Destain Solution (Appendix). 
2.6.3.2 Western blotting 
Separated proteins were transferred to nitrocellulose membrane (GE Healthcare) by 
applying 20V for 50 min in the presence of Transfer Buffer (Appendix).  Successful 
transfer was confirmed by Ponceau S (Sigma) staining to membranes.  Membranes 
were blocked overnight with tris-buffered saline (TBS, see Appendix) + 0.1% Tween-
20 (TBST) plus 5% milk at 4 °C.  Membranes were washed three times with TBST, 
and incubated with the serum to be tested diluted to 1% in TBST + 5% milk for 2 h at 
RT whilst rolling.  Following three further washes, membranes were incubated with 
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anti-mouse IgG – horseradish peroxidase (HRP) conjugate (see Table 2.2) in TBST + 
5% milk.  Membranes were then washed three more times.  Serum IgG binding was 
detected using Amersham ECL detection kit (GE Healthcare) following 
manufacturer’s instructions.  Developed membranes were exposed to photographic 
film (Amersham) and developed using a Photon Imaging System developer (Nikon). 
2.6.4 Pneumococcal protein Luminex™ bead immunoassay 
Luminex™ is a recently introduced multiplex bead immunoassay system where 
multiple target molecules are conjugated to microspheres of multiple colours.  These 
conjugated beads provide the surface for an immunoassay reaction.  Binding is 
measured on a flow cytometric platform.  Beads conjugated to pneumococcal proteins 
were kindly provided by Prof Alex van Belkum (Department of Microbiology and 
Infectious Disease, Erasmus MC, Ziekenhuis, ‘s-Gravendijkwal 230, 3015 CE 
Rotterdam, The Netherlands).  Recombinant pneumococcal protein antigens used in 
the reactions were from a range of strain backgrounds (see Table 7.1).  The purified 
proteins were coupled to SeroMAP beads, a carboxylated bead type developed for 
serological applications. The coupling reaction was been described (Verkaik et al., 
2009).  Briefly, 25 µg recombinant protein was covalently attached to activated 
carboxyl groups on the surface of 5.0 x 106 activated microspheres.  Using positive 
control sera, the multiplex system was validated by comparing binding on a 
singleplex basis to the full set of multiplexed antigens.  Conjugated beads were kept 
refrigerated until use. 
To measure anti-pneumococcal protein IgG levels in test samples, a mixture was 
prepared of equal numbers of each bead type, suspended in PBS + 1% BSA.  Beads 
that had undergone the chemical conjugation protein in the absence of a specific 
pneumococcal protein were included as controls.  Prior to mixing, beads were 
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sonicated in a waterbath and vortexed.  96-well filter membrane plates (Multiscreen 
HTS™, Millipore) were used to hold the beads during the reactions.  Wells were wet 
with PBS + 1% BSA which was then aspirated from below using a vacuum manifold 
(Millipore).   50 µl mixed beads was added to each well.  This resulted in each well 
containing 3000 beads of each bead type.  Beads were washed with PBS + 1% BSA 
and 50 µl serial dilutions of serum added in duplicate.  Plates were incubated for 35 
min at RT protected from light shaking at 600 rpm.  Following two washes with PBS 
+ 1% BSA, beads were resuspended in anti-mouse IgG PE conjugate diluted 1:50 in 
PBS + 1% BSA (see Table 2.2).  Plates were incubated for a further 35 min as 
previously.  Beads were washed two further times and beads resuspended thoroughly 
in 100 µl PBS + 1% BSA.  The fluoresence of beads of each antigen type was 
measured using a Bio-Plex (Bio-Rad) machine.  IgG binding at a given serum dilution 
to a specific protein was defined as the mean MFI of replicate wells. 
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2.7 CYTOKINE MEASUREMENT 
2.7.1 Cytokine ELISAs 
2.7.1.1 IL-17 ELISA 
IL-17 was measured using the Mouse IL-17 Quantikine™ ELISA kit (R&D Systems, 
Minneapolis, MN, USA).  Briefly, 50 µl sample or standard was added to 50 µl of 
Assay Diluent in wells of a 96-well plate pre-coated with IL-17 capture antibody.  
Plates were incubated for 2 h at RT, then washed five times.  100 µl diluted detection 
antibody conjugated to HRP was added to each well, and plates incubated for a 
further 2 h at RT.  Following five further washes, 100 µl tetramethylbenzadine (TMB) 
Substrate Solution was added and plates incubated 30 min at RT protected from light.  
Finally 100 µl Stop Solution was added.  Plates were read at OD450 corrected for 
absorption at OD570.  Concentrations of IL-17 in unknown samples were obtained 
from a standard curve, generated by log-log curve fit using GraphPad 4.0 (Prism), as 
illustrated in Figure 2.5.   
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Figure 2.5.  Derivation of unknown cytokine concentrations from ELISA standard 
curve. 
Log10 absorption (as corrected OD405) was plotted against log10 concentration for dilutions of a 
standard of known concentration.  A log-log curve was fitted using GraphPad 4.0 (Prism), 
from which the concentration of samples (X) could be determined. 
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2.7.1.2 IFN-γ ELISA 
IFN-γ was measured using a Ready-SET-Go!™ IFN-γ ELISA kit (eBioscience).  
Briefly, 100 µl sample, control or standard was added to wells of a 96-well plate pre-
coated with capture antibody.  Plates were incubated for 2 h at RT, then washed five 
times.  100 µl diluted biotinylated detection antibody was added to each well, and 
plates incubated for a further hour at RT.  Following five further washes, 100 µl 
Avidin-HRP conjugate was added, and plates incubated a further 30 min.  100 µl 
TMB Substrate Solution was added and plates incubated 15 min at RT protected from 
light.  Finally 50 µl Stop Solution was added.  Plates were read and data analysed as 
for the IL-17 ELISA. 
2.7.1.3 IL-22 ELISA 
IL-22 was measured using the Mouse IL-22 Quantikine™ ELISA kit (R&D Systems).  
Briefly, 50 µl sample or standard was added to 100 µl of Assay Diluent in wells of a 
96-well plate pre-coated with IL-17 capture antibody.  Plates were incubated for 2 h at 
RT, then washed five times.  200 µl diluted detection antibody conjugated to HRP 
was added to each well, and plates incubated for a further 2 h at RT.  Following five 
further washes, 120 µl TMB Substrate Solution was added and plates incubated 30 
min at RT protected from light.  Finally 120 µl Stop Solution was added.  Plates were 
read and data analysed as for the IL-17 ELISA. 
2.7.1.4 IL-23 ELISA 
IL-23 was measured using the Mouse IL-23 Cytoset™ system (Invitrogen).  Briefly, 
plates were coated with 100 µl capture antibody (1.25 µg/ml) and incubated overnight 
at 4 °C.  Following washing, plates were blocked with PBS/Tw + 0.5% BSA for 1 h at 
RT.  Following further washing, 100 µl sample or standard was added to wells and 
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plates incubated for 2 h at RT.  Following further washing, 100 µl diluted biotinylated 
detection antibody was added to each well, and plates incubated for a further hour at 
RT.  Following washing, 100 µl streptavidin-HRP conjugate was added and plates 
incubated 30 min at RT.  Following five further washes, 120 µl TMB Substrate 
Solution was added and plates incubated 30 min at RT protected from light.  
Following washing, 100 µl Stop Solution was added.  Plates were read and data 
analysed as for the IL-17 ELISA. 
2.7.2 Cytokine Luminex™ assay 
Mouse IL-1β, IL-6, TNFα, KC, IL-12p70 and GM-CSF were measured by 
Luminex™ bead immunoassay (Invitrogen) according to manufacturer’s instructions.  
Briefly, wells of a 96-well filter membrane plate (Multiscreen HTS™, Millipore) 
were wetted with Assay Buffer.  Equal quantities of each bead type were added to 6 
ml Assay Buffer and 50 µl added to each well.  Beads were sonicated and vortexed 
prior to mixing and again prior to adding to wells and washing.  50 µl of standard or 
samples were added to wells in duplicate, and the plate incubated for 1 h at RT 
shaking at 300 rpm.  Beads were washed three times and 50 µl anti-mouse IgG PE 
conjugate (see Table 2.2) added at 1:50 dilution.  Following a further 30 min 
incubation shaking at RT, beads were washed again and resuspended in 130 µl Assay 
Buffer.  Fluoresence of beads was measured using a Bio-Plex (Bio-Rad) machine.  
Cytokine levels were obtained from standard curves generated using Bio-Plex 

















































































































Figure 2.6.  Standard curves for cytokine measurement using Luminex™ bead assay. 
Log10 MFI of serial dilutions of a standard containing known concentrations of multiple 
cytokines measured in parallel using Luminex™.  A log-log curve was fitted using GraphPad 
4.0 (Prism), from which the concentration of samples (X) could be determined. 
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2.8 BIOINFORMATICS 
Pneumococcal proteins sequences were obtained from the NCBI (National Library of 
Medicine, USA) Entrez-Protein Database accessed at 
http://www.ncbi.nlm.nih.gov/protein.   Percentage identity of the amino acid 
sequences of S. pneumoniae proteins from strains D39 and TIGR4 were assessed 





Non-parametric data are presented as median with interquartile range and compared 
by Mann-Whitney U-test or Kruskal-Wallis test.  Parametric data are presented as 
either mean ± standard deviation (SD) to represent the spread of values from a group 
of mice, or mean ± standard error of the mean (SEM) to represent the spread of data 
from in vitro replicates.  Parametric data was compared by Student t-test or analysis 
of variance (ANOVA) with post-hoc tests.  Survival data is presented as Kaplan-
Meier survival curves and compared by log rank test.  In general, P values <0.05 were 
considered significant.  Statistical tests used are stated in text or in figure legends. 
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3 D39 WT and MUTANT COLONISATION-
INDUCED PROTECTION IN CD1 MICE 
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3.1 INTRODUCTION 
Limited data suggests that colonisation with live attenuated mutants lacking either 
capsule (Roche), Pspa/Ply (Roche) or Ply alone (Richards) can protect against lethal 
disease in mice.  The mechanisms of protection remain unclear.  Furthermore, the 
protection that follows WT colonisation, reflecting natural immunity in humans, has 
not been explored. 
In this chapter, the effects of nasopharyngeal colonisation of CD1 mice with WT and 
mutant strains of D39 and TIGR4 S. pneumoniae were examined as follows.  Models 
of colonisation with D39 and TIGR4 WT were established.  The time course of D39 
colonisation was defined, and the immunogenicity and protection induced by 
colonisation was studied.  The time course, immunogenicity and protection following 
colonisation of the mutant strains D39-D∆, D39∆lgt and D39∆pab was then 
compared to that of the parent WT strain.  Finally, the ability of D39 colonisation to 
cross-protect against serotypes TIGR4 and ST3 was also tested. 
These mutants were chosen as they have not been previously studied in such a system.  
All the mutations lead to attenuated virulence (unpublished data, see Introduction) and 
are potential candidates for inclusion in a live attenuated nasal vaccine.  Perhaps most 
importantly, comparison of each mutant with the WT enabled a set of specific 
questions to be asked regarding the induction of protective responses during 
colonisation. 
Limited data suggests that despite more rapid clearance from the nasopharynx, 
colonisation with unencapsulated strains of S. pneumoniae can still protect against 
subsequent pneumonia (Roche et al., 2007).  Colonisation with unencapsulated strains 
of S. pneumoniae may in fact be more immunogenic than with WT, since lack of 
capsule can lead to enhanced pro-inflammatory responses (Hyams et al., 2010a).  
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Direct comparison of D39 WT with D39-D∆ explored how the balance between the 
inflammatory responses and rapid clearance influence immunogenicity and protection 
against pneumonia. 
D39∆lgt lacks surface lipoproteins (see Introduction) which may affect responses to 
colonisation in several ways.  Lipoproteins have important nutrient transporter 
functions (e.g. PiaA and PiuA (Brown et al., 2001a, Basavanna et al., 2009), LivJ 
(Basavanna et al., 2009)).  Poor in vivo growth may therefore limit the ability of ∆lgt 
to establish colonisation.  Furthermore, several lipoproteins specifically mediate 
adherence to the nasopharynx (e.g. PsaA (Tong et al., 2002), PpmA (Cron et al., 
2009), SlrA (Hermans et al., 2006) and the Ami-AliA/AliB complex (Kerr et al., 
2004)).  If density and duration of colonisation are important determinants of 
immunogenicity, these factors could affect the ability of ∆lgt to induce protective 
immunity.  Colonisation can also induce serum antibodies to certain lipoproteins, (e.g. 
PpmA and SlrA (Adrian et al., 2004) and PiuA and PiaA (Whalan et al., 2005)).  
Thus, loss of these antigens from ∆lgt could impact on protective immunogenicity in 
a more specific way.  Finally, lipoproteins are important TLR2 agonists (Travassos et 
al., 2004).  Th17 responses to colonisation that protect against re-colonisation are 
induced in a TLR2-dependent manner (Zhang et al., 2009), and antibody responses to 
S. pneumoniae antigens are affected by TLR2 signalling in vitro.  The role of TLR2 
signaling in the humoral response to colonisation has not been reported.  Inclusion of 
a ∆lgt mutation in this study allowed the importance of these interactions to be 
investigated. 
To investigate the role of duration of colonization in inducing protective immune 
responses, the auxotrophic D39∆pab was used.  It does not grow in vivo without 
PABA supplementation.  It was anticipated that it would be rapidly cleared from the 
nasopharynx.  This avoided the possible inflammatory response to active bacterial 
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killing associated with antibiotic use to terminate colonization.  By controlling for 
rapid clearance, data generated using this mutant strain may aid in the interpretation 
of the data generated by the other mutants. 
In this chapter, we addressed the following specific questions: 
• Is WT colonisation immunogenic? 
• Is WT colonisation protective against lethal pneumonia? 
• Does the loss of capsule, surface lipoprotein or the ability to replicate affect the 
ability of these mutant strains to: 
o colonise the nasopharynx? 
o induce immune responses against bacterial antigens? 
o protect against lethal pneumonia? 
• Is the protection induced through colonization serotype-specific? 
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3.2 RESULTS 
3.2.1 Establishing a nasopharyngeal colonisation model 
3.2.1.1 Identification of S. pneumoniae recovered from nasopharyngeal wash 
To determine the inoculum of the D39 S. pneumoniae strain required to establish 
nasopharyngeal colonisation in CD1 mice, groups of mice were inoculated i.n. with 
bacteria in a volume of 10µl PBS.  This volume was delivered as a single drop to the 
nares of a mouse held vertically without anaesthesia.  Blood agar plates containing 
gentamicin were used to exclude contaminants but this did not prevent growth of 
viridans streptococci recovered on occasion.  Sensitivity to optochin, which 
selectively inhibits growth of S. pneumoniae, was therefore used to confirm that 
recovered bacteria were S. pneumoniae. 
3.2.1.2  Establishing inoculum sufficient to colonise nasopharynx 
Mice received light halothane prior to inoculation as this allowed more consistent 
application of inocula.  Pilot experiments explored whether introducing a target 
inoculum of 0.5-1 x 106 CFU was sufficient to colonise the nasopharynx of CD1 
mice.  There was inconsistent recovery of pneumococci from the nasopharynx of mice 
during the seven days following colonisation, with no bacteria recovered from 50% of 
mice at several timepoints (Figure 3.1A).   
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Figure 3.1. Optimisation of colonising inoculum in CD1 mice.  
(A) Groups of mice (n=4) were nasally inoculated with 0.5-1x106CFU S. pneumoniae D39.  
Nasopharygeal wash was collected from culled mice at fixed timepoints for bacterial culture.  
(B) Bacterial load in day 2 nasopharyngeal wash of mice inoculated with 0.4x107 CFU of D39 
or TIGR4.  Dotted line indicates limit of detection. 
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Using anaesthesia and a higher inoculum of 0.4 x 107 CFU, pneumococci were 
recovered from all mice inoculated with S. pneumoniae D39, and 80% of mice 
inoculated with S. pneumoniae TIGR4 (Figure 3.1B) on day 2 post-colonisation.  
Despite introducing a similar number of bacteria (0.5 x 107 CFU), approximately 10-
fold more TIGR4 bacteria were recovered than D39, suggesting that this strain 
colonises the nasopharynx at a higher density.  No bacteria were recovered from the 
BALF, lungs or blood of mice and all animals remained well despite this high 
nasopharyngeal load.   
3.2.2 Time course of nasopharyngeal colonisation 
3.2.2.1 Time course of colonisation with wild-type D39 
Further groups of CD1 mice (n=4 to 10) were colonised with S. pneumoniae D39 
using an inoculum of 1.0 x 107 CFU.  They were culled at fixed timepoints for 
bacterial culture of nasopharyngeal wash to determine the stability and duration of 
colonisation with the wild-type strain (Figure 3.2 A).  There was a large initial 
reduction in numbers of CFU recovered from a median of 1.74 x 104 CFU/ml 
(interquartile range (IQR) 1.1–4.7) on day 1 to 4.00 x 103 CFU/ml (1.20–11.2) on day 
2.  Similar numbers of bacteria were recovered on day 5, suggesting stable 
colonisation from day 2.  There was a further reduction by day 10 to a median of 5.05 
x 102 CFU/ml (1.70–9.59), and by day 17, bacteria were no longer recovered.   
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Figure 3.2.  Time course of S.pneumoniae D39 WT and mutant nasopharyngeal 
colonisation in CD1 mice. 
Groups of mice (n=4-10) were colonised with 1 x 107 CFU D39 WT, D39-D∆, D39∆lgt or 
D39∆pab , and culled at fixed timepoints for culture of nasopharyngeal wash.  Dots represent 
individual mice, bars indicate group median.  Comparison to D39WT at each timepoint by 
Mann-Whitney U-test (*P<0.05, **P<0.01). 
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3.2.2.2 Time course of colonisation with D39-D∆, ∆lgt and ∆pab mutants 
To assess the ability of the mutant strains to colonise the nasopharynx, groups of CD1 
mice (n=4-9) were inoculated i.n. with 1 x 107 CFU of either D39-D∆, D39∆lgt or 
D39∆pab suspended in 10µl PBS.  Mice were culled at fixed timepoints for 
assessment of nasopharyngeal colonisation density as shown in Figure 3.2 (B-D).  
D39-D∆ was recovered from the nasopharynx from 9/10 mice on the second day 
following colonisation.  The median colonisation density was 4.77 x 103 CFU/ml 
(IQR 0.76–6.27), significantly less than that of D39 WT (P=0.004).  Colonisation 
density fell to 4.02 x 102 CFU/ml by day 2 (IQR 0.77–22.0).  Unlike the D39WT 
colonised mice, all of which remained colonised, only 1 of 5 mice colonised with 
D39-D∆ remained colonised on day 5. 
By day 1, D39∆lgt was recovered from all inoculated mice, with median colonisation 
density 2.85 x 103 (IQR 1.49–4.20), significantly less than D39WT (P=0.016).  2 of 6 
mice had cleared colonisation by day 5, by which time the median density of 
colonisation had fallen to 3.43 x 102 (IQR 0.30–5.72).  Only 2 of 5 mice remained 
colonised at day 10, and all had cleared colonisation by day 17. 
D39∆pab was recovered from all mice on the first day following colonisation with 
median 1.54 x 103 CFU/ml (IQR 0.33–9.22).  In contrast to D39WT and the other 
mutants studied, D39∆pab was recovered from only 1 of 7 inoculated mice by day 2, 
at a low density of only 2.14 x 102 CFU/ml.  
Thus by one day following inoculation, all three mutants were recovered from the 
nasopharynx at significantly lower colonisation densities than for D39WT.  In the 
majority of mice, all three mutants were more rapidly cleared than D39WT.  The 
auxotrophic strain D39∆pab was least able to establish nasopharyngeal colonisation.   
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3.2.2.3 Effect of lack of capsule and ∆pab mutation on TIGR4 colonisation 
density 
To confirm that these patterns were not specific to the strain background of the 
mutants, the colonisation density of genetic mutants of S. pneumoniae TIGR4 were 
compared with their WT parent strain on day 2 following colonisation (n=4-5 per 
group).  Inoculation with TIGR4 WT led to recovery from all mice on day two of a 
median of 4.68 x 104 CFU/ml (2.36– 32.3), as shown in Figure 3.3.  However, when 
inoculated with either TIGR4∆cps or TIGR4∆pab, no bacteria were recovered 
(P=0.0169 compared to wild-type for both mutant strains).  This suggested that the 
faster clearance of S. pneumoniae acapsular and ∆pab mutants was not specific to the 
strain background.  Unlike D39-D∆, TIGR4∆cps was entirely cleared by two days 
post-colonisation, despite greater numbers of WT TIGR4 than D39 at this time.  This 
would suggest that capsule exerts stronger effect in supporting colonisation in the 
TIGR4 strain than it does in D39. 
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Figure 3.3.  Recovery of TIGR4 strains from nasopharynx of CD1 mice.  
Median and IQR of bacterial load in nasal wash collected two days following nasal inoculation 
with 0.5 – 1 x 107 CFU of either TIGR4 WT, TIGR4∆cps (acapsular mutant) or TIGR4∆pab  





3.2.3 Immunogenicity of nasopharyngeal colonisation 
Having demonstrated that the mutant strains of D39 were cleared more rapidly from 
the nasopharynx than the parent WT strain, the next questions to be addressed were 
whether colonisation was immunogenic and whether it was protective against 
pneumonia.  For these experiments, groups of 20 mice were colonised with S. 
pneumoniae strains as described below.  Serum was collected from 10 mice per group 
for immunogenicity studies.  Mice were subsequently challenged as described in 
Section 3.2.4. 
3.2.3.1 Serum anti-whole cell IgG responses to colonisation with D39 strains 
To assess the immunogenicity and protective efficacy of nasopharyngeal colonisation, 
further groups of CD1 mice (n=20) were colonised with either D39WT (1.23 x 107 
CFU), D39-D∆ (0.92 x 107 CFU), D39∆lgt (1.56 x 107 CFU) or D39∆pab (1.69 x 107 
CFU).  A further group of control mice received PBS without bacteria.  10 mice per 
group were bled 28 days following colonisation and serum IgG specific to D39WT 
antigens was measured using a whole bacterial cell ELISA.  To increase the 
likelihood that all mice became colonised, and to investigate whether repeat exposure 
boosts antibody responses, a further group of mice (n=10) received two ‘colonising’ 
inoculations 14 days apart.  Serum was collected prior to each inoculation, and then 
28 days following the second inoculation.  The mice were age matched such that the 
second dose in the two-dose groups corresponded to the single colonising dose in the 
single-dose groups.  All mice were subsequently challenged as described in Section 
3.2.4.2 below. 
70% of mice colonised with D39 WT had an IgG titre greater than the range found in 
control sera, with an overall median of 1/2640 (IQR 1/10 – 1/5730, P=0.052 
compared to controls [Mann-Whitney U-test]) (Figure 3.4A).  Fewer mice developed 
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a serum anti-D39 IgG response to colonisation with the mutants which were not 
significantly different to controls.  Only 22% of mice seroconverted following 
colonisation with D39-D∆ with a median titre of 1/36 (IQR 1/10 – 1/321).  30% of 
mice seroconverted following colonisation with D39∆lgt, with a median titre of 1/114 
(IQR 1/10 – 1460).  30% of mice seroconverted following colonisation with 
D39∆pab, with a median titre of 1/21 (IQR 1/10 – 1/656).  In the group of mice 
scheduled to receive 2 colonising doses of D39 WT, all mice seroconverted 14 days 
following the first dose (Figure 3.4B), with a median titre of 1/1340 (IQR 1/810 – 
1/1510).  This was increased to 1/3960 (IQR 1/2870 – 1/14,000) by a second dose 
(P<0.0001 compared to PBS controls).  Thus, repeated exposure boosted whole cell 
antibody responses. 
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Figure 3.4.  Serum anti-D39 IgG following colonisation with D39 strains in CD1 mice. 
(A) Serum anti-D39 IgG titres 28 days following colonisation with D39 WT, or mutants or 
controls (PBS) measured by whole cell ELISA.  (B) Anti-D39 serum IgG titre prior to or 
following each of two nasal colonisation inocula given 14 days apart.  Dots represent titre of 




3.2.3.2 Serum anti-capsular polysaccharide IgG responses to colonisation with 
D39 strains 
In is not clear whether nasopharyngeal colonisation with S. pneumoniae is sufficient 
to induce a systemic IgG response against CPS.  Serum IgG responses to type 2 
capsular polysaccharide (PPS2) were therefore measured by ELISA in the sera of 
mice colonised with either D39 WT or mutants (Figure 3.5A).  Only one of ten mice 
colonised with D39 WT developed an anti-capsule response, and this was of low level 
(OD405 0.5 at 1:20 dilution).  No mice colonised with the mutants studied developed 
anti-capsule IgG.  It appeared therefore that the antigens in the whole cell ELISA that 
were recognised by the positive sera were not capsular polysaccharide.   
In the absence of a positive control serum for PPS2, to further confirm that the 
reactive antigens in the whole cell ELISA were not PPS2, four sera of mice colonised 
with D39 WT with high anti-D39 whole cell titres were tested by competitive 
inhibition ELISA.  In this assay, binding of serum IgG to solid-phase antigens was in 
competition with increasing concentrations of soluble PPS2 (Figure 3.5B).  Even at 
100 µg/ml, soluble PPS2 was unable to inhibit binding, evidence that this antigen was 
not binding IgG in these positive samples. 
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Figure 3.5.  Serum anti-capsular IgG following colonisation with D39 strains in CD1 
mice. 
(A) Serum IgG against type 2 capsular polysaccharide (PPS2) 28 days following colonisation 
with D39 WT, or mutants or controls (PBS) measured by ELISA.  Dots represent OD405 at 
1:20 serum dilution for individual mice, bars represent median of group.  (B) Competitive 
inhibition ELISA.  Effect of increasing concentration of soluble PPS2 on binding of IgG from 
sera of mice colonised with D39 to D39 coated-ELISA plates (Mean +/- SD, 100% represents 
binding in absence of inhibitor, n=4). 
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3.2.3.3 Serum IgG responses to colonisation with TIGR4 
To investigate whether the serum response to whole cell antigens was strain specific 
and whether the lack of PPS2 specific antibody was serotype specific, a further group 
of mice (n=20) were colonised with 0.52 x 107 CFU S. pneumoniae TIGR4.  10 mice 
were bled on day 28 for serum IgG against whole cell TIGR4.  All mice were 
subsequently challenged as described in Section 3.2.4.5 below.  Titres up to 1/400 
were detected in sera from naïve control mice (Figure 3.6A).  60% of mice colonised 
with TIGR4 WT developed an IgG titre outside this control range, with a median titre 
of 1/1080 (IQR 1/129 – 1/1430) versus a median for controls of 1/87 (IQR 1/13 – 
1/387, P=0.029).  TIGR4 colonisation also induced cross-reactive IgG against D39 
antigens with a titre of 1/1760.   
Anti-type 4 capsular polysaccharide (PPS4) IgG was also measured in the serum of 
mice colonised with TIGR4 WT (Figure 3.6B).  In this assay, pooled serum from 
mice that had received systemic immunisation with the 7-valent pneumococcal 
conjugate vaccine Prevenar™ was used as a positive control.  These positive control 
mice received 2 intraperitoneal injections of 100 µl (=0.2 x standard human dose) 
vaccine 14 days apart and were bled 28 days following the second vaccination.  
Whilst systemic immunisation with protein conjugated CPS induced systemic anti-
PPS4 IgG (titre = 1/29,000), colonisation with TIGR4, an encapsulated strain of this 






























Figure 3.6.  Immunogenicity of colonisation with TIGR4 WT in CD1 mice. 
Serum IgG anti-TIGR4 WT whole cell (A, as titre) and anti-PPS4 (B, as OD405 at serum 1:20 
dilution) on day 28 following colonisation with TIGR4 WT or controls (PBS) measured by 
ELISA.  Dots represent individual results, bars represent median of group.  Medians 
compared by Mann-Whitney U-test. 
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3.2.4 Protection against lethal pneumonia 
3.2.4.1 Pilot studies of protection against D39 pneumonia 
Pilot experiments were performed to assess the potential magnitude of the protective 
effect of colonisation with WT and mutant strains of S. pneumoniae against lethal 
D39 pneumonia.  In the first pilot, groups of 6-week old CD1 mice (n=10 per group) 
were colonised with 0.1 x 107 CFU of D39 WT, D39∆lgt or D39 –D∆.  Controls 
received PBS.  After 28 days, all mice were challenged with 0.75 x 107 CFU D39 i.n., 
which led to 60% survival in the control group (Figure 3.7).  There was a trend 
towards greater survival in mice that had been colonised with D39 WT (90%, 
P=0.14), but no suggestion of protection with either D39∆lgt or D39 –D∆.  This pilot 
experiment indicated that a higher challenge inoculum was required to ensure the 
development of lethal infection in the majority of control mice to power the study for 
testing of protection. 
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Figure 3.7.  Protective efficacy of colonisation-induced protection against D39 
pneumonia in CD1 mice (Pilot 1). 
Kaplan-Meier plots showing survival of mice previously colonised with 1 x 106CFU D39 WT, 
D39-D∆, D39∆lgt or  PBS (controls) and challenged 28 days later with 0.75 x 107 CFU D39 
WT (n=10 per group, comparisons to control group by log rank test). 
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Colonisation with both D39 and TIGR4 induced serum anti-D39 IgG.  A second pilot 
experiment was designed to estimate the protective effects of colonisation with these 
strains against D39 pneumonia.  Further groups of mice (n=10 per group) were 
colonised with wild-type strains of D39 and TIGR4 at 0.3 x 107 CFU and challenged 
after 28 days with 1.5 x 107 CFU D39.  The median anti-D39 serum IgG titre at the 
time of challenge was 1/2560 (IQR 1/1500 – 1/3320) in mice colonised with D39, and 
was 1/3770 (IQR 1/2070 – 1/5200) in mice colonised with TIGR4.  Again, there was 
a trend towards a protective effective in mice colonised with D39 (50% survival 
versus 30% in controls, P=0.14) (Figure 3.8).  No protection was observed in mice 
that had been colonised with TIGR4 (20% survival). 
167 
 






















Figure 3.8.  Protective efficacy of colonisation-induced protection against D39 
pneumonia in CD1 mice (Pilot 2). 
Kaplan-Meier plots showing survival of mice previously colonised with 0.3 x 107CFU D39 WT, 
TIGR4 WT or  PBS (controls) and challenged 28 days later with 1.5 x 107 CFU D39 WT (n=10 
per group, comparisons to control group by log rank test). 
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Thus, a challenge inoculum of 1.5 x 107 CFU D39 was appropriate to test protection 
in CD1 mice.  However, if the protective effect of a single colonising dose of D39 
was real, the effect was relatively modest, and larger groups of mice would be 
required to test this.  A power calculation indicated that a group size of 20 mice would 
be required.  This pilot study also suggested that TIGR4 colonisation was unlikely to 
protect against D39 challenge, and this element of cross-protection was not pursued 
further. 
3.2.4.2 Effect of colonisation with D39 strains on lethal D39 pneumonia  
Based on the data obtained from pilot experiments, a protection experiment was 
performed   to test the ability of colonisation with WT or mutant strains of D39 to 
protect against lethal D39 pneumonia.  Groups of mice (n=20) that had been 
colonised with either D39WT, D39-D∆, D39∆lgt or D39∆pab, were challenged 28 
days post-colonisation with 1.6 x 107 CFU S. pneumoniae D39 WT i.n.  A further 
group of mice that had received two colonising inocula of D39 WT, 14 days apart, 
were challenged 28 days following the second colonising dose.  The timing was such 
that the second colonising dose and challenge were at the same time as for the single 
dose groups.  The inocula and immune responses elicited by colonisation of these 
mice have already been described in Section 3.2.3.1 above.  
Only those groups that had been colonised with D39 WT were significantly protected 
against pneumonia (Figure 3.9).  40% of D39 WT colonised mice survived compared 
to 15% of controls (P=0.03).  Survival was greater still (55%, P=0.001) in those mice 
who received two colonising doses.  None of the three D39 mutant strains tested 
elicited significant protection against challenge. 
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Figure 3.9.  Protective efficacy of previous colonisation with D39 strains on 
subsequent lethal D39 WT pneumonia in CD1 mice. 
Kaplan-Meier plots showing survival of mice previously colonised with 1 or 2 doses of D39 
WT, or 1 dose of D39-D∆, D39∆lgt, D39∆pab or PBS (controls) and challenged 28 days later 
with 1.6 x 107 CFU D39 WT (n=20 per group, comparisons to control group by log rank test). 
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3.2.4.3 Correlation between serum anti-D39 IgG responses to D39 colonisation 
and protection against D39 pneumonia 
To explore the relationship between immunogenicity and protection, the correlation 
between immunogenicity (as geomean titre of anti-D39 whole cell IgG for the group) 
and protection (as percentage survival of the group) for the different colonisation 
regimes was examined (Figure 3.10).  Protection was found to correlate very closely 
with immunogenicity on this basis (P=0.001, r2=0.94).  Although this does not imply 
that serum IgG is the mechanism of protection, it suggests that this assay of 
immunogenicity is likely to be a predictive correlate of protection for the testing of 
other colonisation regimens that elicit protection through similar mechanisms. 
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Figure 3.10.  Immunogenicity of colonisation with D39 strains correlates with their 
protective efficacy against D39 pneumonia. 
Groups of CD1 mice (n=20) were colonised with either D39WT, D39-D∆, D39∆lgt or 
D39∆pab.  Coloured dots and bars represent immunogenicity as geomean anti-D39WT whole 
cell ELISA titre of the group (+/- 95% CI) versus percentage survival (+/- 95% CI) of the group 
against day 28 D39WT pneumonia challenge.  Dotted line shows correlation between 
immunogenicity and protection by linear regression. 
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3.2.4.4 Effect of D39 pneumonia on serum anti-D39 IgG  
Exposure to antigens during the process of infection has a variable effect on induction 
of antibody responses.  To explore whether S. pneumoniae D39 pneumonia is an 
immunogenic event in CD1 mice, the anti-D39 whole cell titres of serum pre- and 28 
days post-infection were compared in surviving naïve control and D39WT colonised 
mice (Figure 3.11).  There was an 5-fold increase in the serum anti-D39 IgG titre 
following infection in previously colonised mice from a median titre of 1/4,270 (IQR 
1/618 – 1/11,200) to 1/19,500 (IGR 1/8,900 – 1/37,600, P=0.03).  Although there 
were only three surviving control mice, all three developed a serum anti-D39 IgG 
response to infection and, the median titre post-infection of control mice was of a 






















Figure 3.11.  Effect of D39 pneumonia on anti-D39 serum IgG titres in previously 
colonised or control CD1 mice surviving D39 pneumonia. 
Mice previously colonised with D39WT or controls were challenged with D39WT  pneumonia 
on day 28.  Serum was collected pre-infection and on day 28 post-infection and survivor sera 
analysed by anti-D39 whole cell ELISA.  Dots represent individual mice, bars represent 
median of group.  Medians compared by Mann-Whitney U-test. 
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3.2.4.5 Effect of TIGR4 colonisation on lethal TIGR4 pneumonia 
To investigate whether colonisation with TIGR4 WT was able to induce protective 
immunity against subsequent TIGR4 WT pneumonia challenge, groups (n=20) of 
TIGR4 WT colonised and control mice were challenged with 5 x 107 CFU TIGR4 
WT i.n (Figure 3.12) at 28 days post-colonisation.  There was a trend towards 
protection with 20% of TIGR4 colonised mice surviving compared to 0% of controls 
(P=0.3 by log rank test).  It is possible that significant protection was not observed in 
this experiment because the challenge inoculum was excessive, as reflected in 0% 
survival of controls. 
 





















Figure 3.12.  Protective efficacy of previous colonisation with TIGR4 WT on subsequent 
lethal TIGR4 WT pneumonia in CD1 mice. 
Kaplan-Meier plots showing survival of mice previously colonised with 0.52 x 107 CFU TIGR4 
WT and challenged 28 days later with 5 x 107 CFU TIGR4 WT (n=20 per group, comparisons 
to control group by log rank test). 
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3.2.5 Effect of duration of nasopharyngeal colonisation on 
immunogenicity and protection 
3.2.5.1 Introduction 
Both D39-D∆, D39∆lgt and D39∆pab were all cleared from the nasopharynx more 
rapidly than D39WT, albeit at different rates (Figure 3.2).  All were found to be less 
immunogenic than D39WT.  Unlike D39WT, none protected against lethal 
pneumonia.  This raises the possibility that the duration of exposure of the immune 
system to bacteria during nasopharyngeal carriage is a critical factor for the induction 
of protective immunity.  The replicative capacity of an auxotroph can be switched on 
and off by the supplementation and withdrawal of a specific factor.  It was 
hypothesised that the addition and withdrawal of PABA supplementation to mice 
colonised with D39∆pab could be used as a tool to control the duration of 
colonisation, and thereby investigate the impact of duration of colonisation on 
immunogenicity and protection against pneumonia. 
3.2.5.2 Effect of PABA supplementation on colonisation with D39∆pab 
The inability of D39∆pab to establish colonisation of the nasopharynx was 
demonstrated in Section 3.2.2.2 above.  To assess the effect of PABA 
supplementation on D39∆pab colonisation density, groups of CD1 mice were 
colonised with 0.8 x 107 CFU D39∆pab.  Drinking water was supplemented with 
PABA at 1 mg/ml for one day prior to colonisation.  Fresh supplementation continued 
daily until 5 days following colonisation, at which point the supplementation was 
stopped.  Mice were culled at fixed timepoints and colonisation density assessed by 
culture of nasopharyngeal wash (Figure 3.13).  To assess whether PABA 
supplementation restored the ability of D39∆pab to colonise, groups of mice (n=5-9 
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per group) were culled at 1, 2, and 5 days post-colonisation.  To assess the effect of 
withdrawal of supplementation, a further group of mice were culled at day 7, two days 
after supplementation had ceased.  This time was chosen as D39∆pab had been 
cleared by two days in the majority of mice in the absence of supplementation as 
described above. 
In the presence of PABA, D39∆pab was recovered from all mice on day 1 and day 2 
post-colonisation.  Median colonisation density was 1.99 x 104 CFU/ml (IQR 0.41–
5.28) on day 1 and 1.88 x 104 CFU/ml (IQR 0.51–5.14) on day 2.  By day 5, 7 of 8 
mice remained colonised at a high density with median 4.77 x 103 CFU/ml (IQR 
1.84–6.25).  The median bacterial CFU recovered following colonisation with 
D39∆pab in the presence of PABA did not differ from D39 WT at any of these 
timepoints.  However, on day 7, two days following cessation of supplementation, 
D39∆pab was not recovered from any mouse. 
To be certain that the effect of PABA was specific to strains containing the ∆pab 
mutation, the effect of PABA on colonisation with 0.54 x 107 CFU D39 WT was 
assessed.  The median bacterial load after two days was 2.46 x 103 CFU/ml (IQR 1.8 
–13.6), not significantly different to that previously obtained in the absence of PABA 
(P=1.00 by Mann-Whitney U-test, data not shown). 
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Figure 3.13.  Effect of para-aminobenzoic acid (PABA) supplementation on colonisation 
density of D39WT and D39∆pab in CD1 mice. 
Time course of bacterial load in nasopharyngeal wash following colonisation with D39∆pab 
with PABA supplementation from day -1 to day +5.  Dots represent individual mice, bars 
represent group median, dotted line represents limit of detection. 
 
 
Thus, PABA supplementation restored the ability of D39∆pab to colonise the 
nasopharynx with a similar density and time course to the wild-type D39 strain.  This 
permits the technique to be used in future to explore in more detail how duration of 
colonisation affects immunogenicity of S. pneumoniae. 
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3.2.5.3 Effect of duration of PABA supplementation on immunogenicity  
Using PABA supplementation as a tool to control duration of colonisation, immune 
responses to D39∆pab colonisation were investigated to explore the relationship 
between colonisation duration and immunogenicity. 
To test whether the duration of nasopharyngeal colonisation has an effect on 
immunogenicity, groups of CD1 mice (n=20) were colonised with D39∆pab (0.55 x 
107 CFU).  One group (PABA+) received PABA supplementation until day 5 post-
colonisation at which time it was stopped.  The other group (PABA-) did not receive 
PABA.  Serum was collected 14 and 28 days following colonisation from 10 mice per 
group and anti-D39WT IgG measured by whole cell ELISA, as shown in Figure 3.14.  
By day 14, only 60% of PABA- mice had developed detectable serum IgG to D39, 
whereas all PABA+ mice had seroconverted.  The overall median (IQR) titre was 
1/148 (1/30 – 1/543) for PABA+ mice versus 1/44 (1/10 – 1/86) for PABA- mice 
(P=0.018).  By day 28, all mice had seroconverted, irrespective of whether 
supplemented with PABA or not.  For the PABA+ group, the median titre was 1/2120 
(1/1170 – 1.6500).  For the PABA- group the median titre was 1/714 (1/107 – 
1/2010), no longer significantly different to the PABA- group (P=0.16).  Thus, 
supplementation with PABA for 5 days leads to earlier seroconversion in response to 
D39∆pab colonisation, but does not affect overall anti-D39 IgG levels by day 28. 
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Figure 3.14.  Effect of PABA supplementation on immunogenicity of nasopharyngeal 
colonisation with D39∆pab in CD1 mice. 
Serum anti-D39WT IgG measured by whole cell ELISA 14 and 28 days following colonisation 
with 0.55 x 107 CFU D39∆pab in the presence (PABA+) or absence (PABA+) of PABA 
supplementation from day -1 to +5.  Controls received PBS.  Dots represent individual mice, 
bar represents median.  Groups compared by Mann-Whitney U-test. 
 
 
To test whether the duration of nasopharyngeal colonisation has an effect on 
protection against subsequent pneumonia, the groups of mice described above 
colonised with D39∆pab (0.55 x 107 CFU) in the presence or absence of PABA 
supplementation until day 5 post-colonisation were subsequently given pneumonia 
challenge on day 28 with 1.2 x 107 CFU D39WT (Figure 3.15) .  A further age-
matched naïve control group (n=15) were also challenged at the same time.  Although 
not statistically significant, there was a trend towards greater protection with 
D39∆pab colonisation in the presence of PABA (35% survival with median survival 
time 6.9 days, versus 20% survival with median survival time 2.9 in controls, 
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P=0.088 by log rank test) than without PABA supplementation (30% survival with 
median survival time 3.0 days, P=0.49). 
 
 






















Figure 3.15.  Protective efficacy of nasopharyngeal colonisation with D39∆pab in 
presence of absence of PABA supplementation against D39WT pneumonia in CD1 
mice. 
Kaplan-Meier plots of survival of mice (n=15-18) colonised with 0.55 x 107 CFU D39∆pab in 
the presence or absence of PABA supplementation from day -1 to +5 or naïve controls intra-
nasally challenged on day 28 with 1.2 x 107 CFU D39WT.  Groups compared by log rank test. 
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Supplementation with PABA enhanced the colonisation density and duration of 
D39∆pab to levels similar to D39WT.  Its cessation led to rapid loss of colonisation 
within two days.  When mice were colonised with D39∆pab in the presence of 
PABA, seroconversion was accelerated and there was a trend towards protection 
against D39WT pneumonia. 
3.2.6 Efficacy of D39 colonisation in cross-protecting against TIGR4 
and ST3 pneumonia 
3.2.6.1 Experimental design and optimisation 
D39WT colonisation induced non-CPS specific serum IgG as detected by whole cell 
ELISA.  To explore whether the antibody response generated was not restricted to the 
D39 strain, an experiment was designed to test the ability of D39WT colonisation to 
protect against lethal pneumonia challenge with either the serotype 4 strain TIGR4 or 
the serotype 3 strain ST3.  Prior to challenge, serum was collected for analysis of IgG 
binding to these different strains of S. pneumoniae in whole cell ELISA. 
The experiment included six groups of mice (n=20 per group), of which three were 
colonised with two doses of D39WT (1.35 x 107 CFU) and three control groups 
received PBS, each 14 days apart.  Ten mice per group were bled for serum collection 
immediately prior to challenge 28 days following the final colonising inoculation.  
The bacterial strain used to challenge groups varied, with one colonised group and 
one control group each receiving either D39WT, TIGR4 or ST3 challenge.  D39WT 
challenge groups were included as a positive control where protection was anticipated 
based on previous data.  The dose of TIGR4 for challenge was reduced 10-fold from 
that used previously to 5 x 106 CFU as disease progression was too rapid with the 
higher dose.  To determine an appropriate challenge dose of ST3, a pilot experiment 
challenging naïve CD1 mice with 1.4 x 106 CFU led to death of all mice with median 
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survival time 2.67 days (see Figure 3.16).  The ST3 challenge inoculum for the cross 
protection experiment was therefore reduced to 5 x 105 CFU.   
 


















Figure 3.16.  Pneumonia challenge of naïve CD1 mice with S. pneumoniae ST3. 
Kaplan-Meier survival curve of mice (n=7) challenged with 1.4 x 106 CFU ST3. 
 
3.2.6.2 Induction of cross-reactive anti-TIGR4 and anti-ST3 serum IgG by D39 
colonisation 
Sera collected from individual mice 28 days following D39WT colonisation were 
analysed by whole cell ELISAs to detect binding of IgG to either D39, TIGR4 or ST3 
(Figure 3.17).  D39 colonisation induced anti-D39 IgG in all mice with median titre 
1/4420 (IQR 1/1960 - 1/91300, P<0.001 versus controls).  D39 colonisation also 
induced anti-TIGR4 in all mice with median titre 1/2780 (IQR 1/1460 – 1/52000, 
P<0.001).  9 of 10 mice had detectable titres of anti-ST3 IgG with median titre 1/517 
(IQR 1/257 – 1/1230).  There was also low level binding from control serum with a 
median anti-ST3 IgG titre of 1/31 (IQR 1/10 – 1/216).  However, titres in colonised 
mice were still significantly higher (P=0.043).  Thus, colonisation with the strain 
183 

























































Figure 3.17.  Cross-reactivity of serum induced by D39WT colonisation of CD1 mice.   
Anti-D39 (A), anti-TIGR4 (B) and anti-ST3 (C) whole cell ELISA titres of day 28 serum 
collected from mice colonised by D39WT or controls.  Dots represent individual mice, bars 
represent group medians, comparison by Mann-Whitney U-test. 
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3.2.6.3 Effect of prior D39 colonisation on subsequent TIGR4 and ST3 lethal 
pneumonia challenge 
Similar to previous results, D39 colonised mice were strongly protected against 
homologous lethal pneumonia challenge with 75% survival versus 25% in controls 
(P=0.002 by log rank test) (Figure 3.18). 
However, when challenged with TIGR4 pneumonia, there was no difference in 
overall survival between D39 colonised and control groups (25% survival each, 
P=0.61 by log rank test) and with similar median survival times (3.75 days in 
colonised versus 4.04 days in controls). 
When challenged with ST3 pneumonia, there was a trend towards enhanced survival 
of colonised mice compared to controls.  35% of colonised survived compared to only 
10% controls, with median survival times 4.03 days and 3.40 days respectively 
(P=0.057 by log rank test). 
Thus although D39 colonisation established via two nasal inoculating doses induced 
IgG against both TIGR4 and ST3 antigens measured by whole cell ELISA, there was 
no significant protection against either TIGR4 or ST3 lethal pneumonia. 
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Figure 3.18.  Cross-protective efficacy of D39WT colonisation against D39, TIGR4 and 
ST3 lethal pneumonia in CD1 mice.   
Kaplan-Meier survival curves of D39WT colonised or control mice (n=20) challenged i.n. 28 
days later wither either (A) 1.5 x 107 CFU D39, (B) 5 x 106 CFU TIGR4 or (C) 5 x 105 CFU 
ST3.  Colonised group compared to control by log rank test. 
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3.3 SUMMARY OF RESULTS 
Using an inoculum of 107 CFU, S. pneumonia strains D39 and TIGR4 were both able 
to colonise the nasopharynx of CD1 mice.  D39 was cleared by 17 days.  Both D39 
and TIGR4 induced serum IgG against whole cell antigens but not against their 
respective capsules.  Competitive inhibition confirmed the absence of anti-capsular 
IgG in the whole cell ELISA.  Prior colonisation with D39 protected against 
subsequent lethal D39 pneumonia.  However, prior colonisation with TIGR4 did not 
protect against TIGR4 pneumonia.  Two colonising doses of D39 induced higher 
levels of serum anti-D39 IgG and a greater degree of protection than a single dose. 
Unencapsulated D39-D∆ colonised the nasopharynx but with fewer bacterial CFU at 
all timepoints than its parent WT strain.  It was cleared in nearly all mice by 5 days.    
Lack of capsule affected TIGR4 to a greater extent, with complete clearance of 
TIGR4∆cps by 2 days post-colonisation.  Whilst D39∆lgt colonised with fewer 
bacterial CFU at most timepoints compared to its WT parent strain, some bacteria 
were still recovered in 40% of mice after 10 days.  D39∆pab was recovered from all 
mice after 1 day, but neither D39 ∆pab nor TIGR4∆pab were recovered after 2 days.  
D39-D∆, D39∆lgt and D39∆pab did not induce significant serum anti-D39 IgG in 
this model, and were not protective against D39 lethal pneumonia.  The survival of 
groups of mice colonised with WT and mutant strains of D39 strongly correlated with 
levels of serum anti-D39 IgG. 
Supplementation of mouse drinking water with PABA restored the ability of 
D39∆pab to colonise the nasopharynx with similar numbers of bacteria recovered 
after 1, 2 and 5 days to those observed with D39 WT.  Cessation of supplementation 
at day 5 led to rapid clearance of D39∆pab by day 7.  Colonisation with D39∆pab in 
the presence of 5 days of PABA led to more rapid seroconversion with higher serum 
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anti-D39 IgG levels at 14 days but not at 28 days post-colonisation.  There was a 
trend towards protection against lethal D39 pneumonia only observed when D39∆pab 
colonisation was supported for five days with PABA. 
Colonisation with D39 WT also induced serum IgG cross-reactive with TIGR4 and 
ST3 antigens.  However, it did not cross-protect against lethal challenge with these 
strains in the challenge models used. 
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4 EFFECTS OF PRIOR COLONISATION ON 




In the previous chapter, colonisation with D39 protected CD1 mice against 
subsequent lethal pneumonia.  However, a significant proportion of colonised CD1 
mice were unprotected despite seroconversion.  The observation that prior 
colonisation can protect outbred mice is important in relating this model to naturally 
acquired protection in human populations.  However, a more consistent model is 
required to characterise the mechanism of protection in detail.  In an attempt to 
achieve consistency of results, an equivalent model of colonised-induced protection 
was established in CBA/Ca mice, an inbred mouse strain vulnerable to lethal 
pneumonia challenge with S. pneumoniae D39 (Gingles et al., 2001a).  This CBA/Ca 
model is the basis of the remaining chapters of this thesis. 
This chapter assessed the effect of prior colonisation on the pathogenesis of 
subsequent pneumonia.  This will provide insight into how the adaptive immune 
response to colonisation may protect against subsequent disease.  Richards studied the 
effects of prior colonisation with a Ply-deficient mutant on bacterial numbers in target 
organs following lethal pneumonia challenge (Richards et al., 2010).  However, the 
earliest timepoint studied was 24 h following infection, but which time 50% of control 
mice had already died.  It is not known how prior colonisation affects the progression 
of early pneumonia where its protective effect might be most important.  It is also not 
clear whether the effects of previous colonisation on subsequent pneumonia 
pathogenesis are due to antibody or whether cell-mediated immunity including Th17-
cell responses are important. 
This chapter opens with experiments confirming that D39 colonised the nasopharynx 
of CBA/Ca mice without spreading to other organs.  The immunogenicity and degree 
of protection against subsequent lethal pneumonia were then defined.  The chapter 
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then detailed the pathophysiology of this lethal pneumonia model and described how 
this is affected by prior colonisation.  In a series of experiments at timepoints, 
bacterial loads in target organs were assessed to identify how colonisation affects 
progression of disease.  Cytokine responses at the mucosal and systemic level provide 
indication of the types of adaptive immune response induced by colonisation.  
Cellular changes were characterised by microscopic examination of broncheo-alveolar 
lavage fluid (BALF), and by flow cytometric and histological assessment of infected 
lungs.  Finally, the effect of prior colonisation on alveolar macrophages phagocytosis 
of bacteria by was studied using fluorescently labeled S. pneumoniae. 
In this chapter, we addressed the following specific questions: 
• Does D39 colonisation protect CBA/Ca mice against lethal pneumonia? 
• Does colonisation induce mucosal or systemic antibody responses? 
• Does colonisation induce protection at the mucosal or systemic level? 
• Does prior colonisation prime for enhanced cytokine or cellular responses during 
pneumonia? 
• Do these observations suggest which immune effector mechanisms may be 
responsible for protection? 
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4.2 RESULTS 
4.2.1 Colonisation and protection model in CBA/Ca mice 
4.2.1.1 Time course of D39 nasopharyngeal colonisation 
To confirm that nasal inoculation would establish nasopharyngeal colonisation 
without spread in CBA/Ca mice, groups (n=4-5) were colonised with 0.4-0.62 x 107 
CFU S. pneumoniae D39 and culled at fixed timepoints.  The amount of S. 
pneumoniae were measured in nasal wash fluid on day 2,8, and 11, and from BALF, 
lung homogenate and blood on days 2 and 11 (Figure 4.1).  5 of 5 mice were 
colonised on day 2, with median density 5.7 x 103 CFU/ml (IQR 2.9-12.0).  By day 
11, 4 of 5 mice remained colonised, at a median 1.4x103 CFU/ml (IQR 0.16-3.66).  
No bacteria were recovered from any of 4 mice at 28 days.  Thus this inoculum 
established that colonisation persisted for at least 11 days but was cleared by 28 days. 
In 1 of 5 mice, a barely detectable number of S. pneumoniae were recovered from 
BALF (≤50 CFU/ml), but no S. pneumoniae were recovered from lung homogenate or 
blood at any timepoint. 
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Figure 4.1.  Nasopharyngeal model in CBA/Ca mice.  
Groups of mice (n=5-6) were nasally inoculated with 0.4 - 0.62x107CFU S. pneumoniae D39.  
Nasopharygeal wash and broncheo-alveolar lavage (BAL) was collected from culled mice at 
fixed timepoints for bacterial culture.  Dots represent data from individual mice, bars represent 
median for group.  Dotted line indicates limit of detection.  Nasopharyngeal bacterial load 
compared between day 2 and 11 by Mann-Whitney U-test. 
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4.2.1.2 Immunogenicity of nasopharyngeal colonisation 
Immunogenicity of D39 colonisation in CBA/Ca mice was assessed by measuring 
anti-D39 IgG levels (Figure 4.2) and IgA and IgM levels (Figure 4.3) in both the 
BALF (n=5-6 colonised, n=3-6 controls) and serum (n=14 colonised, n=3-9 controls) 
by whole cell ELISA.  BALF was assayed undiluted to maximise sensitivity.  Serum 
was initially assayed at 1:20 dilution and then a titre was determined by limiting 
dilution. 
Colonisation led to the generation of significantly higher levels of anti-D39 IgG 
(P=0.002) and IgA (P=0.009) in the BALF, with some mice showing small amounts 
of anti-D39 IgM in BALF.  Anti-D39 IgG was also present in serum of colonised 
mice at a median titre of 1/273 (IQR 1/60-1/869), but undetectable in controls 
(P=0.002).  Only 4 of 14 mice developed serum anti-D39 IgA.  Whilst some mice 
developed a serum anti-D39 IgM response to colonisation, most did not and these 
mice had similar results to control mice.  There was a very slight difference in median 
anti-D39 IgM levels between colonised and control mice (colonised median OD405 
0.66 (IQR 0.51-0.77) versus controls 0.46 (IQR 0.38-0.54), P=0.015), implying that 
colonisation led to less than a 50% increase in antibody level compared to that already 
























































Figure 4.2.  Anti-D39 IgG responses to D39 colonisation in CBA/Ca mice. 
IgG responses to D39 in BALF (A) or serum (B and C) obtained from colonised or control 
mice measured using whole cell ELISAs.  Responses are presented both as OD405 at 1:20 
serum dilution (B) and as titres (C).  All comparisons between colonised and control mice 





















































































Figure 4.3.  Anti-D39 IgA and IgM responses to D39 colonisation in CBA/Ca mice. 
IgA (A and B) and IgM (C and D) responses to D39 in BALF (A and C) or serum (B and D) 
obtained from colonised or control mice measured using whole cell ELISAs.  All comparisons 
between colonised and control mice performed by Mann Whitney U-test. 
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4.2.1.3 Protection against lethal pneumonia 
To assess the protective efficacy of nasopharyngeal colonisation of inbred CBA/Ca 
against lethal S. pneumoniae D39 pneumonia, groups of mice (n=19 colonised, 18 
controls) were colonised with 0.5 x 107 CFU D39 in 10µl PBS, or PBS alone 
(controls).  28 days later, mice received pneumonia challenge with 0.5 x 107CFU D39 
i.n.  Mice were monitored for signs of disease, and culled when terminally sick.  
Kaplan-Meier survival curves were generated as shown in Figure 4.4.  All control 
mice developed fatal disease with a median survival of 30 h.  However, 94% of 
previously colonised mice survived pneumonia challenge, a highly significant result 
(P<0.0001).   
 



















Figure 4.4.  Effect of prior D39 colonisation on subsequent D39 pneumonia in CBA/Ca 
mice.  
Kaplan-Meier survival curves of previously colonised or control CBA/Ca mice following 
pneumonia challenge with 5x106 CFU D39 S. pneumoniae in 50 µl PBS on day 28 post-
colonisation (n=18 or 19).  Survival compared by log rank test. 
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4.2.2 Overview of experiments to characterise pathophysiology  
The effect of prior colonisation on disease progression appeared to operate within the 
first 24 h following infection.  To understand the differences in disease process 
between colonised and control mice a series of experiments were designed to 
characterise the bacterial loads, the levels of inflammatory mediators and the cellular 
changes in various target organs at timepoints prior to 24 h. 
Groups of mice (n=6-12) were colonised as above and controls received PBS.  28 
days later, all mice were given pneumonia challenge with D39 as above.  Mice were 
then culled at fixed timepoints (4, 9 and 18 h post-challenge) and whole blood, serum, 
BALF and lungs collected for analysis.  Whole blood, BALF and lung homogenate 
were cultured to assess the burden of bacteria.  Levels of innate inflammatory 
cytokines and chemokines were measured in BALF, and levels of T-helper cell 
cytokines were measured in BALF and serum.  Neutrophil recruitment to alveolar 
spaces was assessed by examination of cytospin preparations of BALF, and 
lymphocyte and subset number in the lung measured by flow cytometry.  In addition, 
lung inflammation was assessed histologically.  In all experiments, the target inocula 
for both colonisation and infection was 1 x 107 CFU.  Actual inocula were within the 
range 0.7-1.8 x 107 CFU for colonisation and 0.4-1.5x107 CFU for challenge.   
4.2.3 Effect of prior colonisation on bacterial CFU in target organs 
during subsequent pneumonia 
To further characterise how previous colonisation may protect against pneumonia, the 
bacterial load in blood, BALF and lung of previously colonised or control mice was 
measured 4, 9 and 18 h following infection.  Figure 4.5 presents the time course of 
bacterial load in target organs in the colonised and control mice.  The same data is 
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also presented in Figure 4.6 as a direct comparison between the colonised and control 
mice at each individual timepoint. 
In control mice (Figure 4.5A), bacteria were recovered from BALF at all timepoints, 
with a median (IQR) of 8.6 x 105 CFU/ml (4.7-12.1) at 4 h.  This did not change 
significantly by 9 or 18 h.  In the lungs, there was a median of 1.2 x 104 CFU/ml (1.0-
2.0) at 4 h.  Whilst not significantly different at 9 h, this had fallen to 6.2 x 103 
CFU/ml (0.7-292) by 18 h post-infection (P=0.009 vs 9 h, NS vs 4 h).  Bacteraemia 
was assessed at 9 and 18 h.  At 9 h post-infection, 4 of 6 mice were bacteraemic, with 
a broad range in the numbers of bacteria in the blood (median 1.3 x 103 CFU/ml 
(0.02-38)).  The same proportion were bacteraemic at 18 h, but all mice that were 
bacteraemic had >105 CFU/ml of bacteria in the bloodstream. 
In the BALF of previously colonised mice (Figure 4.5B), there was no change in 
numbers of bacteria recovered from BALF between 4 and 9 h.  However, numbers fell 
by 18 h (9 hour median 1.0 x 106 CFU/ml (0.58-4.9) versus 18 hour median 3.5 x 105 
CFU/ml (1.0-25.4), P=0.002 compared to 9hrs, P=0.001 compared to 4 h).  In the 
lungs of previously colonised mice (Figure 4.5B), there was a median of 3.6 x 104 
CFU/ml (1.9-4.2) at four h.  This rose to 9.4 x 104 CFU/ml (3.9-25.2) (P=0.036) by 9 
h, but then fell significantly to a median of 5.6 x 102 CFU/ml (1.4-40.0) at 18 h 
(P=0.002 vs 9 h, P=0.008 vs 4 hrs).  No bacteria were recovered from the blood of 

























































Figure 4.5.  Bacterial load in target organs during D39 pneumonia in control or 
previously colonised mice. 
Time course of recovered bacterial CFU in BALF, lung or blood of (A) control or (B) previously 
colonised CBA/Ca mice.  Samples were harvested at 4h, 9h and 18h following challenge with 
0.5-1.5x107 CFU D39 Pnc.  Symbols indicate median and error bars indicate the IQR at that 
timepoint.  *P<0.05, **P<0.01 compared to data at 4 h by Mann-Whitney U-test.  Note: the 
same data is also presented in Figure 4.5 as a comparison of bacteria recovered from 















































































Figure 4.6.  Effect of prior colonisation on bacterial load during D39 pneumonia. 
Bacterial CFU in BALF, lung and blood of previously colonised or control CBA/Ca mice at 4h 
(A), 9h (B) and 18h (C) following challenge with 0.5-1.5x107 CFU D39 Pnc.  Dots represent 
data from individual mice, bars represent group medians.  Dotted line indicated limit of 
detection.  Groups compared using the Mann-Whitney U-test.   Note: the same data is also 
presented in Figure 4.4 as a separate time courses for colonised (Fig. 4.4a) and control (Fig. 
4.4b) mice. 
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At no timepoint was there a statistically significant difference in numbers of bacteria 
in BALF or lung between colonised and control mice (Figure 4.6).  However, there 
was a strong trend towards 10-fold fewer bacteria in the lungs of previously colonised 
mice at 18 h (P=0.064) (Figure 4.6), suggesting the possibility that colonisation was 
inducing some protection at this site and timepoint.  Furthermore, at no point were 
any previously colonised mice bacteraemic, unlike the majority of controls at both 9 
and 18 h. 
Thus, previous colonisation strongly protected against the development of 
bacteraemia during subsequent pneumonia challenge.  In addition there was a trend 
towards reduced lung bacterial numbers by 18 h post-infection. 
4.2.4 Effect of prior colonisation on cytokine responses during 
subsequent pneumonia 
To assess the inflammatory response to infection in previously colonised or control 
mice, levels of the innate cytokines KC, IL-6, TNF-α, GM-CSF, IL-1β and IL-12p70 
were measured in BALF at 4 and 18 h post-infection, and are shown in Figure 4.7.  
KC, IL-6, TNF-α, GM-CSF and IL-1β were all detectable at 4 h post-infection in the 
BALF of control mice.  Mean levels of all these inflammatory mediators appeared 
slightly higher at this timepoint in the BALF of colonised mice (Figure 4.7A).  Levels 
were statistically significantly higher for IL-6 (mean 2860 pg/ml (SD 440) versus 
1859 pg/ml (SD 681) controls, P=0.013) and TNF-α (mean 3312 pg/ml (SD 1565) 
versus 1698 pg/ml (SD 713) controls, P=0.044). 
203 
BALF: 4 hours

















































Figure 4.7.  Effect of prior colonisation on levels of innate mediators in BALF during 
pneumonia. 
BALF samples were collected either 4h (A) or 18h (B) following D39 S. pneumoniae 
pneumonia challenge with 0.5-0.9x107 CFU of previously colonised or control CBA/Ca mice 
(n=6 per group).  Levels were measured by Luminex bead assay other than for IL-23 which 
was measured by ELISA.  Group mean + SD are shown.  Results compared using unpaired 
Student t-tests. 
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By 18 h post-infection (Figure 4.7B), levels of all these cytokines were lower than at 
4 h with the exception of IL-12p70 which was only detectable at this timepoint.  
There were no significant differences between colonised and control mice for any of 
these mediators at 18 h.  There was insufficient BALF available to test for levels of 
IL-23 at 4 h post-infection.  However, levels of IL-23 were significantly higher in the 
BALF of colonised mice than controls (P=0.006) at 18 h.  Thus, prior colonisation 
appeared to prime for higher BALF levels of IL-6 and TNF-α at 4 h and IL-23 at 18 h 
post-infection. 
Although not the sole producers of these cytokines, differences in the levels of IL-17 
and IFN-γ between colonised and control mice could be indicative of a colonisation-
induced mucosal or systemic Th17 or Th1 cell responses.  Levels were therefore 
measured in the BALF at 4 and 18 h post-infection and in serum after 18 h and are 
shown in Figure 4.8. 
IL-17 was detectable in the BALF of all colonised mice at both timepoints (Figure 
4.8A).  IL-17 levels increased in colonised mice from 4 to 18 h post-infection 
(P=0.001), and by 18 h were higher than in control mice (P=0.004).  Serum levels of 
IL-17 were also higher in colonised mice than controls, 18 h post-infection (P=0.003) 
(Figure 4.8B).  No IFN-γ was detectable in the BALF or serum of either colonised or 
control mice at either timepoint (Figure 4.8B-C). 
To identify further evidence of Th17 memory, levels of IL-22, another Th17-cell 
signature cytokine, were measured in BALF at 18 h post-infection (Figure 4.8D).  
Again, levels were significantly higher in BALF of colonised than control mice. 
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Figure 4.8.  Effect of prior colonisation on BALF and serum levels of CD4 T-cell 
cytokines during pneumonia. 
BALF and serum samples were collected either 4h or 18h following D39 Pnc pneumonia 
challenge with 5-9x106 CFU of previously colonised or control CBA/Ca mice (n=6 per group) 
and cytokine levels measured by ELISA.  Mean (+SD) are presented for 4h and 18h BALF IL-
17 (A), 18h serum IL-17 and IFN-γ (B), 4h and 18h BALF IFN-γ (C)  and 18h BALF IL-22 (D).  
Dotted line indicates limit of detection.  Colonised and control mice were compared by 
unpaired Student t-test.  Data representative of two replicate experiments with similar results.  
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4.2.5 Effect of prior colonisation on cellular and inflammatory 
processes during subsequent pneumonia 
4.2.5.1 Effect of prior colonisation on lung lymphocyte subsets  
The effect of prior colonisation on the number and subsets of lymphocytes present in 
the lungs of infected mice was assessed at 18 h post-infection (Figure 4.9).  Absolute 
numbers of total lymphocytes, B-cells, T-cells and CD4+ T-cells were measured.  In 
addition, numbers of B- and T-cells as a proportion of all lymphocytes, and CD4+ T-
cells as a percentage of all T-cells were calculated.  There were no differences 
between previously colonised and control mice for any of these parameters. 
In addition to Th17-cells, gamma-delta T-cells are recognized as a potential source of 
IL-17.  Absolute numbers of total lymphocytes and gamma-delta T-cells were 
measured in the lungs 4 h post-infection.  Again, there was no difference between 




















































































































































































































































































































































































































































































































































































































































Figure 4.10.  Effect of prior colonisation on subsets of lung lymphocytes and gamma-
delta T-cell 4 h following pneumonia challenge. 
Total lung lymphocytes, and gamma-delta T-cells measured by flow cytometry of lung 
homogenates collected 4h following pneumonia challenge with 0.5x107CFU D39 Pnc in 
previously colonised or control CBA/Ca mice.  Each dot represents an individual mouse, bars 
represent group medians.  There were no statistically significant differences between 
colonised and control mice for any cell subset measured (P>0.05 by unpaired Student t-test).
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4.2.5.2 Effect of prior colonisation on neutrophil recruitment to BALF  
Although no differences were seen in lung lymphocyte numbers at either 4 or 18 h 
post-infection, there was evidence that colonisation primed for greater cytokine 
responses in the lung following infection.  As neutrophils are the earliest cells 
recruited to alveolar spaces in S. pneumoniae pneumonia, numbers in BALF were 
assessed.  To identify if this correlated with enhanced recruitment of neutrophils to 
alveolar spaces, cytospin preparations of BALF from infected mice were examined 
(Figure 4.11).  The proportion of neutrophils amongst BALF leukocytes was 
measured prior to and at 4, 9 and 18 h post-infection (Figure 4.11A).  The absolute 
numbers of neutrophils (Figure 4.11B) and monocytes/macrophages (Figure 4.11C) in 
BALF were also measured prior to and at 4 and 9 h post-infection. 
Prior to infection, barely any neutrophils were found in the BALF from either groups 
of mice, with >99% monocytes/macrophages present.  However, by 4 h following 
infection, there had been greater recruitment of neutrophils to the alveolar space in 
colonised mice than control mice (mean 2.2 x 105 (SD 0.4) cells/ml BALF versus 1.1 
x 105 (0.7) respectively, P=0.002) (Figure 4.11B).  There was no difference in the 
number of monocytes/macrophages present.  This corresponded to a difference in 
percentage neutrophils at four h (79.4% neutrophils (SD 11.3) in the BALF of 
colonised mice, but only 58.3% (SD 13.9) in controls (P=0.0003) (Figure 4.11A).  
Absolute numbers of macrophages/monocytes rose in both groups of mice by nine h.  
However, neutrophil recruitment predominated such that the BALF from both 
colonised and control mice contained a mean of 93% neutrophils at both 9 and 18 h 
post-infection (Figure 4.11A).  Thus, prior colonisation primed for greater neutrophil 
recruitment at 4 h, but there was no longer a difference by 9 h post-infection. 
210 
% Neutrophils
































































Figure 4.11.  Effect of prior colonisation on leukocyte recruitment to alveolar spaces 
during subsequent pneumonia. 
Numbers of neutrophils and monocyte/macrophages were assessed by haemocytometer 
count and staining of cytospin preparations of BALF collected from previously colonised or 
control CBA/Ca mice either prior to or at 4h, 9h or 18h following pneumonia challenge with 
0.4-1.5x107 CFU D39 Pnc. (A) Neutrophil proportion of total BALF leukocytes.  Data 
presented as mean ± SD (n=6 per group) throughout.  Absolute cell counts were not available 
for 18h timepoint.  Comparisons between groups at a timepoint and comparison for a group 
between two timepoints by unpaired Student t-test. 
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4.2.5.3 Effect of prior colonisation on pulmonary inflammation 
To characterise the overall effect of prior colonisation on pulmonary inflammation 
during pneumonia, lungs were collected from mice 18 h post-infection.  
Haematoxylin and eosin-stained sections were examined and scored for degree of 
inflammatory change by Mr Steve Bottoms, an experienced histopathology research 
technician, who was blinded to which group the samples came from.  This scoring 
system accounted for tissue swelling, cellular infiltrate, haemorrhage and disturbance 
of alveolar architecture.  The lungs of all mice had evidence of inflammation.  Whilst 
the previously colonised mice tended to have higher inflammation scores than non-
colonised controls (median of colonised mice 1.9 (IQR 1.5-3.0) versus controls 1.6 



















Figure 4.12.  Effect of prior colonisation on lung inflammation during subsequent 
pneumonia in CBA/Ca mice. 
Lung inflammation scores assessed by blinded examination of H&E-stained lung sections 
collected 18h following challenge with 5 x 107 CFU S. pneumoniae D39 in previously 
colonised or control mice.  Dots represent individual mice, bars represent medians.  P>0.05 
by unpaired Student t-test.  Sample processing, staining and inflammation scoring was kindly 
performed by Mr Steve Bottoms (UCL Centre for Respiratory Research). 
212 
4.2.6 Effect of prior colonisation on alveolar macrophage association 
during subsequent pneumonia 
Prior colonisation with D39 induced detectable IgG and IgA against D39 antigens in 
BALF.  It was possible that mucosal antibody could opsonise bacteria during 
infection enhancing phagocyte association and uptake.  Phagocyte activity could also 
be greater due to higher TNFα or IL-6 levels in the BALF of previously colonised 
mice.  To investigate the association of bacteria with macrophages within the alveolar 
spaces during infection, previously colonised or control mice were infected with 
0.9x107 CFU D39 fluorescently-labelled with FAM-SE.  BALF was collected after 4 
h, and the fluorescence of alveolar macrophages assessed as an indicator of their 
association with bacteria (Figure 4.13).   The mean MFI of alveolar macrophages was 
not significantly different for the two groups (77.4 (SD 66.9) for colonised mice and 
106.5 (SD 62.6) for controls).  Thus, despite the presence of mucosal antibody and 
enhancement of cytokine responses, there appeared to be no difference in macrophage 


























Figure 4.13.  Effect of prior colonisation on alveolar macrophage bacterial association 
during subsequent pneumococcal pneumonia. 
Previously colonised or control CBA/Ca mice were challenged with 0.9x107 CFU FAM-SE-
labelled D39 Pnc and BALF collected after 4h for flow cytometry.  Macrophages were gated 
according to scatter characteristics and bacterial association assessed as MFI of this 
population.  Dots represent individual mice, bars represent medians.  P>0.05 by Mann-
Whitney U-test. 
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4.3 SUMMARY OF RESULTS 
S. pneumoniae D39 colonised the nasopharynx of CBA/Ca mice and was cleared by 
28 days with a time course similar to that seen in CD1 mice.  There was no significant 
spread to lungs or blood.  Colonisation induced significant anti-D39 IgA and IgG in 
BALF and IgG in serum.  A small number of mice had increased serum IgM to D39 
antigens but this effect was modest.  Colonised mice were strongly protected against 
lethal D39 pneumonia challenge.  Despite similar levels of bacteria in BALF and 
lungs, colonised mice were completely protected against bacteraemia.   
Previously colonised mice were primed for higher BALF levels of IL-6 and TNF-α at 
4 h, and higher levels of IL-17, IL-22 and IL-23 at 18 h post-infection.  In addition, 
prior colonisation led to higher levels of serum IL-17 at 18 h.  No IFN-γ was 
detectable in BALF or serum at any timepoint.  This suggested that previously 
colonised mice may be primed for a Th17 response elicited during pneumonia.   
No differences were seen in any lung lymphocyte subset at 18 h post-infection, or in 
gamma-delta T-cells at 4 h post-infection.  There were more neutrophils in BALF at 4 
h than in control mice but not at 9 h.  However, by 18 h no differences in lung 
inflammation could be observed histologically.  Furthermore, prior colonisation did 
not affect the association of bacteria with alveolar macrophages 4 h post-infection. 
Thus, prior colonisation protects against lethal pneumonia by preventing bacteraemia.  
Although cytokine levels suggest a Th17 response to colonisation, there was little 
evidence for mucosal protection in this model. 
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Data from the previous chapter demonstrated that CBA/Ca mice previously colonised 
with S. pneumoniae D39 survive subsequent lethal D39 pneumonia.  They did not 
develop bacteraemia during pneumonia despite numbers of lung and BALF bacteria 
that are sufficient to cause bacteraemia in controls.  This suggests that mice survive 
lethal challenge because they do not become bacteraemic.  Colonisation led to both 
mucosal and systemic antibody responses against non-capsular antigens detectable in 
serum and BALF.  Pathogenesis studies also revealed significantly higher levels of 
IL-17 and IL-22 in BALF and IL-17 in serum of previously colonised mice during 
subsequent pneumonia, but no detectable IFN-γ.  This may be indicative of a Th17 
response to colonisation.  Thus, both antibody and CD4+ memory T-cells induced 
through colonisation could have roles in colonisation-induced protection. 
Adaptive immune responses induced through colonisation may protect at the mucosal 
level by enhancing clearance of bacteria from alveolar spaces and lungs, and 
systemically by preventing bacteraemia.  Both levels of protection could be mediated 
by antibody or adaptive cellular responses.  Activation of CD4+ memory T-cells of 
the Th17 phenotype during pneumonia could contribute to protection in several ways.  
Th17 responses may affect the integrity of the mucosa and enhance the recruitment of 
phagocytic cells (Iwakura et al., 2008).  They may also increase the killing capacity of 
phagocytes (Lu et al., 2008).  Such responses appear to contribute to protection 
against re-colonisation (Zhang et al., 2009, Malley et al., 2005, Lu et al., 2008). 
There are limited data regarding the relative contributions of these mechanisms to 
colonisation-induced protection.  Colonisation with unencapsulated type 6A S. 
pneumoniae, which protected wild-type C57Bl/6 mice against wild-type type 6A 
challenge, did not protect µMT mice (Roche et al., 2007).  µMT mice have a mutation 
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in the immunoglobulin µ-chain gene, resulting in an absence of mature B cells 
(Kitamura et al., 1991).  Thus they cannot develop antibody responses.  This suggests 
that antibody responses are important in colonisation-induced protection.  Whether 
antibody is functioning at the mucosal or systemic level is not known, nor whether 
colonisation-induced antibody alone would be sufficient to protect.  In this report, 
MHCII-/- mice, which congenitally lack CD4+ T-cells, were also not protected.  CD4+ 
T-cells play a critical role in the development of antibody responses, facilitating B-
cell somatic hypermutation and class switching in germinal centres (Heyzer-Williams 
et al., 2009).  In addition to their inability to develop T-helper cell memory responses 
to colonisation, MHCII-/- mice will also be expected to have diminished antibody 
responses.  Thus, it is not clear whether poor antibody responses rather than absence 
of memory T-cells is responsible for lack of protection in these mice. 
This chapter attempts to define the specific roles of antibody and CD4+ cell responses 
during colonisation-induced protection in CBA/Ca mice.  Numbers of bacteria in the 
lungs and blood of mice were assessed at 18 h following pneumonia challenge as 
indicators of protection.  This timepoint was chosen at it is when the biggest 
differences between colonised and control mice were observed during pathogenesis 
studies, as described in the previous chapter.  Experiments using in vivo CD4-
depletion, µMT mice and passive transfer of serum help to define the relative 
contributions of antibody and CD4+ T-cell responses to colonisation-induced 
protection. 
In this chapter, we addressed the following specific questions: 
• Do the IL-17 responses to colonisation depend on the presence of CD4+ cells 
at the time of challenge? 
• Are CD4+ cells required at the time of challenge to effect protection? 
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• Is antibody necessary for colonisation-induced protection? 




5.2.1 Effect of CD4+ cell depletion on colonisation-induced protection  
To test whether CD4+ T-cells are required to effect protection, a system was needed 
where they would be present at colonisation but absent at pneumonia challenge.  In 
vivo cellular depletion by systemic administration of a monoclonal antibody (mAb) is 
an established technique for depleting specific cell types at particular times in animal 
models.  The mAb GK1.5 was therefore used to deplete CD4+ cells specifically prior 
to challenge. 
5.2.1.1 Optimisation of CD4+ cell depletion 
Prior to administration of GK1.5 to colonised mice in a protection experiment, a pilot 
experiment was performed to optimize CD4+ cell depletion and ensure that systemic 
administration (i.p.) led to efficient depletion both in the spleen and in the lungs.  
Initially, 10-week old CBA/Ca mice (n=1 per group) were administered either 200µg 
GK1.5 i.p. or PBS.  24 h later, 2 mice (1 GK1.5 recipient and 1 control) were given 
pneumonia challenge with 8.5 x 106 CFU D39.  Both challenged and unchallenged 
mice were culled at 18 h post-infection.  In pilot experiments, a single dose of 200µg 
GK1.5 given 24 h pre-infection led to least 69% depletion of CD4+ T-cells from the 
spleen 18 h post-infection.  There was 98% depletion of CD4+ T-cells from the lungs 
at this timepoint.  Illustrative FACS plots showing the effect of GK1.5 are shown in 
Figure 5.1.  To improve the splenic depletion, 2 doses of 250µg GK1.5 were 
administered, on days -2 and -1 prior to infection.  This increased the depletion of 
CD4+ cells from the spleen to 91%.  This 2-dose regimen was therefore used to 
deplete CD4+ cells from colonised and control mice prior to challenge. 
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5.2.1.2 Effect of prior colonisation on bacterial burden during pneumonia in the 
absence of CD4+ cells 
To explore the effect of depletion of CD4+ cells prior to challenge, mice were 
colonised as previously described with 6.5 x 106 CFU D39 (n=6 per group).  Controls 
received PBS.  On days 26 and 27 post-colonisation, all mice received GK1.5 250µg 
i.p.  On day 28, all mice were challenged with 4 x 106 CFU i.n.  Mice were culled 
after 18 h, and blood, serum, BALF and lungs collected.  Efficiency of CD4+ T-cell 
depletion from the spleens of mice included in the experiment was >90% as assessed 
by flow cytometry.  Bacterial CFU recovered from target organs are shown in Figure 
5.2.  There were no significant differences in the number of bacteria recovered from 
BALF or lungs of colonised and control mice.  3 of 6 control mice were bacteraemic 
at 18 h.  However, no previously colonised mice were bacteraemic (P=0.043 by Chi-
squared test).  Furthermore, there was a strong trend towards a lower median bacterial 
load in blood of previously colonised mice (P=0.09 by Mann-Whitney U-test).  To 
confirm these findings, this experiment was repeated and similar results were obtained 
(data not shown).  Thus, depletion of CD4+ cells prior to challenge did not affect the 










Figure 5.1.  Depletion of CD4+ cells by mAb Gk1.5 
Representative flow cytometry dot plots of splenocytes (A+B) and lung homogenates of 
CBA/Ca mice  (C+D) collected 18h following pneumonia challenge with 8.5x106 CFU D39 S. 
pneumoniae either without (A+C) or with (B+D) administration of 200µg GK1.5 i.p. 24h prior 
to infection.  Cells were stained for CD3 and CD8, and percentage CD3+CD8- of total CD3+ 
is shown.  Efficiency of depletion of the CD3+CD8- compartment was subsequently 















































































Figure 5.2.  Effect of prior colonisation on bacterial loads in target organs following 
pneumonia challenge of mice depleted of CD4+ cells. 
Previously colonised or control CBA/Ca mice were depleted of CD4+ cells by administration 
of mAb GK1.5 250µg i.p. 48h and 24h prior to i.n. challenge with 4.0x106 CFU D39 S. 
pneumoniae.  Bacterial CFU were measured in BALF, lung and blood 18h following 
challenge. Dots represent data from individual mice, bars represent group medians.  Dotted 
line indicated limit of detection.  Comparison on numbers of CFU from colonised and control 
mice by Mann-Whitney U-test.   Comparison for presence of bacteraemia by χ2-test.  Data 
representative of two experiments with similar results. 
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5.2.1.3 Effect of prior colonisation on cytokine responses during pneumonia in 
the absence of CD4+ cells 
When CD4+ cells were present, no differences were found in the levels of KC, IL-6, 
TNF-α, GM-CSF, IL-1β and IL-12p70 between colonised and control mice at 18 h 
post-infection.  However, levels of IL-17 were higher in both BALF and serum of 
previously colonised mice, suggestive of a Th17-cell response.  Cytokine levels were 
therefore measured 18 h post-infection in the BALF and serum of the colonised and 
control mice that had been depleted of CD4+ cells prior to challenge, as shown in 
Figures 5.3 and 5.4.  In the absence of CD4+ cells, there was no significant difference 
in BALF IL-17 levels between colonised and control mice (Figure 5.3), with mean 
34.9 ± 26.2 pg/ml in colonised mice and 50.2 ± 14.5 pg/ml in controls (P=0.24).  IL-
17 levels in colonised mice depleted of CD4+ cells were similar to those previously 
obtained in undepleted controls (mean 27.6 ± 18.0 pg/ml (P=0.59).  Interestingly, IL-
17 was barely detectable in the serum of either colonised or control CD4+ cell 
depleted mice following challenge (Figure 5.3).    No significant differences were 
observed between colonised and control CD4+ cell depleted mice in the levels of KC, 
IL-6, TNF-α, GM-CSF, IL-1β and IL-12p70 in BALF (Figure 5.4).  Thus, the 
enhanced levels of IL-17 in BALF and serum during infection, attributable to prior 



















Figure 5.3.  Effect of prior colonisation on BALF and serum IL-17 levels following 
pneumonia challenge of mice depleted of CD4+ cells. 
Previously colonised or control CBA/Ca mice (n=6 per group) were depleted of CD4+ cells by 
administration of mAb GK1.5 250µg i.p. 48h and 24h prior to i.n. challenge with 4.0x106 CFU 
D39 S. pneumoniae.  Serum and BALF IL-17 collected 18h post-infection was measured by 
ELISA.  Group means and SDs are shown, dotted line indicates limit of detection.  
Comparison between BALF IL-17 levels from colonised and control mice by unpaired Student 




















Figure 5.4.  Effect of prior colonisation on levels of innate inflammatory mediators in 
BALF following pneumonia challenge of mice depleted of CD4+ cells. 
Previously colonised or control CBA/Ca mice (n=6 per group) were depleted of CD4+ cells by 
administration of mAb GK1.5 250µg i.p. 48h and 24h prior to i.n. challenge with 4.0x106 CFU 
D39 S. pneumoniae.  BALF was collected 18h post-infection and levels of mediators 
measured by Luminex bead assay.  Group means and SDs are shown.  No significant 
differences were observed between colonised and control mice as assessed by unpaired 
Student t-test. 
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5.2.2 Effect of prior colonisation on subsequent pneumonia challenge 
in antibody deficient µMT mice 
Given the redundancy of CD4+ cells in effecting protection against bacteraemia 
secondary to pneumonia, it was hypothesized that systemic antibody may play an 
essential role in mediating colonisation-induced protection.  To test this hypothesis, 
experiments were performed involving the colonisation and infection of µMT mice, 
which congenitally lack antibody.  C57/BL6 mice (the background strain from which 
µMT were produced) are known to be more resistant to S. pneumoniae pneumonia 
challenge than CBA/Ca mice (Gingles et al., 2001a).  Therefore, prior to the definitive 
experiment, the pneumonia model in µMT mice was confirmed as equivalent to 
CBA/Ca mice as described below. 
5.2.2.1 Establishing µMT mouse pneumonia model 
To confirm that the pneumonia challenge model in µMT mice was equivalent to that 
in CBA/Ca mice, an initial experiment was undertaken to measure the bacterial loads 
in naïve µMT mice following pneumonia challenge.  µMT mice (n=6) aged 10-12 
weeks were infected with 9.2 x 106 CFU i.n.  Mice were culled after 18 h and 
bacterial loads in target organs was assessed, as shown in Figure 5.5.  For one mouse, 
bacteria were barely detectable in BALF and no bacteria were recovered from the 
lung or blood, suggesting that the mouse had not become infected.  All other mice had 
bacteria recovered from both BALF and blood, and for 4 of 5 mice with lung 
infection, bacteraemia was also present.  Median (IQR) CFU counts from BALF, lung 
and blood were 6.6 x 104 CFU/ml (0.15-34), 2.1 x 104 CFU/ml (0.008-2.8) and 1.52 x 
105 CFU/ml (0.0002-17.5) respectively.  These were similar to the bacterial loads in 
these organs in naïve CBA/Ca mice at 18 h following infection.  Thus pneumonia 
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challenge of µMT mice provides an appropriate model for studying protective 
efficacy of colonisation in the absence of antibody. 
5.2.2.2 Effect of prior colonisation on bacterial burden during pneumonia in 
µMT mice 
To investigate the effect of prior colonisation on subsequent pneumonia in the 
absence of antibody, µMT mice (n=6) were colonised with 1.16 x 107 CFU D39.  
Control mice received PBS.  After 28 days, all mice were challenged with 8.4 x 106 
CFU i.n.  Mice were culled at 18 h post-infection to assess bacterial load in BALF, 
lungs and blood (Figure 5.6).  There were no significant differences in the number of 
bacteria recovered from either the BALF, lungs or blood between colonised and 
control µMT mice.  Furthermore, all previously colonised µMT mice were 
bacteraemic at 18 h post-infection.  This is in marked contrast to the strongly 
protective effect of prior colonisation in antibody-sufficient CBA/Ca mice.  These 
data imply that colonised-induced antibody is required for limiting the lung bacterial 

























Figure 5.5.  D39 S. pneumoniae pneumonia model in µMT mice. 
Bacterial CFU recovered from BALF, lung and blood of µMT mice at 18h following challenge 
with 9.0x106 CFU D39 S. pneumoniae.  Dots represent data from individual mice, bars 


































































Figure 5.6.  Effect of prior colonisation on bacterial load in target organs during D39 
pneumonia in µMT mice. 
Bacterial CFU recovered from BALF, lung and blood of previously colonised or control µMT 
mice at 18h following challenge with 8.1 x 106 CFU D39 S. pneumoniae.  Dots represent data 
from individual mice, bars represent group medians.  Dotted line indicated limit of detection.  
Comparison between colonised and controls by Mann-Whitney U-test.  
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5.2.3 Effect of passive transfer of serum from colonised mice on 
subsequent pneumonia challenge 
To determine if systemic antibody alone was sufficient to protect against bacteraemia 
and whether it had any effect on lung bacterial burden passive serum transfer 
experiments were undertaken.  In these experiments, groups of CBA/Ca mice were 
colonised with D39.  Controls received PBS.  Serum was collected from mice 28 days 
following colonisation.  Groups of naïve recipient mice received pooled passive 
serum i.p. prior to challenge as described below.  Mice were culled 18 h post-
challenge and blood, lung and BALF collected.   Bacterial loads in target organs were 
assessed.   
5.2.3.1 Pilot experiment: effect of ‘low dose’ passive serum transfer on bacterial 
burden during pneumonia 
In an initial pilot experiment, serum pools were prepared from three mice that had 
been colonised with 2.0 x 106 CFU i.n. and six control mice.  The anti-D39 IgG titre 
for the pooled serum was 1/959.  Naïve recipients (n=6 per group), aged 6-8 weeks, 
were given 100µl of either pooled colonised (‘immune’) or control serum i.p.  16 h 
later all mice were challenged with 2.0 x 106 CFU i.n.  The bacterial loads in BALF, 
lung and blood at 18 h post-infection are shown in Figure 5.7.  There were no 
significant differences in the amount of bacteria recovered from any organ between 
recipients of immune or control serum.  It was noted that all recipients of control 
serum had high-level bacteraemia (>104 CFU/ml) at 18 h, despite the challenge 
inoculum not being high.  This was possibly attributable to the recipient mice being 
aged 6-8 weeks old at challenge.  In the experiments described previously where 
actively colonised mice were subsequently challenged, mice were 6-8 weeks old at 
colonisation and 10-12 weeks of age by the time of challenge.  The relatively small 
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amount of serum passively transferred may have been insufficient to protect against 
challenge in more vulnerable younger mice.  A further experiment was designed to 
overcome both of these issues. 
5.2.3.2 Effect of ‘high dose’ passive serum transfer on bacterial burden during 
pneumonia 
To increase the amount of passively transferred antibody, further groups of mice were 
colonised with D39 at 7.5 x 106 CFU i.n.  Serum was pooled from 19 colonised 
donors (‘immune serum’) and 14 control donors.  The anti-D39 IgG titre of the 
immune serum was 1/2260.  Recipient mice were aged 10-12 weeks at the time of 
challenge in line with previous active colonisation experiments.  Naive recipients 
(n=6 per group), received 2 doses of 225µl immune or control serum i.p. at 6 h and 
again 30 min prior to challenge.  All recipient mice were challenged with 8.5 x 106 
CFU i.n.  Bacterial load in target organs was assessed 18 h post-infection (Figure 5.8).  
There was no difference in bacterial numbers in the BALF of recipients of immune or 
control serum.  However, the median bacterial CFU was significantly lower 
(P=0.026) in the lungs of recipients of immune serum.  Furthermore, only 1 of 6 
recipients of immune serum was bacteraemic, compared to 5 of 6 controls (P=0.04). 
To determine the efficiency of passive antibody transfer, the anti-D39 IgG levels in 
serum and BALF collected 18 h post-infection was measured by whole cell ELISA 
(Figure 5.9).  All recipients of immune serum had detectable anti-D39 IgG in serum, 
with median titre 1/321 (IQR 1/194-1/411) (Figure 5.9A).  Thus, the serum anti-D39 
IgG level was approximately 7-fold less in the serum of recipients during infection 
than in actively colonised unchallenged mice.  Anti-D39 IgG levels in the BALF of 
recipients of immune serum was also significantly higher than that of recipients of 
control serum (P=0.002) (Figure 5.9B).  These data show that systemic antibody is 












































































Figure 5.7.  Effect of low dose passive transfer of serum from previously colonised 
mice on bacterial loads in target organs following pneumonia challenge of recipients. 
100 µl of serum pooled from either previously colonised (n=3, pooled titre=1/959) or control 
(n=6) CBA/Ca mice was administered to naïve CBA/Ca recipients (n=6 per group) 16h prior to 
pneumonia challenge with 2x106 CFU D39 S. pneumoniae.  Bacterial CFU were measured in 
BALF, lung and blood 18h following challenge. Dots represent data from individual mice, bars 
represent group medians.  Dotted line indicated limit of detection.  Absent data points are due 
to contamination of cultures.  No significant differences observed between colonised and 











































































Figure 5.8.  Effect of high dose passive transfer of serum from previously colonised 
mice on bacterial loads in target organs following pneumonia challenge of recipients. 
225 µl of serum pooled from either previously colonised (n=19, pooled titre=1/2260) or control 
(n=14) CBA/Ca mice was administered to naïve CBA/Ca recipients (n=6 per group) 6h and 
30min prior to pneumonia challenge with 8.5x106 CFU D39 S. pneumoniae.  Bacterial CFU 
were measured in BALF, lung and blood 18h following challenge. Dots represent data from 
individual mice, bars represent group medians.  Dotted line indicated limit of detection.  



































Figure 5.9.  Effect of prior colonisation of donor mice on recipient serum and BALF 
anti-D39 IgG titres. 
225 µl of serum pooled from either previously colonised (n=19, pooled titre=1/2260) or control 
(n=14) CBA/Ca mice was administered to naïve CBA/Ca recipients (n=6 per group) 6h and 
30min prior to pneumonia challenge with 8.5x106 CFU D39 S. pneumoniae.  Anti-D39 IgG 
was measured in recipient serum and BALF collected 18h following challenge.  Dots 
represent data from individual mice, bars represent group medians.  Groups compared by 
Mann-Whitney U-test. 
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5.3 SUMMARY OF RESULTS 
In the absence of CD4+ cells at the time of pneumonia challenge, there was no 
increase in IL-17 levels in the BALF of previously colonised mice.  Furthermore, IL-
17 was barely detectable in the serum in either group.  Despite this, previously 
colonised mice were still strongly protected against bacteraemia in the presence of a 
significant bacterial burden in the lung.  These data suggest that memory CD4+ T-
cells are a likely source of the enhanced IL-17 levels achieved through prior 
colonisation, but that such responses are redundant in the protection against 
bacteraemia.  Colonisation did not induce protection in the absence of antibody in 
µMT mice.  Thus colonisation-induced antibody responses are necessary to protect 
against bacteraemia during D39 pneumonia.  Passive i.p. transfer of serum from 
previously colonised mice to naive recipients was sufficient to protect against 
bacteraemia.  It also led to fewer bacteria within the lungs compared to controls.  
Anti-D39 IgG was found in both the serum and BALF of recipients.  This implies that 
during infection there is either leak or transfer of systemic antibody into the alveolar 
spaces.  Overall, the data presented in this chapter demonstrate that colonisation-
induced serum antibody is both necessary and sufficient to protect against 
bacteraemia during subsequent pneumonia, and that CD4+ cells are redundant. 
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6 FUNCTION OF COLONISATION-




During S. pneumoniae pneumonia, if bacterial growth is not controlled within alveolar 
spaces and lung tissues, bacteria may gain access to the circulation.  Antibody present 
in the alveolar spaces may potentially control early infection by several mechanisms.  
Neutralisation of specific virulence factors required for invasion (Garcia-Suarez et al., 
2004) may contain bacteria within the airways, whilst enhancement of 
opsonophagocytosis may assist in the airways or within lung tissue.  Once in the 
bloodstream, S. pneumoniae replication may lead to lethal progression of disease, 
unless cleared by phagocytosis within the reticulo-endothelial system.  Again, specific 
antibody may enhance this phagocytosis. 
In the previous chapter, colonisation-induced serum antibody was both necessary and 
sufficient to protect against bacteraemia during subsequent pneumonia (Chapter 5).   
In this model, antibody was also present in the alveolar spaces during infection.  In 
addition, antibody was able to leak or be actively transferred to the mucosa following 
systemic administration (Chapter 5).  Data obtained following infection with 
fluorescently labeled bacteria (Chapter 4) suggested that colonisation did not affect 
early phagocytosis by alveolar macrophages.  Furthermore, there were no differences 
in the numbers of bacteria recovered from BALF and lungs of colonised and control 
mice during pneumonia (Chapter 4).  These observations suggest that serum antibody 
may be mediating protection primarily by facilitating rapid clearance of bacteria from 
the bloodstream through opsonophagocytosis.     This hypothesis was investigated in 
this chapter by testing the functional ability of colonisation-induced serum antibody in 
a series of in vitro and in vivo assays. Binding of colonisation-induced serum IgG to a 
range of bacterial strains was assessed.  The effect of colonisation on serum 
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enhancement of bacteria-phagocyte association was explored.  Finally, the clearance 
of bacteria directly inoculated into the bloodstream was studied. 
In this chapter, we addressed the following specific questions: 
• Does colonisation-induced serum IgG to bind the surface of S. pneumoniae? 
• Can colonisation-induced serum antibody enhance phagocytosis of S. 
pneumoniae? 





6.2.1 Effect of prior colonisation on serum IgG binding to bacterial 
surface 
Colonisation-induced serum antibody was found to contain IgG that recognised D39 
antigens in a whole cell ELISA.  To test whether the anti-D39 IgG induced through 
colonisation specifically recognised surface-located antigens, further immunoassays 
were performed by flow cytometry using whole viable bacteria in suspension.  These 
assays compared binding of serum IgG pooled from either control CBA/Ca mice 
(‘naïve’) or 28 days following D39 colonisation (‘immune’) to three D39 strains: D39 
WT, D39∆lgt (lacking surface lipoproteins) and D39-D∆ (lacking capsule) (see 
Figure 6.1) and to two TIGR4 strains: TIGR4 WT and TIGR4∆cps (see Figure 6.2).   
There was negligible IgG binding with naïve serum to either D39 WT or D39∆lgt 
(Figure 6.1).  However, in the absence of capsule, there was low level IgG binding 
from naïve serum to D39-D∆ (mean MFI 0.83 ± 0.12) (P=0.002 versus D39WT).  
There was significantly greater IgG binding from immune than naïve serum for 
D39WT (P=0.006), D39-D∆ (P<0.001) and D39∆lgt (P<0.001), with stronger 
binding to D39-D∆ and weaker binding to D39∆lgt than to D39WT with immune 







































Figure 6.1. Effect of prior D39 colonisation on serum IgG binding to surface of D39 
strains 
Serum IgG binding from D39-colonised (‘immune’) or control (‘naïve’) mice to D39WT, D39-
D∆ and D39∆lgt was assessed by flow cytometry.  Bacteria were incubated in 50% pooled 
serum (n=6 per group) then anti-mouse IgG-PE.  (A) Typical histograms depicting IgG binding 
to each bacterial strain using pooled immune or naïve serum or no serum (PBS).  There were 
no differences in background bacterial fluorescence between strains in the absence of serum.  
(B) Mean and SEM of IgG binding (n=4 replicates per set of conditions) after subtraction of 
background fluorescence.  Groups compared by unpaired Student t-test.  Data representative 
of two experiments performed with separate serum pools with similar results. 
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There was negligible IgG binding to encapsulated TIGR4 from either naïve or D39-
immune serum (Figure 6.2).  There was low level IgG binding from naïve serum to 
unencapsulated TIGR4∆cps (P<0.0001 versus TIGR4), and this increased slightly 
with immune serum, although the level of IgG binding was still low (mean 0.09 ± 
0.021 compared to 5.18 ± 0.23 for D39∆D).  This suggests that D39 colonisation 
induces IgG cross-reacting with TIGR4 non-capsular antigens.  However, levels are 
low and only detectable in the absence of the capsule. 
6.2.2 Effect of prior colonisation on in vitro serum opsonophagocytosis  
The ability of serum IgG from colonised mice to bind the surface of D39 suggested 
the possibility that this opsonisation may enhance their phagocytosis.  This would 
explain the marked ability of prior colonisation to protect against bacteraemia 
secondary to pneumonia.  To test whether serum from colonised mice enhanced 
bacterial association with phagocytes, an in vitro neutrophil association assay was 
kindly performed by Dr Catherine Hyams.  This assay utilized freshly isolated human 
neutrophils which were incubated with FAMSE-labeled D39WT bacteria that had 
been pre-incubated with serial dilutions of pooled CBA/Ca serum (Figure 6.3).  There 
was a clear dose-response effect of colonised serum enhancing association of D39 
bacteria with the neutrophils (P<0.001 for all dilutions).  When this experiment was 
repeated using serum from µMT mice which congenitally lack antibody, no 
enhancement of phagocytosis was observed with serum from colonized mice (Figure 
6.4).  Thus, colonisation induces serum containing IgG that binds the bacterial surface 




































Figure 6.2. Effect of prior D39 colonisation on serum IgG binding to surface of TIGR4 
strains 
Serum IgG binding from D39-colonised (‘immune’) or control (‘naïve’) mice to TIGR4 WT and 
TIGR4∆cps was assessed by flow cytometry.  Washed viable bacteria were incubated in 50% 
pooled serum (n=6 per group) followed by anti-mouse IgG-PE.  (A) Representative 
histograms depicting IgG binding to each bacterial strain using either pooled immune or naïve 
serum or no serum (PBS).  There were no background differences in bacterial fluorescence 
between strains in the absence of serum.  (B) Mean and SEM of IgG binding (n=4 replicates 
per set of conditions) after subtraction of background fluorescence.  Groups compared by 



































Figure 6.3. Effect of prior D39 colonisation of CBA/Ca mice on serum-mediated 
enhancement of bacteria-neutrophil association 
Flow cytometry assay of human neutrophil association with FAM-SE labelled D39 after 
incubation in pooled serum from colonised or control CBA/Ca mice (n=6 per group) or PBS. 
(A) Representative histogram depicting fluorescence of neutrophils after incubation with 
bacteria pre-incubated with 20% serum from colonised or control mice or with PBS.  (B) Mean 
neutrophil MFI  ± SEM (n=4 replicates for each condition).  Dotted line represents 
fluorescence with pre-incubation with PBS alone.  Colonised and control serum compared 



























Figure 6.4. Effect of prior D39 colonisation of µMT mice on serum-mediated 
enhancement of bacteria-neutrophil association 
Flow cytometry assay of human neutrophil association with FAM-SE labelled D39 after 
incubation in pooled serum from colonised or control µMT mice (n=6 per group) or PBS.  
Mean neutrophil MFI  ± SEM are presented (n=4 replicates for each condition).  Dotted line 
represents fluorescence with pre-incubation with PBS alone.  No significant differences were 
observed when colonised and control sera were compared across dilutions by one-way 
Anova. 
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6.2.3 Effect of prior colonisation on bloodstream bacterial clearance  
6.2.3.1 Effect of prior colonisation on bloodstream bacterial clearance by passive 
serum pre-opsonisation 
To test whether such enhanced phagocyte association can lead to increased clearance 
of bacteria from the bloodstream, an experiment was performed where bacteria were 
incubated for 30 min in pooled undiluted serum from either colonised or control 
CBA/Ca mice, then washed prior to i.v. inoculation.  Three naïve CBA/Ca mice 
received bacteria pre-incubated in serum from colonised mice.  Four naïve CBA/Ca 
mice received bacteria pre-incubated in control serum.  The actual inocula measured 
following pre-incubation were similar for the two groups (4.3 x 105 CFU for 
colonised and 5.0 x 105 for controls) indicating that pre-incubation had not affected 
the amount of viable bacteria the two groups received.  Mice were tail-bled at two h 
and terminally bled at five h post-challenge.  Viable bacteria were recovered from all 
mice as shown in Figure 6.5.  There was a broad range in the numbers recovered from 
both groups at both timepoints, with no significant differences between pre-incubation 
with colonised and control serum. 
It was possible in this passive pre-opsonisation model that bacterial cell division 
within the blood was greater than the enhancement in phagocytosis afforded by 
colonisation-induced antibody.  Thus, although no differences were seen, this may 
reflect the insufficiency of the amount of antibody remaining on the bacterial surface 
at the time of inoculation, rather than an ability of this antibody to enhance 
bloodstream clearance per se. 
247 

























Figure 6.5.  Effect on bloodstream clearance of D39 in naïve mice following pre-
incubation of bacteria with serum of colonised or control mice 
Log10 bacterial CFU recovered from the blood of naïve mice challenged by in inoculation with 
5x105 CFU D39 following pre-incubation in 50 µl pooled serum of colonised or control mice at 
107 CFU/ml serum.  Dots represent individual mice, bars represent group median.  Groups 
compared at each timepoint by Mann-Whitney U-test. 
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6.2.3.2 Effect of prior active colonisation on bloodstream bacterial clearance  
To test whether there is enhanced clearance of bacteria from the bloodstream of 
previously colonised mice, actively colonised CBA/Ca mice (colonisation inoculum 
1.6 x 107 CFU D39) or controls were inoculated with 5 x 106 CFU D39 i.v. 28 days 
post-colonisation.  Mice were bled at 2 and 5 h, and recovered CFU are shown in 
Figure 6.6.  There were 104-fold fewer bacteria recovered from the bloodstream of 
previously colonised mice than controls at both timepoints tested (P=0.02 at both 
times).  Thus, prior colonisation with D39 leads to marked enhancement of clearance 
of D39 bacteria from the bloodstream. 
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Figure 6.6.  Effect of prior colonisation on bloodstream clearance of intravenous 
inoculum 
Box-and-whisker plot showing log10 bacterial CFU recovered at 2 and 5 h from the blood of 
colonised or control mice inoculated i.v. with 5x106 CFU S. pneumoniae D39 on day 28 post-
colonisation (n=6 per group).  Groups compared at each timepoint by Mann-Whitney U-test. 
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6.3 SUMMARY OF RESULTS 
Colonisation with D39 induces serum IgG that bound the surface of D39.  There was 
greater binding to unencapsulated D39-D∆ than to its parent wild-type strain.  There 
was reduced binding to D39∆lgt.  There was negligible binding to the surface of 
encapsulated WT TIGR4.  When unencapsulated, there was more binding to 
TIGR4∆cps, but still significantly less than to unencapsulated D39.  These results 
suggested that colonisation induced serum IgG that recognised non-capsular antigens 
located on the surface of D39, and to a lesser extent on TIGR4.  At least some of these 
antigens were likely to be lipoproteins.  Serum from colonised CBA/Ca mice 
enhanced the association of D39 bacteria with human neutrophils, but serum from 
colonised µMT mice did not.  This may indicate enhanced opsonophagocytosis 
attributable to colonisation-induced antibody.  Using serum from colonised mice to 
pre-incubate D39 bacteria prior to i.v. inoculation did not enhance their clearance 
from the bloodstream, possibly reflecting the limited amount of antibody present on 
the bacteria at the time of inoculation.  However, previous colonisation led to over 
104-fold fewer bacteria being recovered from the bloodstream following direct i.v. 
inoculation, indicating the capacity of colonisation-induced serum to clear 
bloodstream bacteria. 
Overall, colonisation induces serum IgG that binds the bacterial surface, enhances 
opsonophagocytosis, and leads to rapid clearance of bacteria from the bloodstream. 
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7 ANTIGENIC TARGETS OF 
COLONISATION-INDUCED SERUM IgG 
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7.1 INTRODUCTION 
To date, the only proven correlate of protection against invasive human pneumococcal 
disease is opsonophagocytic anti-capsular antibody (Jokinen et al., 2004).  Antibodies 
induced by immunisation with purified pneumococcal proteins are also protective in 
animal models of pneumococcal disease (Briles et al., 2000a, Brown et al., 2001b, 
Giefing et al., 2008).  In some cases, anti-protein antibody protects through 
opsonophagocytosis, indicating that this is not the sole preserve of anti-capsular 
antibody.  Furthermore, natural antibodies to cell-wall polysaccharide can also be 
protective against pneumococcal sepsis in animal models (Briles et al., 1981, 
Goldenberg et al., 2004). 
The colonised-induced protection against invasive disease demonstrated in Chapter 4 
appeared to be mediated by serum antibody (Chapter 5) that is opsonophagocytic and 
enhances bloodstream clearance (Chapter 6).  Colonisation induced serum IgG 
binding D39 antigens in whole cell ELISA at titres over 1/1000 in nearly all mice 
(Chapter 4).  Similarly, nearly all colonised mice survived lethal pneumonia challenge 
(Chapter 4).  In contrast, serum IgA and IgM that bound D39 antigens was induced in 
only a small proportion of colonised mice, and therefore cannot explain the degree of 
protection observed.  Thus, colonisation-induced serum IgG is mediating protection 
against lethal pneumonia in this model. 
Binding of serum IgG from colonised mice to the surface of both encapsulated and 
non-encapsulated D39 strains was demonstrated using flow cytometry (Chapter 6).  
This would suggest that at least some antigenic targets of colonisation-induced IgG 
are non-capsular antigens.  Reduced binding to the D39∆lgt mutant implies that a 
proportion of these antigens may be surface lipoproteins.  There was also weak 
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binding to the surface of unencapsulated TIGR4∆cps, suggesting that serum IgG may 
cross-react with surface-expressed proteins from other strains of S. pneumoniae. 
This chapter attempted to identify antigenic targets of colonisation-induced serum IgG 
which may be mediating its protective effects.  Individual and pooled sera from 
colonised and control mice were tested for their ability to bind a range of 
pneumococcal polysaccharide and protein antigens.  Anti-capsular and anti-CWPS 
responses were measured by ELISA.  Serum IgG binding to pneumococcal proteins 
was explored using immunoblotting against lysates of different pneumococcal strains.  
Finally, binding to specific recombinant pneumococcal proteins was tested by 
immunoblotting and Luminex bead immunoassay techniques. 
In this chapter, we addressed the following specific questions: 
• Does colonisation induce serum anti-capsular antibody? 
• Does colonisation induce serum anti-CWPS antibody? 
• Does colonisation-induced serum IgG bind to pneumococcal proteins, and if 





7.2.1 Anti-polysaccharide antibody responses to colonisation 
Serum antibody to both capsular and cell wall polysaccharide can be protective in 
animal models of invasive pneumococcal disease.  Anti-capsular polysaccharide 
antibody can be induced through colonisation, although this appears to be very 
variable in both humans and mouse models, and may depend on serotype.  Serum 
anti-type 2 capsular polysaccharide and anti-cell wall polysaccharide were therefore 
measured by ELISA in the serum of D39 colonised (n=11-13) or PBS controls (n=5-
8).  Colonised mice received 0.6 x 107 CFU D39.  All mice were bled after 28 days. 
7.2.1.1  Anti-capsular polysaccharide antibody responses 
No anti-type 2 capsular IgG or IgA was detected in the serum of either colonised or 
control mice (Figure 7.1).  Whilst serum IgM against capsule was detected, the levels 
were very low, with a median OD405 at 1:20 serum dilution of 0.29 (IQR 0.21-0.52) in 
colonised mice and 0.16 (0.05-0.25) in controls (P=0.057).  These median OD levels 
were equivalent to titres of approximately 1/64 for colonised mice and 1/38 for 
controls.  Thus, no IgG or IgA against capsular polysaccharide was induced through 
colonisation.  Whilst there was a trend towards marginally higher levels of anti-
capsule IgM in colonised mice, this difference was no greater than the background 





































Figure 7.1. Effect of D39 colonisation on serum anti-type 2 capsular polysaccharide 
antibody. 
Serum anti-type 2 capsular polysaccharide (PPS2) antibody responses 28 days following 
colonisation with S. pneumoniae strain D39 measured by ELISA at 1:20 serum dilution.  
(n=14 for colonised mice, n=8 for controls).  Dots represent individual mice, bars represent 









































Figure 7.2.  Effect of D39 colonisation on serum anti-cell wall polysaccharide antibody. 
Serum anti-cell wall polysaccharide (CWPS) antibody responses 28 days following 
colonisation with S. pneumoniae strain D39 measured by ELISA at 1:20 serum dilution.  
(n=14 for colonised mice, n=3 for controls).  Dots represent individual mice, bars represent 
group medians, comparison by Mann-Whitney U-test. 
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7.2.1.2 Anti-cell wall polysaccharide antibody responses 
Limited serum samples from control mice were available for this analysis.  
Nevertheless, there was no evidence of either serum anti-cell wall polysaccharide 
IgG, IgA or IgM responses induced by colonisation (Figure 7.2).  Thus, it appeared 
that the marked efficacy of colonisation-induced systemic antibody in protecting 
against bacteraemia in this model was not being mediated by anti-polysaccharide 
responses. 
7.2.2 Serum anti-protein IgG responses detected by immunoblot of 
bacterial lysates 
To screen for the presence of IgG against unknown bacterial proteins, lysates of S. 
pneumoniae were prepared, the proteins separated by SDS-PAGE, and the blotted 
membranes probed with serum pooled from either colonised or control mice (n=6 
mice per pool) (Figure 7.3).  These serum pools are referred to as ‘immune’ or 
‘control’ serum hereafter.  Coomassie blue stained gel and immunoblots of proteins 
from lysates of D39 WT and D39∆lgt are shown in Figure 7.3.  Staining the gel 
revealed a large number of proteins present.  When the D39 WT immunoblot was 
probed with immune serum, however, only four strong bands and a limited further 
number of weaker bands were visible.  No bands were visible when membranes were 
probed with control serum.  When the immune serum was used to probe proteins from 
the D39∆lgt lysates, several bands of approximately 35-45kDa were absent.  A 
number of pneumococcal lipoproteins are known to be in this size region.  Thus, 
colonisation with D39 induced serum IgG against a limited number of protein 
antigens, including some lipoproteins.  As the sequence of many pneumococcal 
proteins is conserved between serotypes, the ability of D39 colonisation-induced 
serum IgG to bind proteins derived from other S. pneumoniae strains was tested.  
258 
Lysates were prepared of strains TIGR4 and 0100993 and immunoblotted to detect 
IgG binding from colonised serum (Figure 7.3).  Although there were some 
differences, especially in the larger proteins, similar patterns of bands to D39 were 
detected.  This suggested that serum IgG induced by D39 colonisation cross-reacted 
with similar proteins in different pneumococcal strains.  To identify whether there is 
variation in which proteins dominated the serum IgG response to D39 colonisation 
between mice, lysates of D39 were also probed by individual sera from seven 
colonised mice (Figure 7.4).  Similar binding patterns were seen between sera, 
differing only in overall binding strength.  This suggested that specific proteins 






Figure 7.3.  Serum IgG binding to pneumococcal lysate proteins in pooled sera of 
colonised and control mice.  
Immunoblots of IgG binding in pooled sera from colonised and control mice to whole cell 
lysates of D39, D39∆lgt, TIGR4 and ST3 S. pneumoniae strains separated by SDS-PAGE. A 
Coomassie brilliant blue stained SDS-PAGE of the D39 lysate is shown (CBB).  Data 






Figure 7.4.  Serum IgG binding to pneumococcal lysate proteins in individual sera of 
colonised mice.  
Immunoblots of IgG binding to whole cell lysates of D39 using individual sera from 7 
colonised mice. 
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7.2.3 Identification of specific protein targets of colonisation-induced 
serum IgG 
To identify specific protein targets of colonisation-induced serum anti-D39 IgG, two 
approaches were taken.  Firstly, immunoblotting was performed using two sets of 
recombinant pneumococcal proteins.  One set consisted of fifteen proteins derived 
from the genome of the TIGR4 strain of S. pneumoniae.  The second set consisted of 
proteins derived from the genome of the 0100993 strain (Table 7.1).  These TIGR4 
proteins were selected as they are known to induce serum antibody responses in 
humans following either colonisation or pneumonia (Giefing et al., 2008).  The 
second approach was bead immunoassay using Luminex beads conjugated to sixteen 
pneumococcal proteins from several strain sources (Table 7.1).  The broadly similar 
immunoblot binding patterns seen with bacterial lysates of D39, 0100993 and TIGR4 
suggested that using proteins from heterologous strains was likely to positively 
identify some target antigens.  As negative controls, both assays incorporated TIGR4 
pilus proteins absent in D39 (RrgB in immunoblots and RrgA in bead immunoassay 
(Gianfaldoni et al., 2007)).  To aid the interpretation of negative results which could 
be due to antigenic variation rather than lack of antibody against homologous antigen, 
the predicted amino acid sequences of the proteins based on the D39 and TIGR4 
genomes were compared.  These were obtained by BLAST analysis of the amino acid 
sequences.  All protein antigens and the BLAST results are listed in Table 7.1, along 
































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   


































































































































     
   
   
   
   
   
   
   
   
   
   
   
   
   
   






































































7.2.3.1 Detection of serum IgG binding to S. pneumoniae proteins by immunoblot 
To identify binding of IgG in immune and control serum to TIGR4 proteins, the 
proteins were separated by SDS-PAGE and IgG binding with immune and naive 
serum to specific proteins identified by Western blotting (Figure 7.5).  When probed 
with immune serum there were dense bands indicating IgG binding to SktP (lane 1), 
PsaA (lane4) and PcsB (lane 6).  Binding was also evident to MalX and AmiA (lane 
2), PspA (lane 5) and SP2141 (lane 6).  The densest band when probed with immune 
serum was SktP (lane 1).  Although there was a faint band when this protein was 
probed with control serum, the marked difference was indicative of colonisation 
augmenting the level of IgG to this antigen.  Similar faint binding was also seen for 
Ply (lane 4) with both immune and control serum.  There was no IgG binding to 
LysM, SP1954, AliB, PspC, Cbf1, PavB or the negative control protein RrgB with 
either immune or naïve serum.  Thus, colonisation with S. pneumoniae strain D39 
appeared to induce serum IgG capable of binding to the TIGR4 recombinant proteins 
PsaA, PcsB, MalX, AmiA, PspA, SP2141 and SktP. 
Further immunoblots were performed as above against four pneumococcal 
lipoproteins synthesised from strain ST3 genes, as shown in Figure 7.6.  There was 
faint binding of both immune and naïve serum IgG to PiuA and SP0149.  No binding 
was evident for PiaA or SP0749.  Thus, colonisation did not appear to induce IgG to 
any of these four proteins. 
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Figure 7.5.  Serum IgG binding to individual S. pneumoniae TIGR4 proteins.  
(A) Coomassie brilliant blue stained gel of recombinant pneumococcal proteins separated by 
SDS-PAGE.  The recombinant protein antigens (predicted size in kDa) in each lane were: 1, 
SktP-C (35.1); 2, LysM (19.2), MalX (43.9), and AmiA (71.8); 3, SP1954 (50.8) and AliB 
(70.7); 4, PsaA (33.7), Ply (52.9) and PspC (55.9); 5, Cbf1 (36.5) and PspA (62); 6, PcsB-N 
(28.3) and SP2141 (72.7); 7, RrgB (negative control, 66) and PavB (83); M, size markers.  (B) 
Immunoblots of IgG binding in pooled sera from colonised and control mice to recombinant 






Figure 7.6.  Serum IgG binding to individual pneumococcal ST3 prolipoproteins.  
(A) Coomassie brilliant blue stained gel of recombinant pneumococcal prolipoproteins 
separated by SDS-PAGE.  The protein antigens in each lane were: 1, PiaA; 2, PiuA; 3, 
SP0149; 4, SP0749; M, size markers.  (B-C) Immunoblots of IgG binding in pooled sera from 
colonised (B) and control (C) mice to recombinant Pnc prolipoprotein antigens. 
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7.2.3.2 Detection of serum IgG binding to S. pneumoniae proteins by Luminex 
bead immunoassay 
A Luminex bead immunoassay for 16 Pnc proteins was used to partially confirm the 
immunoblot results and identify additional antigens recognised by sera from colonised 
mice, as shown in Figure 7.7.  Conjugated beads were kindly provided for this 
purpose by Prof Alex van Belkum (Erasmus MC, Rotterdam, The Netherlands).  IgG 
binding to S. pneumoniae proteins was assessed at 10% and 1% dilution of serum 
pooled from colonised and control mice.  The Luminex assay demonstrated IgG 
binding to PspA, PsaA, PhtD and PpmA in immune serum (Figure 7.7A) but not 
control serum (Figure 7.7B).  Comparison of binding levels of binding to these 
antigens between the two serum pools demonstrated greater than 10-fold difference in 
MFI for these four antigens at both dilutions (Figure 7.7C-D).  There was no binding 
to the other protein antigens tested by Luminex with either serum (PspC, CbpD, SlrA, 
PsaD, PhtE, SP0376, Eno, Ply, NanA, Hyal, IgAse, negative control RrgA).  For 
those antigens tested in both immunoblot and bead immunoassay, concordant results 
were obtained for the two methods (positive for PspA and PsaA; negative for PspC 






















































































Figure 7.7.  Serum IgG binding to individual pneumococcal proteins by Luminex bead 
assay.  
IgG binding to Pnc protein-conjugated beads (Luminex) in pooled sera from colonised or 
control serum, detected with anti-mouse IgG-PE. Data points represent means of two 
replicate wells.  Data are shown as (A) MFI for each protein against serum dilutions from 
colonised (A) and control (B) mice.  For each protein antigen, IgG binding as log10 MFI in 
serum from control mice is plotted against that from colonised mice at 10% (C) and 1% (D) 
serum dilution.  Only for PhtD, PsaA, PspA and PpmA (labelled) were there greater than 
tenfold differences in MFI between colonised and control sera.  Data representative of two 
experiments with different serum pools with similar results. 
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7.3 SUMMARY OF RESULTS 
Colonisation with D39 did not induce significant antibody responses against either 
type 2 capsular polysaccharide or against CWPS.  Immunoblotting against lysates of 
D39 using pooled colonised serum demonstrated IgG binding to several proteins, with 
similar patterns in individual sera of colonised mice.  Several bands were absent using 
D39∆lgt, confirming earlier flow cytometry data that suggested some lipoprotein 
targets.  Furthermore, similar cross-reactive binding patterns were seen with S. 
pneumoniae strains TIGR4 and ST3.  Thus, colonisation with D39 induced serum IgG 
against a limited number of conserved protein antigens, including some lipoproteins. 
Immunoblotting demonstrated that D39 colonisation induced serum IgG that bound 
seven proteins expressed from a TIGR4 genetic background: PsaA, PcsB, MalX, 
AmiA, PspA, SP2141 and SktP.  Luminex bead immunoassay confirmed the results 
for PsaA and PspA, and identified PhtD and PpmA in addition.  In total, nine 
antigenic targets of protective serum IgG were identified (Table 7.1), the majority of 





8.1 GENERAL DISCUSSION 
Observational human data (Lipsitch et al., 2005) and investigations using animal 
models of disease (Roche et al., 2007, Richards et al., 2010) suggest that exposure of 
the immune system to S. pneumoniae during carriage events may induce adaptive 
responses that protect against subsequent disease.  In this thesis, colonisation-induced 
protection against lethal S. pneumoniae strain D39 pneumonia was shown to be 
mediated by induction of serum anti-protein IgG capable of clearing bloodstream 
bacteria via opsonophagocytosis.  Protection was demonstrated in both inbred 
(CBA/Ca) and outbred (CD1) strains of mice.   Furthermore, the ability to replicate 
has been shown to be required to induce protection in the CD1 model. 
8.1.1 Colonisation model 
Nasopharyngeal bacterial load was assessed both to confirm that the WT strains were 
able to establish colonization, and to compare the bacterial load with that of mutant 
strains.  This was done by culture of nasopharyngeal wash fluid, an established 
method (Wu et al., 1997b, Matthias et al., 2008, Magee and Yother, 2001).  This 
technique is not expected to isolate every bacterial cell from within the nasopharynx.  
However, numbers of bacteria recovered by wash are similar to those recovered by 
homogenisation of nasopharyngeal tissue (Briles et al., 2005).  Thus, this method is 
likely to be a robust means of detecting meaningful changes in colonising load and 
eventual clearance. 
Using inocula of approximately 107 CFU, colonisation of the nasopharynx was 
achieved with both WT S. pneumoniae strains D39 and TIGR4.  This is similar to the 
inoculum size used by both Wu (Wu et al., 1997b) and Weiser (McCool and Weiser, 
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2004) in their WT colonisation models.  It is interesting to note that having tested a 
range of inoculum sizes, Wu found that this inoculum generally led to the most 
consistent colonisation without causing disease.  Richards (Richards et al., 2010) 
established D39 colonisation in outbred MF1 mice using a much smaller inoculum of 
105 CFU, and found this offered lasting colonisation at high density over 28 days.  
Although they measured bacterial load in tissue homogenate rather than wash fluid, it 
is unlikely that this explains the difference between their model and the one described 
in this study.  It may be a reflection of the mouse strain.  Indeed, Joyce colonised 
BALB/c mice with 108CFU D39 leading to a time course more similar to that seen in 
this study (Joyce et al., 2009).  
The inoculum required to establish colonisation naturally in humans in unknown.  It 
would be methodologically challenging to measure the number of bacterial CFU 
actually entering the nares during aerosol or droplet transmission.  In the only 
reported study of experimental human colonisation, doses of 5-17 x 103 CFU of 
serotype 23F strain suspended in 100 µl were sufficient to establish colonisation in 6 
of 14 volunteers.  Compared to total body size this volume is proportionally much 
smaller than the 10 µl used in all reports of experimental mouse colonisation.  Much 
of the inoculum given to a mouse may be lost due to physical factors (swallowing or 
sneezing), whereas most inoculum given to humans is likely to initially remain within 
the upper airway, and this may explain the need for the larger inocula required in 
mice. However, S. pneumoniae is not a natural pathogen of mice and may therefore 
find it more difficult to establish nasopharyngeal colonisation in a mouse compared to 
a human. 
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8.1.2 Challenge model 
For the challenge experiments a large inoculum leading to rapidly progressive disease 
in the majority of mice was chosen in order to test whether colonisation induced a 
strong enough immune responses to protect against severe disease. Colonisation of 
both outbred CD1 and inbred CBA/Ca mice with strain D39 protected against 
subsequent lethal challenge with D39.  Protection was stronger in the CBA/Ca model 
than the CD1 model, probably reflecting several factors.  In repeat experiments, 
immunogenicity of colonization was more uniform in the CBA/Ca mouse strain.  This 
may reflect greater consistency of colonization following nasal inoculation.  In 
addition, genetic variation between outbred CD1 mice may result in varying 
immunogenicity of specific antigens reflecting different MHC binding potential.  
Colonization of CD1 mice with the TIGR4 strain did not protect against TIGR4 
challenge.  The rapid progression of disease in control mice in this model suggests the 
challenge dose may be too large to identify a modest protective effect.  Thus, only 
limited conclusions can be drawn in this regard. 
8.1.3 Innate cytokines 
This study utilised a challenge model whereby unprotected mice developed lethal 
bacteraemia secondary to pneumonia.  In such a setting, it is expected that a large 
challenge inoculum introduced into the lungs would lead to robust inflammatory 
responses.  Thus, the adaptive responses induced through prior colonisation would 
only be evident over and above those already evoked by this strong innate response.  
The effects of previous colonisation were tested against this background. 
The concentration of inflammatory mediators were measured in BALF at 4 and 18 h 
following infection.  Significant levels of pro-inflammatory cytokines were found in 
BAL within 4 h of infection. The levels fell from 4 h to 18 h for KC, IL-6, TNF-α, 
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GM-CSF and IL-1β, consistent with previous reports of models of pneumococcal 
pneumonia with differing mouse and bacterial strains (Wang&Bergeron I&I 2001; 
Beg&Berg I&I 1998).  There was a trend towards slightly higher levels of these 
cytokines in previously colonised mice at 4 h, significantly so for IL-6 and TNF-α.  
The biological significance of these small differences is not clear. They may have 
contributed to the greater neutrophil recruitment that had occurred by 4 h, itself a 
modest increase relative to that observed in naïve mice.  There are several potential 
sources for these cytokines that may have been affected by previous colonisation.  A 
major contributor is likely to be alveolar macrophages.  Sub-lethal lung infection with 
S. pneumoniae is reported to have prolonged effects on AM recruitment and 
phenotype lasting at least until day 14 post-infection (Kirby et al., 2006).  It is 
expected that nasopharyngeal colonisation will lead to aspiration of small numbers of 
bacterial cells into the lower respiratory tract.  These are rapidly cleared, and hence 
negligible numbers were recovered in BALF and none in lung homogenate in this 
study.  Whether colonisation with asymptomatic micro-aspiration is sufficient to 
induce similar changes within the lung is not known, but this could explain why 
previously colonised mice had higher levels of these cytokines even by 4 h post-
infection.  Other rarer pulmonary-resident cells types may be similarly affected by 
small sub-clinical inocula aspirated during carriage including γδ-T-cells.  These 
expand and develop an activated phenotype in sub-lethal infection models (Kirby et 
al., 2007).  Furthermore, through direct contact, γδ-T-cells could modulate responses 
from AMs themselves (Wands et al., 2005). 
8.1.4 CD4 cells and IL-17 
Pulmonary infection of naïve mice with S. pneumoniae also leads to local innate 
production of IL-17.  This is IL-23 and γδ-T-cell dependant (Ma et al., 2009).  In 
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addition, nasopharyngeal colonisation with S. pneumoniae is sufficient to induce both 
mucosal and systemic Th17-cell memory responses (Zhang et al., 2009).  The ability 
of Th17 cells, primed during previous colonisation, to respond during pneumococcal 
pneumonia, and add to innate IL-17 during infection, has not been demonstrated to 
date.  In this study, following infection, previously colonised mice had higher levels 
of IL-17 in both BALF and serum.  Depletion of CD4+ cells, prior to challenge, led to 
abolition of the enhanced BALF IL-17 levels and to a substantially lower level of IL-
17 in the serum.  Thus, the difference between colonised and control mice was CD4+ 
cell dependant.  Such responses were however redundant in preventing the 
development of bacteraemia in previously colonised mice.  Depletion of CD4+ cells 
also had little effect on numbers of bacteria within the lungs.  Thus, if these CD4+ 
cell dependant differences in IL-17 do represent a Th17 cell response, it would appear 
redundant in effecting protection in this challenge model. 
This rapidly lethal model utilises a large challenge inoculum, and there is a significant 
rise in IL-17 levels in BALF even in naïve mice from 4 h to 18 h.  This is associated 
with a brisk neutrophil influx.  It may be that any potential benefits of a Th17-cell 
response are overwhelmed at the mucosal level in this model.  It is possible that 
challenge with a smaller inoculum would lead to a more modest innate response, and 
that the Th17-cell response to previous colonisation would become more important in 
enhancing local clearance of bacteria.  This hypothesis requires further investigation. 
The mucosal microenvironment itself also appears to preferentially polarise naïve T-
cells towards a Th17 rather than a Th1 phenotype (Zygmunt et al., 2009, Pepper et al., 
2009), perhaps due to higher levels of factors such as TGF-β and IL-6.  The ability of 
nasal immunisation with heat-killed whole cell S. pneumoniae to induce Th17-cell 
responses is dependant on the presence of CT (Malley et al., 2001).  CT enhances 
production of IL-6 and thus may contribute to Th17 cell polarisation.  Where viable 
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bacteria are used to colonise the nasopharynx, induction of Th17 memory is possible 
without CT.  This process is TLR2 dependant (Zhang et al., 2009).  The importance 
for TLR2 in induction of Th17 responses in this model is not known, but could 
involve TLR2-dependant production of cytokines such as IL-6, IL-1β or TGF-β from 
APCs.  Alternatively, the recognised ability of TLR2 signalling to polarise dendritic 
cells towards production of IL-23 (Roses et al., 2008), required for the maintenance of 
Th17 cells, may be important. 
8.1.5 Antibody responses 
D39 colonisation of WT CBA/Ca mice led to protection against subsequent lethal 
challenge.  µMT mice however were not protected.  Duration of nasopharyngeal 
colonisation in µMT mice is similar to that in WT mice (van Rossum et al., 2005).  
Thus they represent an appropriate model to test the contribution of colonisation-
induced antibody at the time of challenge, without significant effect on T-cell 
responses.  Passive transfer of serum pooled from colonised mice was sufficient to 
protect naïve recipients from bacteraemia during subsequent challenge.  Thus, 
colonisation-induced serum antibody is both necessary and sufficient to protect in this 
model. 
Colonisation of CBA/Ca mice with S. pneumoniae strain D39 induced IgG in serum 
that bound D39 antigens in whole cell ELISA in nearly every mouse.  Levels of serum 
IgM against D39 were marginally higher in colonised mice than controls, but this 
mainly reflected responses in a small number of individual mice, as for serum IgA.  
Passive transfer of this serum was sufficient to protect against bacteraemia and limit 
bacterial CFU in the lungs.  Thus, colonisation-induced D39-specific IgG is the most 
likely mediator of the protective effect of serum. 
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In CD1 mice levels of D39-specific serum IgG correlated with levels of protection 
against lethal pneumonia.  Thus, groups of mice receiving a booster dose of WT D39 
were more protected than those receiving a single dose, and those receiving mutant 
strains were less protected.  The precise mechanism of protection has yet to be 
determined in the CD1 model, as the greater consistency of responses in the CBA/Ca 
model meant this model was chosen for the detailed evaluation of immune effectors 
required for protection.  Hence, it is theoretically possible that factors other than 
serum IgG were responsible for protection in the CD1 model, and that serum IgG was 
merely a correlate of some other effecter mechanism.  Indeed, following nasal 
vaccination with heat-killed whole cell vaccine protection against re-colonisation 
correlates with serum antibody levels against various Pnc proteins, but antibody is 
entirely redundant in effecting protection (Trzcinski et al., 2005).  Antibody induction 
through colonisation merely correlates with the induction of the Th17–cell response 
that is actually responsible for protection.  Whether this is the case in the CD1 model 
would require further investigation.  
The specificity of D39-colonisation induced antibody responses was assessed by flow 
cytometry, whole cell and polysaccharide ELISA, immunoblot and multiplex bead 
immunoassay.  D39-D∆ bound more IgG from serum pooled from colonised CBA/Ca 
mice than its encapsulated parent strain in flow cytometry experiments.  This supports 
the argument that there is binding to non-capsular antigens, but itself does not prove 
absence of IgG binding to capsule.  The strongest evidence that no IgG against 
capsular antigen is induced through colonisation is derived from the ELISA data.  
Neither D39 nor TIGR4 colonisation of CD1 mice, nor D39 colonisation of CBA/Ca 
mice induced serum IgG against the homologous capsular polysaccharide.  Thus the 
IgG that bound D39 antigens in whole cell ELISA at high titre was binding non-
 279 
capsular antigen.  This was confirmed by competitive inhibition assay in which excess 
soluble CPS did not abrogate IgG binding in whole cell ELISA.   
Type 4 CPS is known to be immunogenic in mice (Jones et al., 2009) and humans as 
either plain (Cadoz et al., 1985) or conjugate polysaccharide (Rennels et al., 1998).  
Absence of serum anti-type 4 CPS IgG following TIGR4 colonisation of CD1 mice 
must reflect how the polysaccharide antigen is recognised by the immune system in 
this context.  Little is known about induction of anti-type 2 CPS responses.  There are 
no published data on its immunogenicity in humans, and very limited data from 
murine models.  Colonisation of MF1 mice appeared to induce low level serum IgM 
against type 2 capsule, but no IgG response was reported (Richards et al., 2010).  
Immunisation of BALB/c mice with a TIGR4 strain induced low level anti-type 4 
CPS serum antibody responses which were boosted following PCV immunisation 
(Rabquer et al., 2007).  Colonisation has a variable effect on induction of serum anti-
CPS IgG responses in humans, which may depend on bacterial strain, CPS type and 
previous host exposure.  In a longitudinal family study, serotypes 9V, 14, 18C, 19F 
and 23F induced anti-CPS responses, but serotype 6B did not (Goldblatt et al., 2005).  
Following carriage in a childhood study, responses were detected to of serotypes 11A 
and 14, but not to serotypes 6B, 19F and 23F (Soininen et al., 2001).  The data 
generated in this thesis support these findings that, in mice, a single nasopharyngeal is 
not sufficient to induce a serum anti-CPS IgG response.  This may depend on 
interactions between particular CPS serotypes with host genetic background and this 
may also explain data obtained from human observations. 
Flow cytometry studies of binding to the bacterial surface suggested that colonisation 
induced serum IgG to subcapsular antigens, a proportion of which were likely to be 
lipoproteins as there was reduced binding to the ∆lgt mutant.  This was confirmed by 
IgG binding to bacterial proteins and lipoprotein antigens in immunoblots of bacterial 
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lysates.  Interestingly, immunoblots with sera from individual mice gave very similar 
patterns to one another, suggesting that there were several immunodominant proteins 
causing similar IgG responses to colonisation amongst these inbred mice. It would be 
interesting to investigate whether this is true for other inbred mouse strains, and 
whether responses in outbred CD1 mice are more diverse, perhaps contributing to the 
weaker protection seen in this model. 
This study did not attempt to identify the site of induction of antibody responses 
following colonisation.  It is expected that both NALT and cervical lymph nodes 
would house germinal centres where B-cells would encounter bacterial antigens.  
Some antigen is likely to reach the lungs during colonisation, and could be trafficked 
to mediastinal lymph nodes by dendritic cells or AMs (Kirby et al., 2009).  However, 
the significantly higher bacterial load in the upper airway would predict that its 
associated lymphoid organs would be most important.  This could be tested using 
antigen specific B-cell ELISPOT assays to identify antigen specific memory B-cell 
populations from various lymphoid organs, as has been attempted by others (Richards 
et al., 2010).   
8.1.6 ∆pab mutants 
Bacterial viability during colonisation is likely to contribute to both colonisation 
duration and immunogenicity.  Several factors serve to reduce the number of viable 
bacteria at any given timepoint following inoculation.    These exclude extracellular 
bacterial death, physical removal in mucus (Nelson et al., 2007), and in situ 
phagocytosis (Matthias et al., 2008).  Using mutant bacteria (D39∆pab and 
TIGR4∆pab) the role of active replication in the nasopharynx was explored.  Both the 
D39∆pab and the TIGR4∆pab strains were rapidly cleared within 2 days of 
inoculation.  With PABA supplementation, the ability of D39∆pab to colonise was 
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restored, paralleling the restoration of virulence of the ∆pab mutant in the i.p. sepsis 
model (Dr Khandavilli, unpublished data described in Introduction).  Using this 
technique to control duration of colonisation may avoid pro-inflammatory effects 
associated with bacterial lysis after exposure to antibiotics to terminate colonization 
which may have secondary effects on adaptive immune response (Moore et al., 2005).   
Compared to its WT parent strain, D39∆pab was poorly immunogenic following 
colonisation.  Supplementation with PABA for five days restored the ability of 
D39∆pab to colonise, and enhanced the speed of anti-D39 IgG seroconversion.  It 
may be that supplementation for longer would have greater impact on 
immunogenicity and lead to significantly enhanced protection.  The data support the 
hypothesis that for a given strain of S. pneumoniae, the duration of colonisation is 
important in generating protective immunity.  Whether the ‘area under the curve’ 
(reflecting total antigen present over time ie extent as well as duration of colonisation) 
is more important than duration alone is not clear, but could be explored using the 
conditional colonization of the D39∆pab strain.  Minimum duration is likely to vary 
with both mouse and bacterial strain.  Mutants have been reported which are 
attenuated in their colonisation density and duration yet colonisation is still sufficient 
to induce protective immune responses (Roche et al., 2007).  Extrapolating from the 
data in this thesis, the wild-type parent strains of those mutants may be even more 
protective.  
Although a strain that is not capable of replication at all is unlikely to induce 
protection via this route, this can be overcome by use of an adjuvant.  Indeed, the 
unencapsulated heat-killed vaccine studied by Malley (which is by definition 
incapable of replication) (Malley et al., 2001) is only immunogenic when used with 
CT.  Repeat colonisation can boost immunogenicity and protection as reported here 
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and by others (Roche et al., 2007).  Thus, repeat administration of a replication-
incompetent strain, such as D39∆pab, may increase immunogenicity.   
8.1.7 Unencapsulated mutants 
There are no previous reports that directly compare the immunogenicity of otherwise 
identical encapsulated and unencapsulated strains. Compared to its parent WT strain, 
colonisation with D39-D∆ and TIGR4∆cps led to lower levels of CFU and more rapid 
clearance in CD1 mice.  In addition, D39-D∆ was les immunogenic and not protective 
in CD1 mice compared to its WT parent strain, suggesting that several doses of D39-
D∆ may be required to induce sufficient protection against D39WT challenge. 
The primary clearance of encapsulated Pnc from the nasopharynx appears to be 
mediated by an adaptive Th17-cell response (Zhang et al., 2009).  The early 
neutrophil influx in the first 2-3 days is insufficient to clear encapsulated Pnc 
(Matthias et al., 2008).  Clearance depends on the evolution of a Th-17 cell 
orchestrated influx of mononuclear phagocytes later in colonisation.  Whilst 
unencapsulated S. pneumoniae are more readily phagocytosed by neutrophils in vitro 
than their encapsulated parent strains (Hyams et al., 2010a), neutrophils appear 
redundant in clearing unencapsulated S. pneumoniae from the nasopharynx (Nelson et 
al., 2007).  They are cleared more rapidly due to increased mucus trapping (Nelson et 
al., 2007).  This may provide an additional reason for reduced immunogenicity of 
unencapsulated strains.  Removal of unencapsulated bacteria from the nasopharynx by 
purely physical factors would leave fewer bacteria available for neutrophil 
phagocytosis, a component of antigen pre-processing necessary for the induction of 
adaptive immune responses to colonisation (Matthias et al., 2008).  In this regard, it 
would be interesting to directly compare the immunogenicity and protective efficacy 
of colonisation with those unencapsulated strains that are known to protect (Roche et 
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al., 2007) with those of their WT parent strains.  It is possible that WT strains in 
general would emerge as more immunogenic than unencapsulated isogenic mutants. 
8.1.8 ∆lgt mutants 
D39∆lgt also colonised with fewer CFU and was cleared more rapidly in CD1 mice.  
Unfortunately, a strain with this mutation on the TIGR4 background was not available 
during this thesis to confirm that this observation was specific to this strain.  Many 
lipoproteins provide important nutrient transporter functions (Basavanna et al., 2009), 
and their absence impairs bacterial growth (Khandavilli, unpublished data [see 
Introduction]).  Thus, the effects on growth of lack of lipoproteins may contribute to 
the reduced colonisation ability of the D39∆lgt strain.  Furthermore, several 
lipoproteins are important in mediating adherence to nasopharyngeal epithelium.  
Mutants lacking PpmA (Cron et al., 2009), SlrA (Hermans et al., 2006) and the Ami-
AliA/AliB complex (Kerr et al., 2004) are cleared more rapidly from the nasopharynx 
than their parent WT strains, whilst antibodies against PsaA can prevent 
nasopharyngeal colonisation (Johnson et al., 2002).  Since D39∆lgt lacks all surface 
lipoproteins, it is likely to have significantly impaired adhesion to the epithelium, 
contributing to its more rapid clearance.  This could be explored further using in vitro 
models of epithelial adherence (Rose et al., 2008). 
TLR2 signalling is important in the induction of Th17-cell responses through Pnc 
colonisation.  Thus, mice lacking TLR2 have delayed clearance of S. pneumoniae 
(van Rossum et al., 2005, Zhang et al., 2009).  Reduced TLR2 signalling from 
D39∆lgt may therefore impair the induction of the Th17 response which ultimately 
facilitates clearance of colonisation.  Theoretically, this may facilitate prolonged 
colonisation compared to WT.  However, the reduced growth and adherence of 
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D39∆lgt appears to be dominant and thus the mutant is cleared more rapidly than its 
parent wild-type strain. 
D39∆lgt was less immunogenic and not protective compared to its parent WT strain 
in CD1 mice.  This could reflect several phenotypic differences between the strains, 
arising from the ∆lgt mutation.  Firstly, impaired immunogenicity may simply reflect 
shortened colonisation duration, as for the other mutant strains and this could possibly 
be overcome by using administration of multiple doses.  Secondly, it may be that 
serum antibody against lipoprotein makes up a significant part of the response to 
colonisation with the WT strain in CD1 mice (as was shown by flow cytometry with 
serum from CBA/Ca mice).  Thus, absence of these antigens may lead to reduced IgG 
detected in whole cell ELISA.  Finally, the absence of bacterial lipoproteins 
(important TLR2 agonists) in D39∆lgt may lead to reduced TLR2 signaling.  TLR2 
signaling is important in the induction of Th17-cell responses through Pnc 
colonisation (van Rossum et al., 2005, Zhang et al., 2009).  Whether TLR2 signaling 
is important in the induction of antibody responses to colonisation is not known and 
requires further investigation.  However, TLR2 signaling has been shown to be 
important in the induction of anti-protein and anti-carbohydrate antibody responses 
(Sen et al., 2005).  Distinguishing between these factors to identify why D39∆lgt 
colonisation has reduced protective efficacy would be difficult, and it is likely to 
reflect the complex interaction of all these processes which makes their in vivo 
dissection challenging.  Studies using strains containing multiple mutations, possibly 
administered with multiple doses to WT and TLR2-deficient mice may help to 
determine the key factors in colonisation-induced protective immunity.  
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8.1.9 Opsonophagocytosis 
Serum from colonised mice contained IgG that bound the bacterial surface.  Serum 
from colonised CBA/Ca mice also enhanced the ability to S. pneumoniae D39 to 
associate with human neutrophils.  These were used as large numbers of phagocytic 
cells were readily available, unlike the smaller numbers that could be obtained from 
mice.  Serum from colonised µMT mice which lack antibody did not enhance this 
interaction, demonstrating that it is likely to be the antibody component of serum from 
colonised mice which is responsible.  If sufficient serum was available, antibody 
depletion of serum would further support this.  In this flow cytometry assay, results 
reflect both internalisation of the bacteria through phagocytosis and binding to the 
phagocyte surface without internalisation (Hyams et al., 2010a, Yuste et al., 2008).  
Previous studies of the relative contribution of internalisation and phagocytosis to 
total bacterial association using quenching of surface fluoresence with Trypan blue 
and blocking phagocytosis with cytochalasin D suggest most of the neutrophil 
association is due to phagocytosis (Hyams et al., 2010a). Limited quantities of serum 
precluded these approaches in this study, and it was considered more important to 
demonstrate the functional consequences of the interaction with phagocytes in vivo. 
Previous colonisation did not significantly affect the numbers of bacteria recovered 
from BALF at any timepoint, and in vivo alveolar macrophage phagocytosis measured 
using fluorescently-labelled bacteria at four h post-infection was not enhanced by 
prior colonisation despite the presence of mucosal IgG and IgA against D39 antigens 
in BALF. Furthermore, although there was a trend towards reduced lung bacteria by 
18 h in previously colonised mice, this difference was also present following passive 
transfer, demonstrating that serum antibody is responsible for this difference and that 
mucosally-produced antibody is not required. Overall, the data suggest that mucosal 
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antibody responses were not important for the protection seen after colonisation.  This 
may be because the levels were too low relative to the large challenge inoculum.  
Future experiments will address whether mucosal antibody can help clearance of a 
lower challenge inoculum, which might more accurately reflect the normal situation 
found during microaspiration of S. pneumoniae from the nasopharnyx in colonised 
humans. 
In addition to opsonisation of bacteria, colonisation-induced serum antibody may also 
protect at the mucosal level by neutralising the bacterial factors required for invasion.  
Rapid clearance of bloodstream bacteria following i.v. challenge in previously 
colonised mice indicates that enhanced opsonophagocytosis alone would be sufficient 
to explain the absence of bacteraemia in previously colonised mice following 
pneumonia challenge.  It is difficult to demonstrate in the presence of this 
opsonophagocytosis whether colonisation-induced antibody is capable of neutralising 
bacterial invasion, such that bacteria enter the bloodstream at a slower rate in 
previously colonised mice.  The ability of colonisation-induced serum antibody to 
block bacterial adhesion to epithelial cells could be explored in vitro.  It may be 
possible to investigate this in vivo on a background of selective phagocyte depletion 
(Zhang et al., 2009) prior to pneumonia challenge. 
8.1.10 Cross-reactive antibody 
Colonisation of CD1 mice with D39WT induced serum IgG that cross-reacted in a 
whole cell ELISA with TIGR4 and ST3 antigens.  A quantitative comparison was not 
possible as these assays have not been standardized to quantify absolute antibody 
concentrations.  The presence of cross-reactive serum IgG following D39 colonisation 
of CBA/Ca mice was also demonstrated by immunoblotting against bacterial lysates 
of ST3 and TIGR4 strains.  Other than bands representing proteins larger than 100 
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kDa (which might reflect dimers or trimers of common antigens rather than separate 
D39-specific antigens), this revealed a broadly similar pattern of bands to the 
homologous D39 strain, as has been recently reported following colonisation with 
acapsular strains (Roche and Weiser, 2010).  Flow cytometry studies demonstrated 
cross-reactive IgG binding to the TIGR4 strain, but less than to D39, and only in the 
absence of the capsule.  Presence of IgG against a range of recombinant TIGR4 
protein antigens was demonstrated by immunoblot.  It is possible that the serotype 4 
capsule may impede the binding of cross-reacting antibody to subcapsular protein 
antigens more effectively than the serotype 2 capsule.  This hypothesis could be 
explored using capsular switch strains which are genetically identical with regard to 
protein antigens and differ solely in their capsular types (Hyams et al., 2010b).   
Cross-protection induced through colonisation with unencapsulated mutants has been 
previously reported (Roche et al., 2007).  Despite inducing serum IgG against D39 
antigens, colonisation of CD1 mice with D39 did not protect against subsequent 
TIGR4 challenge.  However, even colonisation with the TIGR4 strain failed to 
prevent fatal challenge with the TIGR4 strain, suggesting for this strain 
nasopharyngeal colonisation of CD1 mice may not induce effective protective 
immune responses.  Interpretation is limited by the high mortality in the control group 
in this experiment.  There was a strong trend towards some cross-protection against 
ST3 (P=0.057).  There was only 10% survival in the ST3-challenged controls, and it 
is possible that challenge of D39-colonised mice with a smaller ST3 inoculum would 
demonstrate statistically significant cross-protection.  Given the stronger homologous 
protection induced by D39 colonisation of CBA/Ca mice, it is possible that these mice 
would be cross-protected against heterologous challenge.   
Data from the CD1 model suggest that cross-reaction in WC ELISA does not 
correlate with cross-protection.  Future studies may be able to clarify whether IgG 
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binding to the bacterial surface measured by flow cytometry correlates better with 
cross-protection, and whether allelic protein antigen variation or hindrance of anti-
protein binding by capsule type is more important.   
8.1.11 Specific protein antigens 
The combination of immunoblotting and Luminex assay identified nine specific 
proteins, including four lipoproteins, that are immunogenic following D39 
colonisation of CBA/Ca mice: PspA, PsaA, PpmA, AmiA, MalX, PhtD, StkP, 
SP2141 and PcsB.  Except for PpmA (see Table 7.1), the recombinant proteins used 
for these assays were obtained from heterologous strains, demonstrating that these are 
likely to be target antigens for cross-reactive antibody.  A negative result obtained 
with these assays must be taken with caution, as it may not necessarily indicate that 
the antigen is not immunogenic during colonisation.  A number of proteins were 
expressed in truncated form, and antibody binding antigens in non-expressed domains 
or conformational antigens affected by truncation would not be identified by this 
approach.  Although nearly all antigens tested were highly conserved (see Table 7.1), 
a smaller number such as PspC are not, and failure to detect IgG binding may reflect 
absence of cross-reaction rather than absence of antibody against these antigens.  If 
recombinant D39 antigen had been used in these assays, binding may have been 
identified.   
Despite only 57% identity in amino acid sequence, colonisation with the D39 strain 
induced serum IgG that bound TIGR4 PspA in both immunoblot and Luminex assay.  
This would imply that this variation did not affect epitopes recognised by 
colonisation-induced antibody.  D39 colonisation of MF1 mice has also been shown 
to induce anti-PspA serum IgG (Richards et al., 2010).  As for all the specific antigens 
identified, it is not known whether the IgG is binding to PspA epitopes which are 
 289 
important for protection or whether anti-PspA is functionally important in the 
protection demonstrated here.   
Recombinant PspA (Wu et al., 1997a), PhtD (Adamou et al., 2001), StkP and PcsB 
(Giefing et al., 2008) are individually protective in animal models of pneumococcal 
disease.  The protective serum antibody induced by murine immunisation with SktP 
or PcsB demonstrates opsonophagocytic killing in vitro.  Recombinant PpmA is also 
protective when administered in conjunction with other protein antigens (Audouy et 
al., 2007).  Immunisation with PsaA alone protects against colonisation, but not 
against disease. To date, there is no evidence that immunisation with AmiA, MalX or 
SP2141 is protective against disease.  Conversely, the antigens PiuA, PiaA and PspC 
are strongly immunogenic and protect against disease when given as recombinant 
proteins in mouse models.  However, colonization did not induce a detectable 
antibody response to these antigens.  For PspC this could be due to allelic variation, as 
discussed above.  However, PiuA and PiaA are very highly conserved between S. 
pneumoniae strains and known to be expressed during infection (LeMessurier et al., 
2006) Brown unpublished data), so it is unclear why they do not induce an antibody 
response after nasopharyngeal colonisation with live bacteria.  Which of the antigens 
for which antibody responses were found were responsible for the marked protection 
against bacteraemia in CBA/Ca mice is not known. The degree of protection perhaps 
suggests antibodies to multiple antigens were responsible, as protein antigens 
administered in combination offer stronger protection (Ogunniyi et al., 2007).  It may 
be possible to deplete serum of specific antibodies to reveal the non-redundancy of 
specific responses in effecting protection.  Such studies are likely to require larger 
quantities of serum, which may necessitate establishing colonisation models in larger 
animals. The weak binding in immunoblots of serum IgG from control mice to Ply, 
PiuA and SP0149 was similar to that in serum of colonised mice.  This may reflect 
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cross-reactive natural antibody following previous exposure to other non-
pneumococcal Streptococcus species which posses structurally related cytolysins 
(Jefferies et al., 2007) or lipoproteins (Whalan et al., 2006). 
Overall, it appears that experimental colonisation of mice biases the adaptive immune 
response towards anti-protein antibodies.  Perhaps their inherent T-dependant nature 
leads to their immunodominance during colonisation.   
The importance of TLR signalling in the induction of antibody responses has recently 
become apparent (Ganley-Leal et al., 2006).  Specifically, TLR2-deficient mice have 
poor anti-phosphorylcholine IgG responses to S. pneumoniae immunisation 
(Vasilevsky et al., 2008), and poor anti-surface protein IgG responses to Salmonella 
enterica (Cervantes-Barragan et al., 2009).  Even commercially available PPS and 
PCV formulations have been shown to be routinely contaminated with TLR2 ligands 
that are indispensible for induction of anti-CPS IgG responses (Sen et al., 2005).  It is 
possible that the potent TLR2 signalling capacity of antigens such as lipoproteins 
contributes to their immunodominance during colonisation.  That may explain the 
dominance of lipoproteins as target for colonisation-induced serum IgG in this study, 
and the dominance of PsaA over PspA, PspC and Ply in other reports (Palaniappan et 
al., 2005). 
Although a number of Pnc proteins have been identified in this study, it is likely that 
there are further antigens recognised by sera from colonised mice.  Other approaches 
such as 2D gel electrophoresis or ANTIGENome screening (Giefing et al., 2008) may 
be required to obtain greater resolution enabling more comprehensive identification of 
immunodominant responses. 
It is likely that the immunodominant proteins will vary between different colonising 
strains.  This has been reported following colonisation with unencapsulated TIGR4 
and serotype 6A and a wild-type serotype 23 strain.  Whilst antibody against several 
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proteins was induced, TIGR4∆cps induced antibody predominantly against PspA and 
PpmA, 6A∆cps induced antibody against PsaA, and the serotype 23F strain induced 
antibody against just PpmA.  Interestingly, none of these responses were necessary as 
colonisation with a mutant deficient in all three proteins still induced protection.  This 
is a useful strategy for determining redundancy but cannot prove that a specific 
antibody target is necessary.  Were protection not seen following colonisation with a 
mutant strain, it may reflect the impact of the mutation on colonisation itself (e.g. 
duration) as found with the D39 and TIGR4 mutant strain studied in this thesis, rather 
than lack of antibody against a specific protein target.  How and why the bacterial or 
mouse strain background affects the pattern of antibody responses to colonisation 
warrants further detailed investigation, These studies will be difficult, however, due to 
the effects of specific mutations on the dynamics of infection and interaction with 
host immune effectors independent of their effect on immune responses. 
8.1.12 Relevance of findings for human populations 
Are such adaptive anti-protein responses important in protecting humans?  It is 
difficult to separate the effects of the developing innate immune responses from those 
of the adaptive immune response following such ubiquitous natural exposure.  Human 
S. pneumoniae nasopharyngeal colonisation induces antibodies to a range of S. 
pneumoniae protein antigens (Giefing et al., 2008, Laine et al., 2004, Goldblatt et al., 
2005, Simell et al., 2009, Melin et al., 2008).  The epidemiology of S. pneumoniae 
disease is also consistent with colonisation inducing protective humoral immunity 
against proteins antigens, with anti-protein responses increasing and the incidence of 
invasive S. pneumoniae infection, especially septicaemia, falling in older children 
(Laine et al., 2004, Lipsitch et al., 2005).  If anti-protein responses are cross-
protective this would explain why the incidence of invasive S. pneumoniae disease 
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caused by all serotypes falls after infancy at similar rates, irrespective of prevalence of 
carriage (Lipsitch et al., 2005).  Furthermore, immune senescence affects antibodies 
to S. pneumoniae proteins to a greater degree than antibodies to the capsule (Simell et 
al., 2008) which could contribute to the increased incidence of invasive S. 
pneumoniae infection in the elderly.   
Affinity purified natural IgG against StkP and PcsB has recently been shown to 
promote opsonophagocytic killing in vitro.  Thus, it is possible that naturally acquired 
anti-protein IgG in human serum may facilitate killing of S. pneumoniae in vivo.  S. 
pneumoniae pneumonia in humans is often associated with negative blood cultures 
(Werno and Murdoch, 2008).  Furthermore, blood culture is also often negative in 
focal pneumococcal infection such as meningitis, despite infection arising through 
haematogenous spread (Kirkpatrick et al., 1994).  This could be explained by the 
presence in serum of natural antibodies against S. pneumoniae antigens sufficient to 
enhance bloodstream clearance but not to protect against occasional colonies 
establishing focal infection in protected ‘sanctuary’ sites.  It has been observed that 
patients presenting with non-bacteraemic pneumococcal pneumonia have higher 
serum anti-Ply IgG than those with bacteraemic pneumonia (Musher et al., 2001).  
Such observations do not prove that pre-existing serum anti-protein antibody prevents 
progression to bacteraemia in humans, but they are consistent with this hypothesis. 
At present, vaccine-induced opsonophagocytic antibodies to capsular polysaccharide 
are the only known correlate of human protection against invasive S. pneumoniae 
disease (Bogaert et al., 2004b), and serological surveys in children have only 
investigated antibody responses to a limited number of S. pneumoniae protein 
antigens.  Murine data identifying important immunodominant antigens to S. 
pneumoniae colonisation could inform which protein antigens should be included in 
serological studies of human responses to S. pneumoniae colonisation.  There is 
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increasing interest in the identification of protein antigens which are immunogenic 
following natural exposure.  Studies are in progress in several geographical locations 
investigating these responses in the context of S. pneumoniae carriage particularly in 
areas of high prevalence (Prof David Goldblatt, personal communication).  Future 
studies may investigate whether risk of subsequent recolonisation or disease correlates 
with naturally-induced anti-protein antibody responses.  This may guide future multi-
valent protein vaccine design.  It is of note that several of the protein antigens 
currently in early clinical phase vaccine studies were discovered through empiric 
analysis of S. pneumoniae proteome using sera from exposed humans.  Since over 
12% of TIGR4 genes are conserved hypothetical proteins of unknown function (The 
Institute for Genomic Research, 2010), there are likely to be other protective antigens 
to be discovered. 
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8.2 SUMMARY OF FINDINGS 
Using mouse models, this thesis has demonstrated that nasopharyngeal colonisation is 
immunogenic, inducing both mucosal and systemic antibody responses to bacterial 
antigens.  Furthermore, previous colonisation is protective against subsequent lethal 
pneumonia in both inbred and outbred mice. 
Colonisation with WT strains led to higher levels and longer duration of colonisation 
than with unencapsulated, ∆pab or ∆lgt strains.  Unlike the D39 WT strain, D39 
mutants were less immunogenic and were not protective against lethal pneumonia, 
perhaps reflecting the reduced numbers of bacteria present during shorter periods of 
colonisation.  Extending the duration of colonisation of the D39∆pab strain with 
PABA supplementation led to enhanced immunogenicity, supporting the hypothesis 
that a persistent bacterial load in the nasopharynx has a direct influence on the speed 
and magnitude of the immune response.  The contribution of bacterial lipoproteins as 
both antigens and TLR2 agonists may also be important in inducing protective 
responses to colonisation.   
Protection against lethal S. pneumoniae pneumonia in previously colonised mice 
strongly correlated with the absence of bacteraemia.  During pneumonia, previously 
colonised mice had higher mucosal levels of IL-6 and TNF-α and more rapid 
recruitment of neutrophils to alveolar spaces.  Previously colonised mice also had 
significantly enhanced levels of mucosal and systemic IL-17.  This enhancement was 
dependent on the presence of CD4+ cells at the time of challenge.  Despite this, 
previous colonisation did not lead to a reduced mucosal bacterial load in this infection 
model.  CD4+ cells and the enhanced IL-17 response were redundant in protecting 
against progression to bacteraemia.  However, serum antibody induced through 
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colonisation was both necessary and sufficient to protect against the bacteraemia 
associated with lethal progression of disease. 
Serum IgG induced through colonisation bound non-capsular surface antigens 
including lipoproteins, but not capsular polysaccharide.  This serum enhanced 
phagocytosis of S. pneumoniae in vitro and the clearance of bacteria from the 
bloodstream in vivo.  Nine pneumococcal protein targets of protective colonisation-
induced serum IgG were identified, including four lipoproteins.  Most of these 
antigens are highly conserved between S. pneumoniae strains, explaining the 
induction of cross-reactive serum IgG through colonisation with the D39 strain. 
These data support the hypothesis that induction of serum anti-protein IgG through 
colonisation protects against invasive pneumococcal disease.  This finding provides 
important insight into the dynamics of pneumococcal disease in repeatedly exposed 
human populations, and may direct future work to the identification of novel antigens 
for inclusion in future pneumococcal vaccines. 
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DEA BUFFER (FOR ELISA) 
1M diethanolamine, 0.5 mM MgCl2 [1 litre]  
Add 97 ml diethanolamine (Sigma) to 850 ml distilled water in a fume hood. 
Mix well with magnetic stirrer. 
Add 0.1 g MgCl2.6H2O (Sigma) and allow to dissolve. 
Adjust pH to 9.8 ± 0.05 slowly adding 6M HCl. 
Store protected from light at RT for up to 6 months. 
 
10X TRIS-BUFFERED SALINE 
50mM Tris, 150 mM NaCl, pH 7.4 [1 litre] 
Add 80g NaCl to 800 ml water. 
Add 2g KCl. 
Add 30 g of Tris base (Fisher). 
Adjust to pH 7.4 with HCl. 
Make to 1 litre with water. 
 
COOMASSIE BRILLIANT BLUE SOLUTION 
0.1% Coomassie blue R350, 20% methanol, 10% acetic acid [400 ml] 
Add 80 ml methanol to 120 ml distilled water. 
Dissolve 0.4 g Coomassie blue R350 and filter. 
Add 200 ml 20% acetic acid in distilled water. 
 
DESTAIN SOLUTION 
50% methanol, 10% acetic acid [1 litre] 
Add 500 mL methanol to 300 mL water  
Then add 100 mL acetic acid, and bring to 1 litre with water 
 
10X TRANSFER BUFFER 
Glycine 36.3 g 
Tris (base) 150 g 
SDS  3.75 g 
Make to 1 litre with distilled water. 
 
TRANSFER BUFFER WITH METHANOL 
Add 80 ml 10X Transfer Buffer to 80ml methanol. 
Dilute to 1X with 240 ml distilled water. 
 
